curriculum vitae - university of california, san diego... · web viewtransplant cardiology...

CURRICULUM VITAEBARRY H. GREENBERG, M.D.

NAME: Barry H. Greenberg, M.D.

PLACE OF BIRTH: Brooklyn, New York

MARITAL STATUS: Married to Jennifer Keithly Greenberg

HOME ADDRESS: 4853 Bayliss CourtSan Diego, CA 92130

OFFICE ADDRESS: Sulpizio Cardiovascular Center University of California, San Diego 9434 Medical Center Drive La Jolla, CA 92093-7411

CORRESPONDENCE: Office: (858) 657-5267 (Administration) (858) 657-8530 (Clinical)

FAX: (858) 657-5028Home: (858) 794-7912E-mail: [email protected]

EDUCATION

1962 - 1966 Brooklyn College,Brooklyn, New York; B.A., 1966

1966 - 1970 Upstate Medical CenterSyracuse, New York; M.D., 1970

1970 - 1971 Internship, Internal MedicineGeorge Washington University HospitalWashington, DC(Chairman: Wallace N. Jensen, M.D.)

1973 - 1975 Resident in MedicineYale-New Haven HospitalNew Haven, Connecticut(Chairman: Samuel O. Thier, M.D.)

1975 - 1977 Postdoctoral Fellow in CardiologyUniversity of CaliforniaSan Francisco, California(Division Head: William W. Parmley, M.D.)

UNIVERSITY AND HOSPITAL STAFF APPOINTMENTS

1971 - 1973 Staff Associate, National InstituteHeart, Lung and BloodLipid Metabolism BranchNational Institutes of HealthBethesda, Maryland(Division Head: Robert I. Levy, M.D.)

1976 - 1977 Assistant Research Physician ICardiovascular Research InstituteSan Francisco, California

1977 - 1992 Director, Coronary Care UnitOregon Health Sciences UniversityPortland, Oregon

1977 - 1981 Assistant Professor of MedicineDivision of CardiologyOregon Health Sciences UniversityPortland, Oregon

1981 - 1986 Associate Professor of Medicine with TenureDivision of CardiologyOregon Health Sciences UniversityPortland, Oregon

1984 - 1985 Visiting ColleagueRespiratory UnitRoyal Postgraduate Medical SchoolHammersmith HospitalLondon, England(Director: Prof. Peter Barnes)

1987 - 1995 Professor of MedicineDivision of CardiologyOregon Health Sciences UniversityPortland, Oregon

1988 - 1995 Collaborating ScientistOregon Regional Primate Research CenterBeaverton, Oregon

1991 - 1992 Visiting ProfessorLaboratoire de Médicine ExpérimentaleCollege de FranceParis, France(Director: Prof. Pierre Corvol)

1995 - present Professor of MedicineUniversity of California, San DiegoSan Diego, California

2

1995 - 2005 Director, Heart Failure/Cardiac Transplantation Program

2004 - present Faculty Member of the Sam and Rose Stein Institute for Research on AgingUniversity of California, San Diego San Diego, California

2005 - present Director, Advanced Heart Failure Treatment ProgramUniversity of California, San DiegoSan Diego, California

MILITARY SERVICE

1971 - 1973 U.S. Public Health Service Assigned to the Lipid Metabolism Branch of the National Institutes of Health

Bethesda, Maryland

HONORS AND AWARDS

1962 - 1966 Recipient of New York State Regents' Scholarship1966 B.A., cum laude, Brooklyn College1976 - 1977 Bay Area Heart Association Research Fellowship1983 Elected to Western Society for Clinical Investigation1987 Elected to Western Association of Physicians1989 Elected to American Society of Pharmacology and Experimental

Therapeutics1993 - Present Chosen each year for inclusion in “The Best Doctors in America“2003 - 2007 Selected each year as one of the "The Best Doctors in San Diego"2010 Recipient of the “Passionate Heart Award” from the American Heart

Association, San Diego Chapter

LICENSUREOregon Medical License 10875 (1977 – 1995)California Medical License G029316 (1995 – present)California Fluoroscopy License 144556

CERTIFICATION

1971 National Board of Medical Examiners1975 American Board of Internal Medicine1977 American Board of Internal Medicine - Cardiovascular Disease2010 American Board of Internal Medicine – Advanced Heart Failure and Transplant Cardiology

PROFESSIONAL SOCIETIES

American Heart Association, Fellow of the Councils of Circulation, Clinical Cardiology, and ThrombosisFellow of the American College of Cardiology

3

Heart Failure Society of America (Founding Member)International Society for Heart and Lung TransplantationInternational Society for Heart Research, American SectionWestern Association of Physicians

RESEARCH SUPPORT

1978 - 1979 Principal Investigator: American Heart Association, Oregon Affiliate Grant: "Long term vasodilator therapy for chronic congestive heart failure". $10,000

1980 - 1981 Principal Investigator: American Heart Association, Oregon Affiliate Research Grant: "Long term vasodilator therapy of mitral regurgitation". $16,700

1981 - 1982 Principal Investigator: Medical Research Foundation of Oregon: "Does long term vasodilator therapy improve left ventricular performance in aortic insufficiency?" $9,700

1982 - 1986 Principal Investigator: NHLBI 1-R01-HL28146 "Long term vasodilator therapy in aortic insufficiency." Funded for total of $541,300 over 4 years.

1983 - 1984 Principal Investigator: American Heart Association, Oregon Affiliate Grant: "Isometric exercise in heart failure: Effects of vasodilators". $18,250

1985 - 1986 Principal Investigator: NHLBI-R01-28146-04S1 "Long term vasodilator therapy of aortic insufficiency (competitive supplement for year 04)". $173,166

1985 - 1992 Principal Investigator: NHLBI 84-21 "Studies of left ventricular dysfunction (SOLVD) - Clinical centers". Funded for total of $1,263,836.

1985 - 1986 Principal Investigator: American Heart Association, Oregon Affiliate Research Grant: "Effects of peptide mediators on coronary vasomotor tone". $25,950

1985 - 1986 Principal Investigator: Dant Foundation of Oregon Research Grant: "Establishment of a Vascular Pharmacology Laboratory". $8,900

1988 - 1989 Principal Investigator: American Heart Association, Oregon Affiliate Research Grant "Fish Oil Effects on Atherosclerotic Arteries". $30,000

1990 - 1991 Principal Investigator: Medical Research Foundation of Oregon: "EDRF activity in the microvasculature of an experimental model of heart failure." $17,000

1991 - 1992 Principal Investigator: NIH Fogarty International Fellowship: "Expression of vasoactive genes in heart failure". $48,000

1994 - 1995 Preceptor for Dr. Jay Ambrose: Research Fellowship award from the Oregon Affiliate of the American Heart Association “Sarcoplasmic reticulum ATPase and phospholamban gene expression in an experimental model of myocardial infarction”. $21,000

4

1994 - 1996 Preceptor for Dr. Jay Ambrose: Individual National Research Service Award Application from NIH: “Relaxation abnormalities and Gene Expression after MI”. $48,100

1999 – 2000 Principal Investigator: Merck & Company Investigation of the “Effect of Losartan on AT1 Receptor Upregulation in the Remodeling Heart”. $37,200

1999 – 2000 Principal Investigator: SmithKline Beecham Investigation of “Carvedilol”. $30,000

2000 – 2005 Principal Investigator: NHLBI RO1: "TNF regulation of the AT1 receptor and its role in post MI Fibrosis". $1,064,000

2001 – 2003 Mentor for Randy Cowling, Ph.D.: Western States Affiliate of the AHA Postdoctoral Fellowship “Molecular Mechanisms of Cytokine-Induced Upregulation of the AT1 Receptor in Cardiac Fibroblasts.”

2003 – 2005 Principal Investigator: Novartis -Enoxaparin Treatment Post-Myocardial Infarction Inhibits Extra-Cellular Matrix Deposition and Improves Survival. $99,782

2004 – 2006 Mentor for Michikado Iwata, MD: Western States Affiliate of the AHA Postdoctoral Fellowship “Role of Angiotensin – Converted Enzyme 2 and Angiotensin –(1-7) in Cardiac Remodeling After Myocardial Infarction.”

2004 – 2006 Mentor for Xaiowei Zhang, MD: Western States Affiliate of the AHA Postdoctoral Fellowship “Integrins Modulate Cardiac Fibroblast Functions Related to Post-MI Extra-Cellular Matrix Remodeling.”

2005 – Present Co-Investigator: NIA/UCSD - QOL Health Measurement in Patients - Tracking Clinical Outcomes

2005 – 2008 Co-Investigator: 1R21HL080358-01: “Development of Mouse Model to Study Fibroblast Functions”. $424,440.00.

2005 – 2009 Co-Investigator: 1R01HL073355-01A1: “BNP and Neuroimmune Characteristics of CHF and Depression”. $3,008,179.00

2007 – 2010 Co-Investigator: AHA Grant-In-Aid: “Regulation of Ectodomain Cleavage of Angiotensin converting Enzyme 2 and HS Role in Cardiac Remodeling”.

2010 – 2014 Co-Investigator: 1 RO1 HL096784-01A2; “Exploring Tai Chi as a Behavioral Intervention for Heart Failure Patients” $1,926,890.

2009 – 2013 Principal Investigator: I RO1HL091191: “The Mas Receptor is required for the Favorable Effects of Ang-1(1-7) on Cardiac Remodeling”. $1,789,625.

2010 – 2015 Co-Investigator: 5 R01 HL073355-06. “BNP and Neuroimmune Characteristics of CHF and Depression” $2,434,000

2010 – 2015 Co-Investigator: 1 R01 HS019311-01 “Variations in Care: Comparing Heart

Failure Care Transition Intervention Effects”

5

CURRENT UCSD CONTRACT SUPPORT

2005 – 2009 Principal Investigator: Merck & Co. – PROTECT A Randomized, Double-Blind, Placebo-Controlled Study of the Effects of KW-3902IV in Maintaining Renal Function and Improving the Clinical Outcome of Patients with Congestive Heart Failure and Renal Impairment Who Require Hospital Treatment with Intravenous Loop Diuretics for Fluid Overload.

2006 – Present Principal Investigator: Celladon Corporation - A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Trial of Intercoronary Administration of MYDICAR™ (AAV1/SERCA2a) in Subjects with Heart Failure.

2006 – Present Principal Investigator: Celladon Corporation – Assessment of Antibodies to Adeno-Associated Vector Type 1 in Patients with Heart Failure.

2006 – Present Co-Investigator: Amgen – A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia.

2006 – Present Principal Investigator: Cardiodynamics – Performance Characterization of the BioZ Dx device in Subjects with Cardiac Resynchronization Therapy Devices. Version 1

2006 – Present Co-Investigator: Cardiokine – Lixivaptan versus Placebo in the Treatment of Hyponatremia: A Randomized, Double Blind Trial in Patients with Heart Failure and Volume Overload.

2007 – Present Principal Investigator: Scios – Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF) Protocol No. A 093

2007 – Present Principal Investigator: Cardiodynamics – Prevention of Heart Failure Events with Impedance Cardiography Testing (PREVENT – HF)

2007 – 2009 Principal Investigator: Bayer – Placebo Controlled, randomized, double-blind, Multi-center, multinational Phase IIb study to investigate the efficacy and tolerability of BAY 58-2667 given intravenously in patients with decompensated chronic congestive heart failure. Bay58-2667/12480

2007 – Present Principal Investigator: Corventis – Multi-sensor Monitoring in Congestive Heart Failure Patients.

2008 – 2009 Principal Investigator: Johnson and Johnson – A Randomized, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Rivaroxaban in Subjects with Acute (Open-Label, Active-Controlled) or Chronic (Double-Blind, Placebo-Controlled) Congestive Heart Failure RIVAROXHFA1101/BAY 59-7939-12980

6

2008 – 2009 Principal Investigator: Cytokinetics – A Phase II, Multi Center, Double Blind, Randomized, Placebo-Controlled, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of CK-1827452 in Patients with Stable Heart Failure.

2008 – Present Principal Investigator: Biogen Idec – A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study to Assess The Effects of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated Heart Failure and Renal Insufficiency.

2008 – Present Principal Investigator: Biogen Idec – A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study to Assess the Safety and Tolerability of Oral BG9928 in Patients with Heart Failure and Renal Insufficiency.

2008 – Present Principal Investigator: Nile Therapeutics – A Multicenter, Randomized, Placebo Controlled Phase 2B Study Assessing the Safety and Efficacy of Early Administration of Intravenous SD-NP versus Placebo in the Treatment of Patients with Acute Decompensated Heart Failure (ADHF) – CONDITION HF TRAIL

2008 – Present Principal Investigator: Corthera – A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure

2009 – Present Principal Investigator: Johnson and Johnson – A Double-Blind, Placebo-Controlled, Randomized, Ascending IV Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Stresscopin (JNJ-39588146) in Healthy Subjects and Subjects with Stable Heart Failure.

TRAINEES SUPERVISED

1982-83 David Broudy, M.D. - Fellow in Cardiology1987-89 Howard Lewis, M.D. - Fellow in Cardiology1988-91 Michael Ontkean, D.O. - Fellow in Cardiology1989-90 Kishor Vora, M.D. - Research Fellow in Heart Failure/Transplantation1990-91 Ayokunle Oni, M.D. - Research Fellow in Heart Failure/Transplantation1993 Dana Bowron - Minority High School Research Apprenticeship Program1994-97 Jay Ambrose, M.D. - Fellow in Cardiology1997-98 Johannes Kuiper, M.D. - Fellow in Cardiology1998 Tina Reyes - Independent Study Project (ISP) for UCSD School of Medicine1998-99 Juan Alverge – UCSD Undergraduate Independent Research Study Project (BISP)

Preceptor1998-2004 Randy Cowling, Ph.D. - Post-Doctoral Fellow & as of 2000, Postgraduate

Researcher 1999-2001 Jian Peng, M.D., Ph.D. – Post-Doctoral Fellow & as of 2000, Postgraduate

Researcher1999-2002 Eduardo Fricovsky – Undergraduate Independent Study Course Work & Research

Assistant in NIH Minority Biochemical Research Support Program (MBRS)2000-2001 John Kjekshus, MD – Visiting Scholar (Sabbatical from Oslo University)2001-2003 Melanie Reyes – UCSD Undergraduate

7

2002-Present Michikado Iwata, M.D. – Post-Doctoral Fellow2002-2005 Xiaowei Zhang, M.D., Ph.D. – Postgraduate Researcher2002-2004 Ottar Lunde, MD – Visiting Scholar2002-2004 Alexander Adler, MD – Heart Failure Cardiology Fellow2004 Vanessa Reese – Brown University Undergraduate for UCSD Medical Scientist

Training Program (MSTP) Summer Undergraduate Research Fellowship (SURF)2004-2005 Myung-A Kim, M.D., Ph.D. – Postgraduate Researcher2005 Agyenim Amoako – Delaware State University Undergraduate for Summer

Undergraduate Research Fellowship (SURF). UCSD Medical Scientist Training Program (MSTP)

2005-2006 Dawn Lombado M.D.-Heart Failure Cardiology Fellow2005-2007 Reza Kermani – Independent Study Project (ISP) for UCSD School of Medicine

(MED 296)2005 John Kjekshus, MD – Visiting Scholar (Sabbatical from Oslo University)2007-2008 Keisuke Kida, MD – Post graduate researcher 2008-present Dongheon Yang MD, Ph.D. – Visiting Scholar 2008-present Mi Hyang Kwak , MD, Ph.D., – Visiting Scholar 2010 Ali Evans, Summer Undergraduate Research Fellowship (SURF). UCSD Medical Scientist Training Program (MTSP).2010-2011 Payman Zamani MD – Heart Failure Cardiology Fellow2011-2012 Sami Alim, MD – Heart Failure Cardiology Fellow

CURRENT EDITORIAL BOARDS

Circulation Journal (International Associate Editor 2010 - present)Congestive Heart Failure (Senior Editor 1995 - present)Critical Pathways in Cardiology (2008 – present)European Journal of Heart Failure (2005 - present)Cardiology Today (2008-present)US Cardiology (2008-present)Journal of Geriatric Cardiology (2010-present)Journal of the American College of Cardiology (Associate Editor 2002 - present)Journal of the American College of Cardiology (Focus Issue Editor for Quarterly Heart Failure Focus Issues 2009 - present)

PREVIOUS EDITORIAL BOARDS

American College of Cardiology Current Journal Review (Assistant Editor 1998-2002)Journal of the American College of Cardiology (1995-1999)Journal of Cardiac Failure (1998-2004)Journal of Heart DiseaseJournal of Heart and Lung Transplantation (Senior Editor 1994-1999)

INVITED EDITORSHIPS

Section Editor, Current Cardiology Reports “Epidemiology and Pathophysiology of Heart Failure” 4:185-212, May 2002

Guest Editor, Congestive Heart Failure “Neurohormonal Blockade in the Treatment of Heart Failure: Where Do We Go From Here?” 8:245-280, September/October 2002.

8

Section Editor, Current Cardiology Reports “Epidemiology and Pathophysiology of Heart Failure” 5:181-210, May 2003

Section Editor, Current Treatment Options in Cardiovascular Medicine, “Heart Failure” 5:301-343, August 2003.

Section Editor, Current Treatment Options in Cardiovascular Medicine, “Heart Failure” 5:305-343, August 2004

JOURNAL REFEREE

American Heart JournalAmerican Journal of CardiologyAmerican Journal of PhysiologyAnnals of Internal MedicineChestCirculationCirculation ResearchDrugsEuropean Journal of Clinical InvestigationJournal of the American College of CardiologyJournal of Cardiovascular PharmacologyJournal of Clinical InvestigationJournal of Heart and Lung TransplantationProceedings of the Society for Experimental Biology and MedicineWestern Journal of Medicine

ABSTRACT REVIEWER FOR ANNUAL SCIENTIFIC SESSIONS

American Heart AssociationAmerican College of CardiologyHeart Failure Society of America

COMMITTEE PARTICIPATION AND OTHER ACTIVITIES (UCSD)

CME Dean’s Advisory Committee (1995-present)UCSD Combined Thoracic Organ Transplant Committee (1995-present)Division of Cardiology Fellowship Applicant Selection Committee (1995-present)Division of Cardiology Quality Assurance Committee (1995 – present)Department of Medicine Committee on Appointments and Promotions (DOMCAP) Member (1996-2003)

Chair (1999-2001)Immediate Past Chair (2001-2003)

Ad hoc DOMCAP Committee member (2009)School of Medicine Ad Hoc Committee on Appointments and Promotions (CAP)

Chair, Ad Hoc Committee on Appointments and Promotions (June, 1997, March, 2001)Chair, UCSD School of Medicine Committee for Review of Radiology Department Leadership (May 2012)Subcommittee on Contracting of the Board of Governor's Finance Committee (1998-2001)

9

Chair, UCSD Heart Failure Task Force (1999 – present)Cardiology Liaison, UCSD Medical Student Independent Study Project (2005 – present)Planning Committee for the La Jolla-Yamaguchi-Rome-Seoul Cardiovascular Research Meeting (2009 – present)Ad hoc committee for recruitment physician-scientists and academically oriented physicians into the UCSD cardiology fellowship program (2009 – present)

LEADERSHIP ON NATIONAL COMMITTEES

NHLBI Special Study Section for Cardiovascular Disease (1983)Ad Hoc Reviewer American Heart Association, Arizona Affiliate (1985 - Present)Ad Hoc Reviewer for VA Merit Review Board of Cardiovascular Studies (1988 - Present)Councilor of the Western Association of Physicians (1992 - 1994)Heart Failure Society of America (HFSA):

- Founding Member (1994)- Executive Council (1995 – Present)- Treasurer (2000 – 2002)- Chair, Heart Failure Awareness Ad Hoc Committee (2001-2003)- Chair, Advocacy Committee (2008 – Present)- Secretary (2002 - 2004)- Chair, Education Committee (2003 – 2006)- Vice President (2004-2006)- President (2006-2008)- Immediate Past President (2008-2010)- Co-Chair, Strategic Planning Retreat (2008)- Chair, Nominating Committee (2008 – present)- Chair, Advocacy Committee (2008 – present) - Program Director, Board Review Course for the Advanced Heart Failure and Cardiac

Transplantation Certification Examination (2009 – present).- Chair, Ad Hoc Development Committee (2010- present)

National Advisory Board for Oregon Medical Systems, Inc. (1996 - 1999)Board of Directors of the Advisory Council to Improve Outcomes Nationwide in Heart Failure ACTION-HF (1996 - 2000)Program Committee for the 1999 Annual Scientific Sessions for the International Society of Heart Research (ISHR)Planning Committee for the American Heart Association Western States Affiliate 69 th Annual Fall

Symposium (2001)American College of Cardiology

- Counselor, California Chapter (2005 – Present)- Advocacy Committee (2008 - Present)- Hospital to Home (H2H) Advisory Committee (2009)- Hospital to Home (H2H) Steering Committee (2009 – Present)

RESEARCH STUDY/EXECUTIVE STEERING COMMITTEES

Steering Committee for NHLBI Studies of Left Ventricular Dysfunction (SOLVD; 1985 - 1992)- Publications and Sub-study Committee (Co-Chair; 1985 - 1992)

Steering Committee for NHLBI/VA Beta-Blocker Evaluation of Survival Trial (BEST)(1993 - 2000)

10

Steering Committee for Ro 40-5967 mortality study (MACH-1) in patients with heart failure (1993 - 1999)

Chair, Safety Monitoring Committee for Ibopamine trial in patients with moderate congestive heartfailure (1994 - 1996)

Executive Steering Committee for Vesnarinone Trial (VEST) in heart failure (1994 - 1997)ELITE II Regional Oversite Committee (1997 - 2000)Regional U.S. Leader CHARM (Candesartan in Heart Failure Assessment of Reduction in

Mortality and Morbidity)(1998 – 2005)Data Safety Monitoring Board member for ENABLE-2 study (Endothelin Antagonist Bosentan for

Lowering Cardiac events in Heart Failure (1998 - 2002)Scientific Advisory Council for COHERE National Registry in Heart Failure (1998 – 2008)Steering Committee for Multiple Center Double Blind Placebo Controlled Trial to Evaluate the

Effect of Extended Release Metoprolol Succinate (TOPROL-XL) on Cardiac Remodeling in Asymptomatic Patients (NYHA Class I) with LV Dysfunction (2000-2008)

Data Safety Monitoring Board for MY-022 study of “Oral Enoximone in Intravenous Inotrope – Dependent Subjects (EMOTE)” (2000 – 2004)

Data Safety Monitoring Board for “A Randomized, Double-Blind, Placebo-Controlled, Multi-center, Parallel-Arm Study to Assess the Long Term Effects of Pletal (Cilostazol) versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease”(2001 – 2004)

Steering Committee for STAMINA-HeFT – A Double-blind, Randomized, Placebo-Controlled, Multi-center Study to Assess Darbepoetin Alpha Treatment on Exercise Tolerance in Subjects with Symptomatic Congestive Heart Failure and Anemia (2001 – 2007)

Steering Committee for VASOGEN Study of Immunomodulation Therapy in Heart Failure (2002-2008)

Steering Committee for Organized Program to Initiate Life-saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) (2002 – 2008)

Data Safety Monitoring Board for the VERITAS Study of Tezosentan in Acute Heart Failure (2002 – 2008)

Data Safety Monitoring Board for the “Multi-center, Randomized, Double-Blind, Placebo-Controlled, Efficacy Study on the Effects of Oral Tolvaptan on Left Ventricular Dilatation and Function in Patients with Heart Failure and Left Ventricular Systolic Dysfunction-METEOR TRIAL”.(2002 – 2005)

Steering Committee for REVIVE Trial – A Randomized, Double Blind, Multicenter, Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patients with Left Ventricular Systolic Dysfunction (EF < 35%) and Mild to Moderate Heart Failure (2004 – 2007)

Independent Data Monitoring Committee for EVEREST Trial – A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure (2004 – 2008)

National Principle Investigator for MOMENTUM Trial - A Multicenter Trial of the Orqis Medical CRS for the Enhanced Treatment of CHF Unresponsive to Medical Therapy. (2004 – 2008)

Treatment of Preserved Cardiac Function Heart Failure With An Aldosterone Antagonist (TOPCAT) Sponsored by the NHLBI

-Chair, NHLBI Study section to select coordinating center (2004)-Member, Protocol Review Committee (2005)-Member, Data Safety Monitoring Board (2005 – present)

National Principal Investigator – “A Multicenter, Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Ejection Fraction in Subjects with Stable Chronic Heart Failure” (2005 – 2008)

11

International Steering Committee for the Guidant-Narrow QRS Pivotal Study (2006 – 2008). Chair, Data Safety Monitoring Board, Paracor Heart Failure Trial (2005 – 2010) Chair, Data Safety Monitoring Board for Homeostasis II Trial (2006 – 2011) Chair, Data Safety Monitoring Board for Tezosentan/Cardiac Surgery Trial (2006 – 2008)Member, Steering Committee for the POSEIDEN Trial: A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral BG9928 in Patients with Heart Failure and Renal Insufficiency (2007 – 2009).Member, Independent Data Monitoring Committee for the MARVEL study – A Phase II, Double- Blind, Randomized, Controlled Multicenter Cross-Over Study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in CHF Patients Post-MI (2008-2010).Chair, Data Safety Monitoring Board for the CRT Based Heart Failure Monitoring Study (zLAP) (2008-present).Member, Data Safety Monitoring Board for CHAMPION: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III heart failure patients (2008-present).Chair, Safety Review Committee for TolerabIility and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 in Patients with Ischemic Cardiomyopathy and Angina. (2008).Chair, DSMB of REstore physiological Sleep with an Orexin Receptor Antagonis Almorexant Phase III Studies (RESTORA) (2008-2010)Member, Executive Committee Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects with Acute Heart Failure (RELAX-AHF) (2008- Present)Member, DSMB for the NHLBI Heart Failure Network (HFN) Clinical Trials (2008 – Present).Chair, DSMB of the GRIPHON study- A muhicenter, doublehind, placebo-controlled Phase 3 study to demonstrate the safety and efficacy of ACT-293987 in patients with pulmonary artery hypertension (2010- present).Chair, DSMB of the LAPTOP study “Left Artrial Pressure Monitoring to Optimize Heart Failure therapy study”. (2010-present).Member, DSMB for AMG 423 20100754 trial (ATOMIC-HF) of Omecativ Micarbil to Improve Contractility in Acute Heart Failure (2011 – present).Chair, Executive Steering for study of Neuregulin in the treatment of heart failure (2009 – present).

OTHER ACTIVITIES

Program Chairman for Continuing Medical Education Course, Portland, Oregon: "Exercise and fitness", June 24, 1983

31st Annual Scientific Session of the American College of Cardiology Panel Discussion: "Vasodilator therapy of congestive heart failure", Atlanta, Georgia, April 27, 1982

32nd Annual Scientific Session of the American College of Cardiology, Luncheon Panel Participant: "Does vasodilator treatment prolong life in patients with congestive heart failure?", March 21, 1983

32nd Annual Scientific Session of the American College of Cardiology, Meet the Experts: "Vasodilator treatment of valvular regurgitation", March 21, 1983

12

56th Annual Scientific Session of the American Heart Association, Anaheim, California: Co-chairman for session on "Valvular disease", Nov. 17, 1983

33rd Annual Scientific Sessions of the American College of Cardiology. Meet the Experts, "Vasodilators in congestive heart failure and valvular heart disease", Dallas, Texas, March 27, 1984

33rd Annual Scientific Sessions of the American College of Cardiology: Chairman, Panel Discussion "Should vasodilator drugs be given prophylactically to patients with valvular regurgitation", Dallas, Texas, March 26, 1984

Program Chairman for Continuing Medical Education Course on "Exercise and cardiovascular fitness", Portland, Oregon, June 22-23, 1984

Program Chairman for Continuing Medical Education Course on "Current approaches to the treatment of hypertension", Portland, Oregon, Sept. 14, 1989

Program Chairman for Continuing Medical Education Course on "Heart Failure: Current and future strategies for management", sponsored by the Oregon Health Sciences University, Portland, OR, Oct. 17, 1991

Program Chairman for the Portland Heart Failure Club 1992-1995

Program Chairman for UCSD CME Symposium on “Heart Failure in 1995: New Paradigms and prospects for a common syndrome”, San Diego, California, June 3, 1995

Program Chairman for Joint UCSD-Brazilian Society of Cardiology Symposium on “Focus on the pathogenesis, prevention and treatment of heart failure: A Pan-American perspective”, La Jolla, CA,November 17, 1995

Co-Chairman of meeting: “Presentation of the Results of the EDEN STUDY”, Madrid, Spain,November 7, 1995

Program Chairman for 2nd Annual UCSD CME Symposium on “Heart Failure in 1996: New Insights into Pathogenesis and Treatment”, La Jolla, CA, June 1, 1996

Moderator for session on "Clinical Aspects of Cardiomyopathy: at 69th Scientific Sessions of the AHA", New Orleans, November 12, 1996

48th Annual Scientific Session of the American College of Cardiology: Luncheon

Panel Participant “Left ventricular diastolic function and failure”, Anaheim, CA,March 18, 1997

Program Chairman for 3rd Annual UCSD CME Symposium: “Heart Failure 1997”, La Jolla, CA, June 7, 1997

Symposia Moderator: "Patient Management Issues in Heart Failure" at the 1st Scientific Meeting of the Heart Failure Society of America, Baltimore, MD, Sept. 1997

Moderator for session on "Angiotensin Converting Enzyme Inhibitors in Heart Failure-II", Orlando, Florida, November 12, 1997

13

Founder and Program Chairman for the San Diego Heart Failure Club from 1995 - Present.

Chair, "Clinical Horizons in Heart Failure" session: The Sixth Antwerp-La Jolla-Kyoto Research Conference on Cardiac Function, La Jolla, CA, April 27, 1998

Program Director for 4th Annual UCSD CME Heart Failure Symposium "Heart Failure 1998", La Jolla, CA, June 20, 1998

Program Chair, "New Frontiers in the Management of Heart Failure": Satellite Session of the 2nd Scientific Meeting of the Heart Failure Society of America, Sept. 13, 1998

Moderator for a 3-part interactive case management program at the 2nd Scientific Meeting of the HFSA, "Heart Failure Practice Guidelines: Refining the Role of Beta-Blockade", Boca Raton, Florida, Sept. 14-16, 1998

Moderator for Debates Session at the 2nd Scientific Meeting of the Heart Failure Society of America, Boca Raton, Florida, Sept. 14, 1998

Moderator for Plenary Session “Drug Therapy in Cardiac Failure”. 1st International Congress on Heart Disease, Washington, DC, May 19, 1999

Program Chairman for 5th Annual UCSD CME Symposium “Heart Failure 1999: New Advances on Treatment”, La Jolla, CA, June 12, 1999

Moderator for Plenary Session on “Remodeling and Its Reversal in Heart Failure”. 3rd Annual Scientific Sessions of the Heart Failure Society of America. San Francisco, CA. Sept. 23, 1999

Program Director for UCSD CME Symposium “Heart Failure for the Primary Care Physician”. San Diego, CA. Feb 12, 2000

Participant in Luncheon Panel at the 49th Annual Scientific Session of the American College of Cardiology. “End-Stage Congestive Heart Failure.” Anaheim, CA. March 13, 2000

Participant in symposium. “Is it possible to prevent heart failure? Reviewing the evidence” at the 49th Annual Scientific Session of the American College of Cardiology. Anaheim, CA. March 13, 2000

Program Director for 6th Annual UCSD CME Symposium “Heart Failure in the New Millennium”. La Jolla, CA. June 17, 2000

4th Scientific Meeting of the Heart Failure Society of America: 1) Moderator for Symposium “Novel Approaches to the Prevention or Reversal of

Remodeling.2) Judge for Young Investigators Award.3) Chair for Satellite Symposium “Acute Heart Failure: Parameters for Approval/Use of a

New Agent”.Boca Raton, Florida. September 10-13, 2000

Program Director for 2nd Annual UCSD CME Symposium “Heart Failure for the Primary Care Physician”. San Diego, CA. Feb 10, 2001

14

Program Director for the 7th Annual UCSD CME Symposium “Heart Failure”. La Jolla, CA. May 25, 2001

Faculty Mentor in the University of California Leadership Excellence through Advanced Degrees (UC LEADS) 2000-2001

Moderator for Featured Research Session “Pharmacological Mechanisms in Heart Failure” at the 2001 Scientific Sessions of the American Heart Association. Anaheim, CA. November 12, 2001

Program Director for the 1st Annual HFSA Heart Failure Symposium for the Primary Care Physician. La Jolla, CA. February 9, 2002

Chair, Panel Session on “Heart Failure Disease Management Programs” at the 51st Annual Scientific Session of the American College of Cardiology. Atlanta, GA. March 20, 2002

Program Director for 8th Annual UCSD CME Heart Failure Symposium "Heart Failure 2002", La Jolla, CA, May 25, 2002

Scientific Committee for the La Jolla-Rome-Yamaguchi Research Conference on Cardiac Function. “Therapeutic Horizons in Heart Failure”, December 6-8, 2002

Chair, Panel Session on “New Therapeutic Approaches to Myocardial Failure” at the La Jolla-Rome-Yamaguchi Research Conference on Cardiac Function. “Therapeutic Horizons in Heart Failure, December 7th, 2002

Program Director for the 2nd Annual HFSA Heart Failure Symposium for the Primary Care Physician. New Orleans, LA. February 1, 2003

Program Director for 3rd Annual UCSD CME Symposium “Heart Failure for the Primary Care Physician”. San Diego, CA. February 8, 2003

Program Director for 9th Annual UCSD CME Symposium “Advances & Recognition in the Treatment of Heart Failure”. La Jolla, CA. May 3, 2003

Program Director for the 4th Annual UCSD CME Symposium “Heart Failure for the Primary Care Physician”. San Diego, CA. January 31, 2004

Program Director for the 3rd Annual HFSA Heart Failure Symposium for Primary Care Physician. Dallas, TX. February 7, 2004

Panelist for the California Heart Disease and Stroke Prevention Program Public Forum. San Diego, CA. March 25, 2004

Program Chair for the SCAI Symposium, “Evolution of LVD Management in the Post-MI Patient: Medical and Device Considerations”. San Diego, CA. April 29, 2004

Program Director for 10th Annual UCSD CME Symposium “Advances & Recognition in the Treatment of Heart Failure”. La Jolla, CA. May 8, 2004

Moderator for Featured Research Session “New Developments in the Renin/Angiotensin/Aldosterone System in Heart Failure: Reconciling the Basic with the Clinical Trials” at the 8th Annual Heart Failure Society of America Annual Meeting, Toronto, Ontario, Canada. September 15, 2004

15

Program Presenter, “How to Treat Advanced Heart Failure” How To Session at the Annual American Heart Association Scientific Sessions, New Orleans, Louisiana. November 10, 2004

Program Director 5th Annual UCSD CME Symposium “Heart Failure for the Primary Care Physician” San Diego, CA. February 5, 2005

Program Director for “Heart Failure 2005: Update for the Primary Care Physician.” Heart Failure Society of America. Sacramento, CA. February 12, 2005

Program Chair for “Management of Left Ventricular Dysfunction in the Post-MI Patient: Medical and Device Aspects.” SCAI Annual Scientific Sessions. Jacksonville, FL. May 6, 2005

Program Director 11th Annual UCSD CME Symposium “Advances & Recognition in the Treatment of Heart Failure” La Jolla, CA. June 11, 2005

Program Director Heart Failure Society of America 5th Annual Primary Care Symposium “Update for the Primary Care Physician” La Jolla, CA. February 5, 2005

Program Director 6th Annual UCSD CME Symposium “Heart Failure for Primary Care Physicians”La Jolla, CA. February 4, 2006

Program Director for the Heart Failure Society’s 6th Annual Primary Care Symposium. Houston, TX. February 11, 2006

Program Director for the 12th Annual San Diego Heart Failure Symposium. La Jolla, CA June 3, 2006

Program Director for UCSD 7th Annual Heart Failure Symposium for Internists and Primary Care Physicians. San Diego, CA. February 3, 2007

Program Director for the 13th Annual San Diego Heart Failure Symposium. La Jolla, CA May 5, 2007

Program Director for UCSD 8th Annual Heart Failure Symposium for Internists and Primary Care Physicians. San Diego, CA. January 19, 2008

Program Director for the 14th Annual San Diego Heart Failure Symposium. La Jolla, CA. May 3, 2008

Program Director for the 9th Annual UCSD Heart Failure and Hypertension Symposium for Primary Care and Internal Medicine Physicians. La Jolla, CA. January 17, 2009

Program Director for the 15th Annual San Diego Heart Failure Symposium. La Jolla, CA. June 13, 2009

Program Co-Director for the 1st Annual UCSD State of the Art Cardiovascular Medicine Conference. San Diego, CA, October 9 – 11, 2009

Program Director for the 10th Annual UCSD Heart Failure and Hypertension symposium for Primary care and Internal Medicine Physicians. La Jolla, CA. January 16, 2010

16

Program Director for the 16th Annual San Diego Heart Failure Symposium. La Jolla, CA May 5, 2010

Program Director for the Heart Failure Society of America Board Review Course: Advanced Heart Failure and Transplant Cardiology. Minneapolis, MN. October 1-3, 2010

Program Director for the 11th Annual UCSD Heart Failure Symposium for Primary Care and Internal Medicine Physicians. La Jolla, CA. February 5, 2011

Scientific Planning Committee for the 13th Annual La Jolla-International Cardiovascular Research Conference “Emerging Molecular and Cellular Insights into Heart Failure and Arrhythmias” March 11-13, 2011. La Jolla, CA

Program Director for the 17th Annual San Diego Heart Failure Symposium “Advances in the Recognition & Treatment of Heart Failure” La Jolla, CA. June 25, 2011

Program Director for the Heart Failure Society of America Annual Heart Failure Review Course Chicago, IL. October 20-23, 2011

Program Director for The 1st Annual International Hawaii Symposium on Diagnostic and Therapeutic Modalities in Heart Failure, Kohala Coast, HI. December 1-3, 2011.

Program Director for the 12th Annual UCSD Heart Failure Symposium for Primary Care and Internal Medicine Physicians. La Jolla, CA. February 11, 2012.

Program Director for the 18th Annual San Diego Heart Failure Symposium “Advances in the Recognition & Treatment of Heart Failure” La Jolla, CA. June 2, 2012

Program Director for the Heart Failure Society of America Board Review Course: Advanced Heart Failure and Transplant Cardiology. Minneapolis, MN. September 27-30, 2012

BIBLIOGRAPHY

A. PUBLISHED

1. Chatterjee K, Parmley WW, Massie B, Greenberg BH, Werner J, Klausner S, Norman A. Oral hydralazine therapy for chronic refractory heart failure. Circulation 54: 879-883, 1976.

2. Greenberg BH, Blackwelder W, Levy RI. Primary type V hyperlipoproteinemia. Ann Intern Med 87: 526-534, 1977.

3. Greenberg BH, Chatterjee K, Hoffman P, Miller M, Schiller N. Sudden death in infective endocarditis. Chest 71: 794-795, 1977.

4. Massie B, Chatterjee K, Werner J, Greenberg BH, Hart R, Parmley WW. Hemodynamic advantages of combined oral hydralazine and non-parenteral nitrates in vasodilator therapy of chronic heart failure. Am J Cardiol 40: 794, 1977.

5. Greenberg BH, Botvinick EH, Shames DH, Hart R, Werner JA, Brundage BH, Chatterjee K, Parmley WW. Thallium 201 myocardial perfusion scintigraphy for the evaluation of post coronary bypass patients. Am J Cardiol 42: 167-176, 1977.

17

6. Greenberg BH, Massie BM, Brundage BH, Botvinick EH, Parmley WW. Beneficial effects of hydralazine in severe mitral regurgitation. Circulation 58: 273-279, 1977.

7. Massie BM, Botvinick EH, Brundage BH, Greenberg BH, Shames D, Gelberg H. Relationship of regional myocardial perfusion to segmental wall motion: A physiologic basis for understanding the presence and reversibility of asynergy. Circulation 58: 1154-1163, 1978.

8. Greenberg BH, Chatterjee K, Parmley WW, Werner JA, Norman A. The influence of filling pressure on atrial contribution to cardiac output. Am Heart J 98: 742-751, 1979.

9. Greenberg BH, Drew D, Werner J, Botvinick E, Shames D. Evaluation of Left Ventricular Volume, Ejection Fraction and Segmental Wall Motion by Gated Radionuclide Angiography. Clin Nucl Med 5: 245, 1980.

10. Greenberg BH, Smith N, Clark DG, Rahimtoola SH. Results of aortic valve replacement in patients with aortic stenosis and aortic incompetence and impaired left ventricular function. Coeur 1: 441-457, 1980.

11. Greenberg BH, Massie B. Beneficial effects of after load reduction therapy in patients with congestive heart failure and moderate aortic stenosis. Circulation 61: 1212-1216, 1980.

12. Greenberg BH, DeMots H, Murphy E, Rahimtoola SH. Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency. Circulation 62: 49-55, 1980.

13. Greenberg BH, Rahimtoola SH. Long term vasodilator therapy in aortic insufficiency. Evidence for regression of left ventricular dilation and hypertrophy and improved systolic pump function. Ann Intern Med 93: 440-442, 1980.

14. Greenberg BH, DeMots H, Murphy E, Rahimtoola SH. Mechanism for improved cardiac performance with arteriolar dilators in aortic insufficiency. Circulation 63: 263-268, 1981.

15. Greves J, Rahimtoola SH, McAnulty JH, DeMots H, Clark DG, Greenberg BH, Starr A. Preoperative criteria predictive of late survival following valve replacement for severe aortic regurgitation. Am Heart J 101: 300-308, 1981.

16. Greenberg BH, Rahimtoola SH. Vasodilator therapy for valvular heart disease. JAMA 246(3): 269-272, 1981.

17. Walsh WF, Greenberg BH. Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation 64: 499-505, 1981.

18. Greenberg BH. Hydralazine therapy in aortic insufficiency. Primary Cardiol 8: 35-43, 1982.

19. Strauss WE, McIntyre KM, Parisi AF, Shapiro W and Investigators (including B Greenberg).

Safety and Efficacy Safety and Efficacy of Diltiazem HCL for the treatment of stable angina pectoris. Report of a cooperative clinical trial. Am J Cardiol 49(3): 560-566, 1982.

18

20. Greenberg BH, DeMots H, Murphy E, Rahimtoola SH. Effects of arterial dilation on cardiac performance during rest and exercise in patients with mitral regurgitation. Circulation 65: 181-185, 1982.

21. Greenberg BH, Schutz R, Grunkemeier GL, Griswold HE. Acute effects of alcohol in patients with congestive heart failure. Ann Intern Med 97: 171, 1982.

22. Packer M, Greenberg BH, Massie B, Dash H. Deleterious effects of hydralazine in patients with pulmonary hypertension. N Engl J Med 306: 1326-1331, 1982.

23. Hosenpud JD, Greenberg BH. The preoperative evaluation in patients with endocarditis: Is cardiac catheterization necessary? Chest 84: 690-694, 1983.

24. Greenberg BH. Vasodilator therapy of mitral regurgitation. Primary Cardiol 10: 155-175, 1984.

25. Greenberg BH, Rahimtoola SH. Usefulness of vasodilator therapy in acute and chronic valvular regurgitation. Curr Prob Cardiol 9: 1-46, 1984.

26. Massie BM, Kramer BL, Loge D, Topic N, Greenberg BH, Cheitlin MD, Bristow JD, Byrd R. The ejection fraction response to exercise in asymptomatic aortic regurgitation: Relationship to simultaneous hemodynamic measurements. J Am Coll Cardiol 5: 847-855, 1985.

27. Greenberg BH, Massie B, Bristow JD, Cheitlin M, Thomas D, Broudy D, Kramer B, Krishnamurthy G. Association between the exercise ejection fraction response and systolic wall stress in patients with chronic aortic insufficiency. Circulation 71: 458-465, 1985.

28. Greenberg BH. The role of vasodilators in patients who have valvular regurgitation. Consultant 25: 191-224, 1985.

29. Karaian CH, Greenberg BH, Rahimtoola SH. The relationship between functional class and cardiac performance in patients with chronic aortic insufficiency. Chest 88: 533-537, 1985.

30. Szlachcic J, Massie BM, Greenberg BH, Thomas D, Cheitlin M, Bristow JD. Inter-test variability of echocardiographic and chest x-ray measurements: Implications for decision making in patients with aortic regurgitation. J Am Coll Cardiol 7: 1310-1317, 1986.

31. Siemienczuk D, Greenberg BH, Broudy D. Improved cardiac performance following meal ingestion in patients with congestive heart failure. Chest 90: 193-197, 1986.

32. Barnes PJ, Cadieux A, Carstairs JR, Greenberg B, Polak JM, Rhoden K. VIP in bovine pulmonary artery: Localization, function and receptor autoradiography. Br J Pharm 89: 157-162, 1986.

33. Solu-Medrol A.M.I. Studies Group. (B. Greenberg, Co-investigator) Methylprednisolone as an intervention following myocardial infarction. J Int Med Res 14 (Suppl. 6): 1-10, 1986.

34. Greenberg B, Rhoden K, Barnes P. Activated oxygen species generated by electrical field stimulation affects vascular smooth muscle. J Mol Cell Cardiol 18: 975-981, 1986.

19

35. Greenberg B, Rhoden K, Barnes P. Endothelial cell dependent relaxation is present in human pulmonary artery. Am J Physiol 252 (Heart Circ Physiol 21): H434-H438, 1987.

36. Broudy D, Greenberg B, Siemienczuk D. Static exercise in patients with congestive heart failure and the response to vasodilators. Am J Cardiol 59: 100-104, 1987.

37. Broudy D, Greenberg B, Siemienczuk D. Effects of the calcium antagonist PN 200-110 on cardiac performance in patients with congestive heart failure. J Cardiovasc Pharm 10: 190-195, 1987.

38. Greenberg B, Rhoden K, Barnes P. Vasoactive intestinal peptide causes non-endothelial cell dependent relaxation in bovine and human pulmonary artery. Blood Vessels 24: 45-50, l987.

39. Cornyn J, Greenberg B, Massie B, Cox DC, Loge D, Krishnamurthy G, Bristow JD, Cheitlin MD, Thomas D. Reproducibility of rest and exercise on left ventricular ejection fraction and volumes in chronic aortic regurgitation. Am J Cardiol 59: 1361-1365, 1987.

40. Szlachcic J, Massie BM, Greenberg B, Thomas D, Cheitlin M, Bristow JD. Variability of echocardiographic and chest x-ray measurements in aortic regurgitation. Cardiol Bd Rev 4: 49-61, 1987.

41. Greenberg B, Rhoden K, Barnes P. Calcitonin gene-related peptide (CGRP) is a potent inhibitor of coronary vasomotor tone. Br J Pharm 92: 789-794, 1987.

42. Greenberg B, Siemienczuk D, Broudy D. Hemodynamic effects of PN 200-110 in heart failure. Am J Cardiol 59: 70B-74B, l987.

43. Greenberg B, Siemienczuk D, Broudy D. Isradipine improves cardiac function in congestive heart failure. Am J Med 84(3B): 56-61, 1988.

44. Greenberg B, Massie B, Bristow JD, Cheitlin M, Siemienczuk D, Loge D, Wilson R, Thomas D. Vasodilator therapy of chronic aortic insufficiency: A placebo controlled double-blinded clinical trial. Circulation 78: 92-103, 1988.

45. Wilson R, Greenberg B, Massie B, Bristow JD, Cheitlin M, Thomas D. Response to sub-maximal and maximal exercise in patients with chronic aortic insufficiency. Am J Cardiol, 62: 606-610, 1988.

46. Siemienczuk D, Greenberg B, Morris C, Massie B, Wilson RA, Topic N, Bristow JD, Cheitlin M. Factors associated with progression to aortic valve replacement in chronic aortic insufficiency. Ann Intern Med 110: 587-592, 1989.

47. Greenberg B. Mechanical characteristics of the failing left ventricle. J Cardiovasc Phar 14(Suppl 5): 562-568, 1989.

48. Bouchard A, Yock P, Schiller NB, Blumlein S, Botvinick EH, Greenberg B, Cheitlin M, Massie BM. Value of color Doppler estimation of regurgitant volume in patients with chronic aortic insufficiency. Am Heart J 117(5): 1099-1105, 1989.

49. Greenberg B. Use of vasodilators to treat patients with valvular insufficiency. Choices in Cardiology 3: 315-318, 1989.

20

50. Greenberg B, Siemienczuk D, Massie B, Morris C, Wilson R, Topic N, Bristow JD, Cheitlin M. Chronic aortic valve insufficiency: Identifying patients at risk for progression to surgery. Cardiology Board Review 7: 23-36, 1990.

51. Greenberg B. Management of the hypertensive patient with congestive heart failure. Consultant (Suppl 30): 59-62, 1990.

52. Arai A, Greenberg B. Congestive heart failure - pathophysiology, current therapy and future directions. West J Med 153: 406-414, 1990.

53. Perlmutter N, Edgar S, Tanz R, Greenberg B, Wilson RA. Vasodilator effects of lidocaine on epicardial porcine coronary arteries. Pharmacology 41: 280-285, 1990.

54. Greenberg B. Cardiac contractility and conduction. A comparison of antihypertensives. Am J Kidney Dis (Suppl 4) 16: 30-34, 1990.

55. The SOLVD Investigators (including B. Greenberg). Studies of left ventricular dysfunction-rationale, design and methods: two trials that evaluate the effects of enalapril in patients with reduced ejection fraction. Am J of Cardiol 66: 315-322, 1990.

56. Greenberg B. Selecting high-risk patients with chronic aortic insufficiency. Primary Cardiology 17: 47-59, 1991.

57. Greenberg B. When to intervene in aortic insufficiency. Protocols 2: 3-8, 1991.

58. Ontkean M, Gay R, Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 69: 1088-1096, 1991.

59. Wilson R, Perlmutter N, Jacobson N, Siemienczuk D, Szlachcic J, Bristow JD, Cheitlin M, Massie B, Greenberg B. Effects of long-term vasodilator therapy on electrocardiographic abnormalities in patients with chronic aortic regurgitation. Am J Cardiol 68: 935-939, 1991.

60. Haeusslin EA, Greenberg B, Massie B. Does the magnitude of mitral regurgitation determine the hemodynamic response to vasodilators in chronic congestive heart failure patients? Chest 100: 1312-1315, 1991.

61. The SOLVD investigators (including B. Greenberg). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293-302, 1991.

62. Wilson RA, McDonald RW, Bristow JD, Cheitlin M, Nauman D, Massie B, Greenberg B. Correlates of aortic distensibility in chronic aortic insufficiency and relation to progression to surgery. J Am Coll Cardiol 19: 733-738, 1992.

63. Nauman D, Greenberg B, Morris C, Massie B, Wilson R, Bristow JD, Cheitlin M. Effects of stopping long-term vasodilator therapy in patients with chronic aortic insufficiency. Chest 102: 720-724, 1992.

64. The SOLVD Investigators (including B Greenberg). Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685-691, 1992.

21

65. Bangdiwala SI, Weiner DH, Bourassa MG, Friesinger GC, Ghali JK, Yusuf S for the SOLVD Investigators (including B. Greenberg). Studies of left ventricular dysfunction (SOLVD) registry: rationale, design, methods and description of baseline characteristics. Am J Cardiol 70: 347-353, 1992.

66. Nauman D, Greenberg B. Studies of left ventricular dysfunction (SOLVD). American J of Geriatric Cardiology 2: 28-36, 1993.

66. Benedict CR, Weiner D, Johnstone DE, Bourassa MG, Nicklas J, Kirlin P, Greenberg B, Quinones MA, Yusuf S for the SOLVD Investigators. Comparative neurohormonal responses in patients with impaired and preserved ventricular ejection fraction: Results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. JACC;22 (Suppl A): 146A-153A, 1993.

67.68. Greenberg B, Kishiyama S. Endothelium-dependent and- independent responses to

hypoxia in rat pulmonary artery. Am J Physiol 265: H1712-H1720, 1993.

69. Bittner V, Weiner DH, Yusuf DH, Rogers WJ, McIntyre K, Kostis JB, Kohn RM, Bangdiwala SI, Guillotte M, Bourassa MG, Greenberg B, Woods P, Gregory JJ, Kronenberg M, Ekelund L. Prediction of mortality and morbidity with a six-minute walk test in patients with left ventricular dysfunction. JAMA, 270: 1702-1707, 1993.

70. Benedict CR, Johnstone DE, Bourassa MG, Weiner D, Bittner V, Ray P, Kirlin P, Greenberg B, Kohn RM, McIntyre K, Quiones M, Yusuf S for SOLVD Investigators. Relationship of neurohormonal activation to clinical variables and degree of ventricular dysfunction: A report of the studies of left ventricular dysfunction registry. J AM Coll Cardiol 23: 1410-1420, 1994.

71. Llorens-Cortes C, Greenberg B, Huang H, Clauser E, Michael J-B, Corvol P. Modulation of mRNA expression for angiotensin II receptor subtypes (AT1A and AT1B) analyzed by quantitative RT-PCR amplification. Hypertension. 24: 538-548, 1994.

72. Greenberg B, Quinones M, Koilpillai C, Limacher M, Shindler D, Shelton B, Benedict C for the SOLVD Investigators. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: Results of the SOLVD Echocardiography sub-study. Circulation 91: 2573-2581, 1995.

73. Benedict CR, Francis GS, Shelton B, Johnstone DE, Kubo SH, Kirlin P, Nicklas J, Liang C-S, Konstam MA, Greenberg B, Yusuf S for the SOLVD Investigators. Effect of long - term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol 75: 1151-1157, 1995.

74. Pratt C, Gardner M, Pepine C, Kohn R, Young JB, Greenberg B et al. Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. SOLVD Investigators, Am J Cardiol 75: 1244-1249, 1995.

75. Koipillai C, Quinones MA, Greenberg B, Limacher M, Pratt CM, Benedict C, Shindler D, Shelton B for the SOLVD Investigators. Relation of ventricular size and function to heart failure status and ventricular dysrhythmias in patients with severe left ventricular dysfunction. Am J Cardiol 77: 606-611, 1996.

22

76. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probstfield J, Yusuf S for the SOLVD Investigators. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation. 94: 690-697, 1996.

77. Greenberg BH, Quinones MA, Koipillai C, Limacher M, Schindler D, Benedict C, Shelton B. Left Ventricle Dysfunction: Effects of long-term enalapril therapy on remodeling. Cardiology Review 13: 40-46, 1996.

78. Greenberg, BH, Quinones, MA, Koilpillai C, Limacher M, Schindler D, Benedict C, Shelton B. Effects of long-term enalapril therapy on cardiac structure and function on SOLVD patients. ACE Reports 120: 1-6, 1996.

79. Hermsmeyer K, Miyagawa K, Kelley ST, Rosch J, Hall AS, Axthelm MK, Greenberg B. Reactivity based coronary vasospasm independent of atherosclerosis in rhesus monkeys. J Am Coll Cardiol 29: 671-80, 1997.

80. Baggia S, Perkins K, Greenberg B. Endothelium-dependent relaxation is not uniformly impaired in chronic heart failure. J Cardiovasc Pharmacol 29: 389-396, 1997.

81. Greenberg, B. Refractory Heart Failure. Cardiovascular Reviews and Reports, 19:19-29, 1998.

82. Greenberg BH. Beta-blocker therapy of heart failure. J Heart and Lung Transplant, 1998.

83. Hermann DD, Greenberg BH. Vasodilator therapy in left heart vascular regurgitation. ACC Current J Review, Pp 27-29, Jan/Feb 1998.

84. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F, DeMets DL, White BG, for the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 339: 1810-1816, 1998.

85. Packer M, Cohn JN (editors), Abraham WT, Colucci WS, Fowler MB, Greenberg BH, Leier CV, Massie BM and Young JB on behalf of the Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 83: 2A-38A, 1999.

86. Ambrose J, Pribnow DG, Giraud GD, Perkins KD, Muldoon L , Greenberg BH. Angiotensin Type 1 Receptor Antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle. J Cardiovascular Pharmacology 33: 433-439, 1999.

87. Gurantz D, Cowling RT, Villarreal FJ, Greenberg BH. Tumor necrosis factor- upregulates Angiotensin II Type 1 Receptors on Cardiac Fibroblasts. Circulation Res, 85: 272-279, 1999.

88. Greenberg B. The role of Angiotensin receptor blockers in heart failure: Not yet RESOLVD. Circulation, 100: 1032-1034, 1999.

89. Greenberg BH, Hermann DD. Should All Patients With Heart Failure and Systolic Ventricular Dysfunction Be Anticoagulated With Warfarin? J of Coronary Artery Disease: 9: 2-6, 1999.

23

90. Hermann DD, Greenberg BH: “America’s Silent and Lethal Epidemic”, Opinion Editorial San Diego Union-Tribune, E:B-7, February 15, 2000.

91. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. A cohert analysis of the SOLVD prevention and treatment trials. J Am Coll Cardiol, 35: 681-689, 2000.

92. Cohn JN, Ferrari R, Sharpe N on Behalf of an International Forum on Cardiac Remodeling (including B. Greenberg). Cardiac Remodeling-Concepts and Clinical Implications: A Consensus Paper From an International Forum on Cardiac Remodeling. J Am Coll Cardiol, 35: 569-582, 2000.

93. Levine, TB, Bernnik PJLM, Caspi A, Elkayam U, Geltman EM, Greenberg B, McKenna WJ, Ghali JK, Giles TD, Marmor A, Reisin LH, Ammon S, Lindberg E. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure - the MACH-1 study. Circulation, 101: 758-764, 2000.

94. Greenberg BH, Hermann DD, Pranulis MF, Lazio L, Cloutier D. Reproducibility of Impedance Cardiography Hemodynamic Measures in Clinically Stable Heart Failure Patients. Congestive Heart Failure, 6: 74-80, 2000.

95. Quiñones MA, Greenberg BH, Kopelen HA, Koilpillai C, Limacher MC, Shindler DM, Shelton BJ, Weiner DH for the SOLVD Investigators. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD Registry and Trials: Significance of left ventricular hypertrophy. J Am Coll Cardiol, 35(5): 1237-1244, 2000.

96. Greenberg BH: “Cardiodynamic Effects and Mechanisms of Action of Beta Blockers”. Am J of Managed Care, 6: S303-307, 2000.

97. Franciosa JA, Abraham WT, Fowler M, Gilbert EM, Greenberg B, Massie BM, Chen T, Lukas MA, Nelson JJ for the COHERE Participant Physicians. Rationale, Design, and Methods for a COREG (Carvedilol) Heart Failure Registry (COHERE). Journal of Cardiac Failure 6: 264-275, 2000.

98. Slawsky MT, Colucci WS, Gottlieb S, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, Lejemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 102: 2222-2227, 2000.

99. Greenberg B. “Treatment of Heart Failure: State of the Art and Perspectives”. J Cardiovasc Pharm. 38 (Suppl 2):S59-S63, 2001.

100. Leier, C et al (including BH Greenberg). Nuggets, Pearls, and Vignettes of Master Heart Failure Clinicians. Congestive Heart Failure 7: 245-249, 2001.

101. The Beta-Blocker Evaluation of Survival Trial Investigators (including Greenberg BH – Steering Committee). Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure. N Engl J Med 2001; 344: 1659 – 67.

102. Greenberg B. “Slowing Heart Failure Progression: Optimal Treatment of Mild Heart Failure”. Hospital Physician. 38: 43-49, 2002.

24

103. Cowling RT, Gurantz D, Peng, JF, Dillmann W, Greenberg BH. Transcription Factor NF-B Is Necessary for Up-regulation of Type 1 Angiotensin II Receptor mRNA in Rat Cardiac Fibroblasts Treated with Tumor Necrosis Factor-αor Interleukin-β. J Biol Chemistry 277: 5719-5724, 2002

104. Greenberg BH. Effects of Angiotensin Converting Enzyme Inhibitors on Remodeling in Clinical Trials. J Cardiac Failure 8: S486-S490, 2002.

105. Greenberg B. Heart Failure Awareness 2002-And Beyond. J Cardiac Failure 8: 6-7, 2002.

106. Aranda J, Krause-Steinrauf HJ, Greenberg BH, Heng MK, Kosolcharoen PK, Renlund DG, Thaneemit-Chen S, White M, Cintron G. Comparison of the Beta Blocker Bucindolol in Younger Versus Older Patients with Heart Failure. Am J Cardiol 89: 1322-1326. 2002.

107. Greenberg BH. Endothelin and Endothelin Receptor Antagonists (ERAs) in Heart Failure. Congestive Heart Failure 8: 257-261, 2002.

108. Greenberg B, Borghi C, Perrone S. Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan? European Journal of Heart Failure 5: 13-21, 2002.

109. Greenberg BH. Angiotensin Receptor Blockers in Heart Failure-A Work in Progress. Editorial in J Am Coll Cardiol 40: 1422-1423. 2002.

110. Greenberg, BH, Hermann, DD, Guest Editors. Neurohormonal Blockade in the Treatment of Heart Failure: Where Do We Go From Here? Congestive Heart Failure 8: 245, 2002.

111. Peng JF, Gurantz D, Tran V, Cowling R, Greenberg BH. TNF-Induced AT1 Receptor Upregulation Enhances Angiotensin II-Mediated Fibroblast Responses That Favor Fibrosis. Circulation Research 91: 1119-1126. 2002.

112. Greenberg, BH. Clinical Trials Report. Current Cardiology Reports. 4: 185-186, May 2002.

113. Sawhney N, Hassinkhani A and Greenberg BH. Calcific Aortic Stenosis in the Elderly: A Brief Overview. Am Jour of Geriatric Cardiology. 12: 178-82, 2003.

114. Shekelle P, Rich M, Morton S, Atkinson, S, Tu W, Magilone M, Rhodes S, Barrett M, Fonarow G, Greenberg B, Heidenreich P, Knable T, Konstam M, Steimle A, Stevenson LW. Efficacy of ACE Inhibitors and Beta Blockers in the Management of Left Ventricular Systolic Dysfunction According to Race, Sex, and Diabetic Status: A Meta-Analysis of Major Clinical Trials. J Am Coll Cardiol 41: 1529-38, 2003.

115. Greenberg BH, Gradman, AH, Papademetriou V. Heart Failure with Preserved Systolic Function. Cardiology Review Vol 20: No 11 (Suppl):22-27

116. Eichhorn E, Grayburn P, Mayer S, St. John Sutton M, Appleton C, Plehn J, Oh J, Greenberg B, DeMaria A, Krause-Steinrauf H. Myocardial Contractile Reserve by Dobutamine Stress Echocardiography Predicts Improvement in Ejection Fraction with ß-blockade in Patients with Heart Failure. Circulation 108: 2336-2341, 2003.

25

117. DeMaria AN., Ben-Yehuda O, Berman D, Feld GK, Greenberg, BH, Knoke JD, Knowlton KU, Lew WYW, Tsimikas S. Highlights of the Year in JACC 2003. J Am Coll Cardiol 42: 2156-2166, 2003.

118. Fonarow GC, Albert AN, Gattis WA, Gheorghiade M, Greenberg B, O’Connor CM, Yancy CW, Young J, Abraham WT. The Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) Trial: Rationale and Design. American Heart Journal 148: 43-51, 2004.

119. Mehra MM and Greenberg, BH. Cardiac Resynchronization Therapy: Caveat Medicus! J Am Coll Cardiology 43: 1145-1148, 2004.

120. Franciosa JA, Massie BM, Lukas, MA, Nelson JJ, Lottes S, Abraham WT, Fowler M, Gilbert EM, Greenberg B, for the COHERE Participant Physicians. Beta-Blocker Therapy for Heart Failure in the Community: Findings of a Community-Based Registry. Am Heart Journal; 148: 718-726, 2004.

121. Greenberg B. Non-selective versus selective beta-blockers in the management of chronic heart failure: Clinical implications of the Carvedilol or Metoprolol European Trial. Rev Cardiovasc Med. 5 (suppl 1) S1-S8, 2004.

122. Adler A, Greenberg BH. Use of beta blockers in patients with post-MI left ventricular dysfunction. Curr Treat Options Cardiovasc Med 6: 335-343, 2004.

123. DeMaria AN, Ben-Yehuda O, Berman D, Feld GK, Greenberg BH, Knoke JD. Highlights of the Year in J Am Coll Cardiol 2004. J Am Coll Cardiol; 45: 137-53, 2005.

124. Gurantz D, Cowling RT, Frikovsky E, Weiser CD, Greenberg BH. IL-1β and TNFα upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. J Mol Cell Cardiol, 38: 505-515, 2005.

125. Gurantz D, Yndestad A, Halvorsen B, Lunde O, Ueland T, Aukrust P, Kjekshus J, Greenberg B. Recombinant soluble tumor necrosis factor receptors or intravenous immunoglobulin attenuates post-myocardial infarction gene expression in rats. Cardiovascular Research, 67: 106-115, 2005.

126. Grayburn PA, Appleton CP, DeMaria AN, Greenberg BH, Lowes B, Oh J, Plehn JF, Rahko P, St. John Sutton M, Eichhorn EJ: BEST Trial Echocardiographic Substudy Investigators. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: the Beta-blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol. 45: 1064-71, 2005.

127. Cowling R, Reese V, Gurantz D, Iwata M, Dillman W, Greenberg B. Effect of Cytokine Treatment on Type 1A Angiotensin II Receptor (AT1A) Transcription and Splicing in Rat Cardiac Fibroblasts. Am J Physiol. Heart Circ Physiol. 289: H1-H8, 2005.

128. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate anti-fibrotic and anti-trophic effects. Am J Physiol. Heart Circ Physiol. 289: H2356-H2363, 2005.

129. Demaria AN, Ben-Yehuda O, Berman D, Feld GK, Ginsberg J, Greenberg BH, Lew WY, Sahn D, Tsimikas S. Highlights of the Year in JACC 2005. J Am Coll Cardiol. 47: 184-202, 2006.

26

130. Greenberg B, Zannad F, Pitt B. The Role of Aldosterone Blockade in the Future of Heart Failure Treatment, Post-Acute Myocardiol Infarction and Beyond. Am J Cardiol. 97 (10A): 34F-40F, 2006.

131. Buxbaum, J, Jacobson D, Tajoe C, Alexander A, Kitzman D, Greenberg B, Thaneemit-Chen S, Lavori P, TTR1221in African-American with CHF. J Am Coll Cardiol 47: 1724-5, 2006.

132. Packer, M, Abraham, W , Mehra, M R., Yancy, C W., Lawless, C E., Mitchell, J E., Bijou, R, O’Connor, C M., Massie, B M., Pina, I L., Greenberg, BH., Young, J B., Fishbein, D P., Hauptman, P J., Bourge, R C., Strobeck, J E., Srinvivas, M, Schocken, D, Teerlink, J R. Utility of Impedance Cardiography for the Identification if Short-Term Risk if Clinical Decompensation In Stable Patients with Chronic Heart Failure. J Am Coll Cardiol. 47: 2245-52, 2006.

133. Greenberg B, Mehra, M. All Patients With Heart Failure and Intraventricular Conduction Defect or Dyssynchrony Should not Receive Cardiac Resynchronization Therapy (CRT). Circulation 2006 114: 2685-90, 2006.

134. Greenberg BH, Mehra M, Teerlink JR, Ordronneau P, McCollum D, Gilbert EM. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure. Am J Cardiol. 2:98(7A): 53L-59L, 2006.

135. Franciosa, Joseph A., Nelson, Jeanenne J., Lukas, Mary Ann, Lottes, Sandra R., Massie, Barry M., Fowler, Michael B., Greenberg, Barry, Gilbert, Edward M., Abraham, William T., and the COHERE Participant Physicians. Heart Failure in Community Practice: Relationship to Age and Sex in a B-Blocker Registry. Congest Heart Fail. 12(6): 317-23, 2006.

136. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators. on behalf of the OPTIMIZE-HF Investigators and Coordinators. Systolic Blood Pressure at Admission, Clinical Characteristics, and Outcomes in Patients Hospitalized with Acute Heart Failure: An Analysis from OPTIMIZE-HF. JAMA 296: 2217-2226, 2006.

137. Rutledge T, Reis V, Linke S, Greenberg B, Mills P. Depression in Heart Failure: A Meta-Analytic Review of Prevalence, Interventions Effects, and Associations with Clinical Outcomes. J Am Coll Cardiol. 48: 1527-37, 2006.

138. Packer M, Lukas MA, Tenero DM, Baidoo CA, Greenberg BH; 369 Study Group. Pharmacokinetic Profile of Controlled-Release Carvedilol in Patients with Left Ventricular Dysfunction Associated with Chronic Heart Failure or After Myocardial Infarction. Am J Cardiol. 98(7A): 39L-49L, 2006.

139. Greenberg B, Lottes SR, Nelson JJ, Lukas MA, Fowler MB, Massie BM, Abraham WT, Gilbert EM, Franciosa JA; COHERE Participant Physicians. Predictors of Clinical Outcomes in Patients Given Carvedilol for Heart Failure. Am J Cardiol. 98: 1480-4, 2006.

140. Heart Failure Society of America. Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. (including B. Greenberg) Journal of Cardiac Failure, 12: 10-38, 2006.

27

141. Fonarow, GC, Abraham, WT, Albert, NM, Gatis Stough, W, Gheorghiade, MD, Greenberg, BH, O’Connor, CM, Yancy, and Young, JB. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: An analysis from OPTIMIZE-HF. Am Heart J. 153: 82, e1-11, 2007.

142. Abraham WT, Massie BM, Lukas MA, Lottes SR, Nelson JJ, Fowler MB, Greenberg B, Gilbert EM, Franciosa JA, and the COHERE Participant Physicians. Tolerability, Safety, and Efficacy of B-Blockade in Black Patients with Heart Failure in the Community Setting: Insights from Large Prospective B-Blocker Registry. Cong Heart Failure 13: 16-21, 2007.

143. Massie BM, Nelson JJ, Lukas MA, Greenberg BH, Fowler MB, Gilbert EM, Abraham WT, Lottes SR, Franciosa JA, COHERE Participant Physicians. Comparison of Outcomes and Usefulness of Carvedilol Across a Spectrum of Left Ventricular Ejection Fractions in Patients With Heart Failure in Clinical Practice. Am J Cardiol 99: 1263-8, 2007.

144. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy C, Young JB; OPTIMIZE-HF Investigators and Hospitals. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 297: 61-70, 2007.

145. DeMaria AN, Ben-Yehuda O, Feld GK, Ginsburg GS, Greenberg BH, Lew WY, Lima JA, Maisel As, Narula J, Sahn DJ, Tsimikas S. Highlights of the Year in JACC 2006. J Am Coll Cardiol. 49: 509-27, 2007.

146. Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O’Connor CM, She L, Yancy C, Young J, Fonarow GC, on behalf of the OPTIMIZE-HF Investigators and Coordinators. Relationship Between Admission Serum Sodium Concentration and Clinical Outcomes in Patients Hospitalized for Heart Failure: An Analysis from the OPTIMIZE-HF Registry. Eur Heart J 28: 980-8, 2007.

147. Torre-Amione G, Bourge RC, Colluci W, Greenberg BH, Pratt C, Rouleau JL, Sestier F, Geddes JA, Nemet AJ, Young JB. A Study to Assess the Effects of a Broad-Spectrum Immune Modulatory Therapy on Mortality and Morbidity in Patients with Chronic Heart Failure: the ACCLAIM Trial Rationale and Design. Can J Cardiol. 23: 369-76, 2007.

148. Albert NM, Fonarow GC, Abraham WT, Chiswell K, Gattis Stough W, Greenberg BH, O’Connor C M, Sun JL, Clyde Y, and Young JB. Predictors of Delivery of Hospital Based Heart Failure Patient Education: A Report from OPTIMIZE-HF. J Card Fail. 13: 189-198, 2007.

149. Massie BM, Nelson JJ, Lukas MA, Greenberg B, Fowler MB, Gilbert EM, Abraham WT, Lottes SR, Franciosa JA; COHERE Participant Physicians. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice. Am J Cardiol. 99: 1263-8, 2007.

150. Fowler MB, Lottes SR, Nelson JJ, Lukas MA, Gilbert EM, Greenberg B, Massie BM, Abraham WT, Franciosa JA, for the COHERE Participant Physicians. B-Blocker Dosing in Community-Based Treatment of Heart Failure. Am Heart J. 153: 1029-36, 2007.

151. Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE; REVERT Study Group. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the Reversal of Ventricular Remodeling with Toprol-XL (REVERT) trial. Circulation 116: 49-56, 2007.

28

152. Greenberg B. Can We IMPROVE-CHF Management by Measuring Natriuretic Peptides? Circulation 115: 3045-7, 2007.

153. Greenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, Gheorghiade M, O'Connor CM, Sun JL, Yancy CW, Young JB, Fonarow GC. Influence of Diabetes on Characteristics and Outcomes in Patients Hospitalized with Heat Failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (Optimize HF). Am Heart J. 154:2 77 e1-8, 2007.

154. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O’Connor CM, Pieper K, Sun JL, Yancy CW, and Young JB. Influence of Performance-Improvement Initiative on Quality of Care for Patients Hospitalized with Heart Failure: Results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Arch Intern Med. 167: 1493-502, 2007.

155. Greenberg B, Thomas I, Banish D, Goldman S, Havranek E, Massie BM, Zhu Y, TIcho B, Abraham WT. Effects of Multiple Oral Doses of an A1 Adenosine Antagonist, BG9928, in Patients with Heart Failure: Results of a Placebo-Controlled, Dose-Escalation Study. J Am Coll Cardiol. 50: 600-6, 2007.

156. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 50: 768-77, 2007.

157. Greenberg B, Czerska B, Abraham WT, Neaton JD, Reynolds DM, Mather P, Bourge R, Parker IC, Konstam MA. Rationale, Design, and Methods for a Pivotal Randomized Clinical Trial of Continuous Aortic Flow Augmentation in Patients with Exacerbation of Heart Failure: The MOMENTUM Trial. J Cardiac Fail 13: 715-721, 2007.

158. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O’Connor CM, Piper K, Sun JL, Yancy CW, Young JB, for the OPTIMIZE-HF Investigators and Hospitals. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. J Card Fail. 13: 722-31, 2007.

159. Young JB, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O’Connor CM, She L, Sun JL, Yancy CW, Fonarow GC, on behalf of the OPTIMIZE-HF Investigators and Coordinators. Relation of Low Hemoglobin and Anemia to Morbidity and Mortality in Patients Hospitalized With Heart Failure (Insight from the OPTIMIZE-HF Registry). Am J Cardiol 101: 223–230, 2008.

160. Zhang X, Greenberg B, Cowling R. Improving the Titer of Recombinant Adenovirus by Suppressing Problematic Transgene Transcription during Packaging. BioTechniques 44: 85-89, 2008.

161. Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hilderbrant P, Keren A, Motro M, Moye LA, Otterstad JE, Pratt CM, Ponikowski P, Rouleu JL, Sestier F, Winkelmann BR, and Young JB. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomized trial. Lancet 19: 371: 228-36, 2008.

29

162. Mehra MR, Rockman HA, and Greenberg BH. Highlights of the 2007 Scientific Meeting of the Heart Failure Society of America, Washington, DC, September 16-19, 2007. J Am Coll Cardiol 51: 320-327, 2008.

163. Ghali JK, Anand I, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, and Armstrong P. Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia. Circulation 117: 526-535, 2008.

164. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O’Connor CM, Nunez E, Yancy CW, and Young JB. Day of Admission and Clinical Outcomes for Patients Hospitalized for Heart Failure: Findings from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Circulation: HF 1: 50-57, 2008.

165. DeMaria AN, Bax JJ, Ben-Yehuda O, Clopton P, Feld GK, Ginsburg GS, Greenberg BH, Knoke JD, Lew WY, Lima JA, Maisel AS, Narayan SM, Narula J, Sahn DJ, and Tsimikas S. “Highlights of the Year in JACC 2007”. J Am Coll Cardiol. 51: 490-512, 2008.

166. Yancy CW, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, O’Connor CM, She L, Sun JL, Young JB, and Fonarow GC. Quality of Care of and Outcomes for African-Americans Hospitalized with Heart Failure: Findings from the OPTIMIZE-HF Registry. J Am Coll Cardiol 51: 1675-1684, 2008.

167. Dutta R, Khan A, Rathod A, Greenberg B. Utility of Cardiac Magnetic Resonance Imaging in Evaluating Left Ventricular Pseudoaneurysm. Congest Heart Fail. 14: 91-94, 2008.

168. Greenberg B. Molecular Imaging of the Remodeling Heart: The Next Step Forward. J Am Coll Cardiol. 1: 363-365, 2008.

169. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy CW, Young JB. Factors Identified as Precipitating Hospital Admissions for Heart Failure and Clinical Outcomes: Findings From OPTIMIZE-HF. Arch Intern Med. 168: 847-854 2008.

170. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Nunez E, Yancy CW, Young JB. A Smoker’s Paradox in Patients Hospitalized for Heart Failure: Findings from OPTIMIZE-HF. Eur Heart J. 29: 1983–1991, 2008.

171. Greenberg B. An Ace in the Hole: Alternative Pathways of the Renin Angiotensin System and Their Potential Role in Cardiac Remodeling. J Am Coll Cardiol 52: 755-757, 2008.

172. Abraham WT, Albert NM, Gattis Stough WA, Gheorghiade M, Greenberg BH., O’Connor CM, Sun J, Yancy CW, Young JB, Fonarow GC. Predictors of In-Hospital Mortality in Patients Hospitalized for Heart Failure: Insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) Registry. J Am Coll Cardiol 52: 347-356, 2008.

173. O’Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, Greenberg BH, Yancy C, Young J, and Fonarow GC. Predictors of Mortality after Discharge in Patients Hospitalized with Heart Failure: An Analysis from the Organized

30

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tsimikas%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sahn%20DJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Narula%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Narayan%20SM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Maisel%20AS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lima%20JA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lew%20WY%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Knoke%20JD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Greenberg%20BH%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ginsburg%20GS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Feld%20GK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Clopton%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ben-Yehuda%20O%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bax%20JJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22DeMaria%20AN%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlusDrugs1

Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J, 156: 662-73, 2008.

174. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB. Influence of Beta-Blocker Continuation or Withdrawal on Outcomes in Patients Hospitalized With Heart Failure: Findings from the OPTIMIZE-HF Program. J. Am. Coll. Cardiol. 52: 190-199, 2008.

175. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB. Dosing of Beta-Blocker Therapy Before, During, and After Hospitalization for Heart Failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure). Am J Cardiol. 102: 1524-9, 2008

176. Greenberg B. President’s Page “Springing into Fall”. J. Cardiac Failure; 14: 537-538, 2008.

177. Rossi JS, Flaherty JD, Fonarow GC, Nunez E, Gattis Stough W, Abraham WT, Albert NM, Greenberg BH, O’Connor CM, Yancy CW, Young JB, Davidson C, Gheorghiade M. Influence of Coronary Artery Disease and Coronary Revascularizations Status on Outcomes in Patients With Acute Heart Failure Syndromes: A Report from OPTIMIZE-HF. European J of Heart Failure 10: 1215–1223, 2008.

178. Greenberg B, Czerska B, Delgado RM, Bourge R, Zile MR, Silver M, Klapholz M, Haeusslein E, Mehra MR, Mather P, Abraham WT, Neaton JD, Brown BS, Parker IC, Konstam MA, for the MOMENTUM Investigators and coordinators. Effects of Continuous Aortic Flow Augmentation in Patients with Exacerbation of Heart Failure Inadequately Responsive to Medical Therapy: Results of the Multicenter Trail of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). Circulation; 118: 1241-1249, 2008.

178a. Greenberg B. Letter by Greenberg regarding article, “Continuous aortic flow augmentation: not enough MOMENTUM. Circulation. 119(14), 2009.

179. Mills PJ, Dimsdale JE, Hong SE, Van Den Brande G, Redwine L, Greenberg BH, and Rutledge T. Brief report: Characteristics of Antidepressant Use in Patients with Heart Failure. Patient Preference and Adherence 2: 333-336, 2008.

180. Cannon CP, Greenberg BH. Risk Stratification and Prognostic Factors in the Post-

Myocardial Infarction Patient. Am J Cardiol. 102(5A): 13G-20G, 2008.

181. Hajjar RJ, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A, Ly H, Kawase Y, Wagner K, Borow K, Jaski B, London B, Greenberg B, Pauly D, Patten R, Starlihng R, Mancini D, and Jessup M. Design of a Phase 1/2 Trial of Intracoronary Administration of AAV1/SERCA2a in Patients with Heart Failure. J Card Fail. 14: 355-67, 2008.

182. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. (incl. B Greenberg) Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. N Engl J Med. 359: 2456-67, 2008.

183. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O’Connor CM, Metra M, Massie BM; Protect Steering Committee, Investigators and Coordinators. (incl. B Greenberg) The PROTECT Pilot Study: A Randomized, Placebo-Controlled Dose-Finding Study of the

31

Adenosine A1 Receptor Antagonist Rolofylline in Patients with Acute Heart Failure and Renal Impairment. J Card Fail. 14: 631-40, 2008.

184. Abraham WT, Greenberg BH, Yancy SW. Pharmacologic Therapies Across the Continuum of Left Ventricular Dysfunction. Am J Cardiol. 102: 21G-28G, 2008.

185. Wirtz PH, Hong S, Redwine LS, Tafur, J, Rutledge T, Ziegler M, Greenberg B, Mills PJ. Depressive symptoms are associated with soluble P-selectin reactivity to acute exercise in heart failure. Biological Psychiatry 65: 208-807, 2009.

186. DeMaria AN, Ben-Yehuda O, Baxx JJ, Feld GK, Greenberg BH, Lew WYW, Sahn DJ, Tsimikas S. Highlights of the Year in JACC 2008. J Am Coll Cardiol 53: 373-398, 2009.

187. Mehra MR, Rockman HA, and Greenberg, BH. Highlights of the 2008 Scientific Sessions of Heart Failure Society of America: Toronto, Ontario, Canada, September 20-23, 2008. J Am Coll Cardiol 53: 514-522, 2009.

188. Konstam MA, Jessup M., Francis, G.S., Mann, D.L., Greenberg, B. Advanced Heart Failure and Transplant Cardiology: A Subspecialty is Born. J Am Coll Cardiol. 53: 834-836, 2009.

189. Black HR, Greenberg BH, Weber MA. The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update. Am J Med. 123(11):S2, 2010.

190. Wirtz PH, Redwine LS, Linke S, Hong S, Rutledge T, Greenberg BH, Mills PJ. Circulating levels of soluble intercellular adhesion molecure-1 (sICAM-1) independently predict depressive symptom severity after 12 months in heart failure patients. Brain Behav Immun. 24:366-9, 2010.

191. Flaherty MD, Bax JJ, De Luca L, Rossi JS, Davidson CJ, Filippatos G, Liu Pp, Konstam MA, Greenberg B, Mehra MR, Breithardt G, Pang PS, Young JB, Fonarow GC, Bonow RO, Gheorghiade M; Acute Heart Failure Syndromes International Working Group. Acute Heart Failure Syndromes in Patients with Coronary Artery Disease: Early Assessment and Treatment. J Am Coll Cardiol. 53: 254-63, 2009.

192. Albert NM, Fonarow GC, Abraham WT, Gheorghiade M, Greenberg BH, Nunez E, O’Conner CM, Gattis Stough W, Yancy CW, and Young JB. Depression and Clinical Outcomes in Heart Failure: An OPTIMIZE-HF Analysis. Am J Medicine 122: 366-373, 2009.

193. Jaski BE,Jessup ML,Mancicni DM, Cappola TP, Pauly DF, Greenberg B, Borow K, Dittrich H, Zsebo KM, and Hajjar RJ. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical Trial. J Cardiac Fail 15:171-181, 2009.

194. Flaherty JD, Rossi JS, Fonarow GC, Nunez E, Gattis Stough W, Abraham WT, Albert NM, Greenberg BH, O’Connor CM, Yancy CW, Young JB, Davidson CJ, and Gheorghiade M. Influence of Coronary Angiography on the Utilization of Therapies in Patients with Acute Heart Failure Syndromes: A Report from OPTIMIZE-HF. Am Heart J. 157;1018-25,2009.

195. Fonarow GC, Abraham WT, Albert NM, Gattis-Stough W, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy C, and Young JB, Age and Gender Related Differences in the Quality of Care and Outcomes of Patients Hospitalized with Heart Failure: An Analysis of OPTIMIZE-HF. Am J Cardiol. 104:107-115, 2009.

32

196. Redwine LS, Wirtz P, Hong S, Pandzic I, Cammarata S, Tafur J, Carter SM, Greenberg B, and Mills PJ. A Potential Shift From Adaptive Immune Activity To Non-Specific Inflammatory Activation Associated With Higher Depression Symptoms In Congestive Heart Failure Patients. J Card Fail, 7:607-15, 2009.

197. Gheorghiade M, Adams KF, Cleland JG, Cotter G, Felker MG, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra MR, Metra M, O’Connell J, O’Connor CM, Pang PS, Pina IL, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Stockbridge N. Phase III Clinical Trial Endpoints in Acute Heart Failure Syndromes (AHFS): A Virtual Rountable with the AHFS International Working Group. Am Heart J, 157: 957-70, 2009.

198. Mills PJ, Dimsdale JE, Natarajan L, Ziegler MG, Maisel A, Greenberg BH. Sleep and Health-Related Quality of Life in Heart Failure. Cong Heart Failure, 15:228-33, 2009.

199. Iwata M, Silva E and Greenberg B. Selective and Specific Regulation of Ectodomain Shedding of Angiotensin-converting Enzyme 2 by Tumor Necrosis Factor α-converting Enzyme. AM J Physiol-Cell Physiol 29, C1318-C1329, 2009.

200. Konstam MA and Greenberg B. Transforming Healthcare through the medical home: the example of heart failure. J Card Fail. 25:766-8, 2009.

201. Kim YS, Greenberg B. Update on Renin-Angiotensin-aldosterone blockade in heart failure.Curr Treat Options Cardiovasc Med. 11(6):455-66.

202. Franciosa JA, Ferdinand KC, Yancy CW. On behalf of the Consensus Statement on Heart Failure in African Americans Writing Group (including B. Greenberg); Consensus Statement on Heart Failure in African Americans Writing Group. Treatment of heart failure in African Americans: a consensus statement. Congest Heart Fail; 16(1):37-38, 2010.

203. Greenberg B. Pre-clinical diastolic dysfunction in diabetic patients: where do we go from here? J Am Coll Cardiol. 55(4):306-8, 2010.

204. DeMaria A, Bax JB, Ben-Yehuda O, Feld G, Greenberg B, Hall J, Hlatky M, Wilbur Y, Lew W, Lima A, Maisel A, Narayan S, Nissen S, Sahn D, Tsimikas S. Highlights of the Year in JACC 2009. J Am Coll Cardiol. 55(4):380-407, 2010.

205. Greenberg B. Managing hyponatremia in patients with heart failure. J Hosp Med. 2010 (In Press).

206. Wirtz PH, Redwine LS, Hong S, Linke S, Rutledge T, Greenberg B, Dimsdale J, Mills P. Increases in B-type natriuretic peptide (BNP) after acute mental stress in heart failure patients are associated with alcohol consumption. J Stud Alcohol Drugs 71:786-794, 2010.

207. Ritzema J, Troughton R, Melton I et al on Behalf of the Hemodynamically Guided Home Self-Therapy in severe Heart Failure Patients (HOMEOSTASIS). Study group (incl, BGreenberg, DSMB Chair). Physician-Directed Patient Self-Management of Left Atrial Pressure in Advanced Chronic Heart Failure. Circ AHA J. 121 (9) 1086-1094, 2010.

208. Kim M-A, Yang D, Kida K, Molotkova N, Yeo SJ, Varki N, Iwata M, Dalton N, Peterson K, Siems W-E, Walther T, Cowling RT, Kjekshus J and Greenberg B. Adverse Effects of ACE2 Inhibition in the Post-Myocardial Infarction Heart. J Card Failure 16:777-785,. 2010

33

209. Redwine LS, Wirtz PH, Hong S, Bosch J, Linke S, Ziegler M, Greenberg B, Mills PJ. Depression as a potential modulator of β-adrenergic – associated leukocyte mobilization in heart failure patients. J Am Coll Cardiol. 56: 1720-7, 2010.

210. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Filippatos GS, Fonarow GC,Greenberg BH, Hernandex AF, Khan S, Komajda M, Konstam MA, LIU PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O’Connell J, O’Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F F, Gheorghiade M; Clinical Trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward International AHFS Working Group. Circ Heart Failure (2):314-25 2010.

211. Daniels LB, Clopton P, Jiang K, Greenberg BH, Maisel AS. Prognosis of stage A or B Heart Failure patients with elevated B-type natriuretic peptide levels. J Card Failure (2):93-8, 2010.

212. Metra, M, Teerlink J L, Felker MG, Greenberg B H, Filippatos G, Ponikowski P, Teichman SL, Unemori E, Voors A A, Wetherley BD. Cotter G Dyspnea and worsening heart failure in patients with acute heart failure. Results from the Pre-RELAX-AHF Study. Eur J Heart Failure 12:1130-39, 2010.

213. Zile MR, Colombo PC, Mehra M, Greenberg BH, Brown S, Konstam MA. Progressive improvement in cardiac performance with continuous aortic flow augmentation (aortic flow therapy) in patients hospitalized with severe heart failure: results of the Multicenter Trial of the Orquis Medical Cancion System for the Enhanced Treatment of Heart Failure unresponsive to Medical Therapy (MOMENTUM). J Heart Lung Transplant (1) :86-92,

2010.

214. Udelson J.E.,A.M. Feldman, B.H. Greenberg, B. Pitt, R. Mukherjee, H.A. Solomon, M.A. Konstam. Randomized, Double Blind, Multicenter, Placebo-Controlled Study Evaluating the Effect of Aldosterone Antagonism with Eplerenone on Ventricular Remodeling in Patients with Mild- to Moderate Heart Failure and Left Ventricular Systolic Dysfunction. Circ: Heart Failure; 3: 347-353, 2010.

215. Milo-Cotter O, Teerlink J, Metra M, Felker GM, Ponikowski P, Voors, AA, Edwards C, Weatherly BD, Greenberg B, Filippatos G, Unemori E, Teichman SL, Cotter G. Low lymphocyte ratio as a novel prognostic factor in acute heat failure; Results from Pre -RELAX-AHF. Cardiology 117(3): 190-6, 2010.

216. Francis G, Greenberg B, Hsu D, Jaski B, Jessup M, LeWinter M, Pagani F, Pina I, Semigran M, Walsh M, Wiener D, Yancy C Jr. Clinical competence statement on management of patients with advanced heart failure and cardiac transplant: a report of the ACCF/AHA/ACP Task Force on Clinical Competence and Training. Circulation.122:644-72, 2010.

217. Iwata M, Cowling R, Yeo SJ Greenberg B. Targeting the ACE2-Ang-(1-7) Pathway in Cardiac Fibroblasts to Treat Cardiac Remodeling and Heart Failure. J Mol and Cell Cardiol 51:542-547, 2010.

218. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC; PROTECT Investigators and Committees (Including B Greenberg).

34

Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.N Engl J Med. 7;363(15):1419-28, 2010.

219. Gheorghiade M, Thyssen A, Zolynas R, Nadar VK, Greenberg BH, Mehra M, Sun X, Tian H, Plotnikov AN, Burton P. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.J Heart Lung Transplant. 30(2):218-26, 2011.

220. Troughton RW, Ritzema J, Eigler NL, Melton IC, Krum H, Adamson PB, Kar S, Shah PK, Whiting JS, Heywood JT, Rosero S, Singh JP, Saxon L, Matthews R, Crozier IG, Abraham WT; HOMEOSTASIS Investigators (Including B Greenberg). Direct left atrial pressure monitoring in severe heart failure: long-term sensor performance.J Cardiovasc Transl Res. 4(1):3-13, 2011.

221. Voors AA, Weatherley B, Felker M, Poonikowski Piotr, Unemori E, Cotter G, Teerlink J, Greenberg BH, Filippatos G, Teichman SL, Metra M. Early drop in systolic blood pressure and worsening renal function in acute heart failure: Renal results of Pre-RELAX-AHF. European J Heart Failure. 13(9):961-7, 2011.

222. Iwata M and Greenberg B. Ectodomain Shedding of ACE and ACE2 as Regulators of Their Protein Functions. Current Enzyme Inhibition (In Press) 2011, 7, 42-55

223. Davison B, Cotter G, Sun H, Koch G, Teerlink J, Metra M, Felker M, Voors AA, Ponikowski, Filippatos G, Greenberg B, Teichman SL, Eunemori E. Permutation

criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. Clin Res in Cardiol. 100(9): 745-53, 2011.

224. Jimenez J, Greenberg B and Mills P. Effects of Heart Failure and its Pharmacological Management on Sleep. Drug Discovery Today: Disease Models Winter 8: 161-166, 2011.

225. Cleland JG, Teerlink JR, Senior R, Nifontov EM, McMurray JV, Lang CC, Tsyrlin VA, Greenberg B, Mayet J, Francis D, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Lee JH, Saikali G, Clarke CP, Goldman JH, Wolff AA, Malik FI. The Effects of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Cardiac Function in Systolic Heart Failure: A double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. The Lancet. 378(9792):676-83, 2011.

226. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011 Jul 19; 124(3):304-13.

227. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM; NHLBI Heart Failure Clinical Research Network (Including B Greenberg).Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 364(9):797-805, 2011.

35

228. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS; CHAMPION Trial Study Group(including B Greenberg). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 201. 377(9766):658-66, 2011.

229. Anand IS, Greenberg BH, Fogoros RN, Libbus I, Katra RP; Music Investigators. Design of the Multi-Sensor Monitoring in Congestive Heart Failure (MUSIC) study: prospective trial to assess the utility of continuous wireless physiologic monitoring in heart failure. J Card Fail. 17(1):11-6, 2011.

230. Greenberg B and Cowling RT. An ACE for my Sweet Heart. J Am Coll Cardiol 21:59:748-750. 2012.

231. Greenberg B. Acute Decompensated Heart Failure. Circ J. 2012 Feb 17.

232. Ponikowski P, Metra M, Teerlink JR, Unemori E, Felker GM, Voors AA, Filippatos G, Greenberg B, Teichman SL, Severin T, Mueller-Velten G, Cotter G, Davison BA. Design of the RELAX in Acute Heart Failure Study. Am Heart J. 2012 Feb; 163(2):149-155

233. Greenberg BH, Anand IS, Burnett JC Jr, Chin J, Dracup KA, Feldman AM, Force T, Francis GS, Houser SR, Hunt SA, Knostam MA, Lindenfeld J, Mann DL, Mehra MR, Paul SC, Piano MR, Ross HJ, Sabbah HN, Starling RC, Udelson JE, Yancy CW, Zile MR, Massie BM. The Heart failure Society of America I 2020: A Vision for the Future. J Card Fail. 2012 Feb;18(2):90-3

234. DeMaria AN, Bax JJ, Ben-Yehuda O, Feld GK, Greenberg BH, Hall J, Hlatky M, Lew WY, Lima JA, Maisel AS, Narayan SM, Nissen S, Sahn DJ, Tsimikas S. Highlights of the Year in JACC 2011. J Am Coll Cardiol. 2012 Jan 31:59(5):503-37.

235. Anand IS, Tang WH, Greenberg BH, Chakravarthy N, Libbus I, Katra RP; Music Investigators. Design and Performance of a Multisensor Heart Failure Monitoring Algorithm: Results From the Multisensor Monitoring in Congestive Heart Failure (MUSIC) Study.J Card Fail. 18(4):289-95, 2012.

B. PENDING

1. Pang PS, Douglas K, Fonarow GC, Sopko G, Greenberg B, Collins SP, Storrow AB, Peacock WF, Aldeen AZ, Levy P, Diercks D, Brandimarte F, Filippatos G, Mebazaa A, Mehra M, Dickstein K, Abraham WT, Williams MV, Adams JG, Gibler WB, Gheorghiade M. A Consensus Proposal for an Early Enrollment Strategy in Acute Heart Failure Syndromes Clinical Trials: The Rationale, Challenges, and Opportunities.

2. Greenberg B. Angiotensin signaling in cardiac fibroblasts. FASEB Journal.

36

http://www.ncbi.nlm.nih.gov/pubmed/22343198

C. BOOKS (Written)

1. Greenberg BH, Hermann D. Contemporary Diagnosis and Management of Congestive Heart Failure. (1st Edition), Handbooks in Health Care Co., Newtown, PA, 2002.

2. Greenberg BH, Barnard D. Contemporary Diagnosis and Management of Congestive Heart Failure. (2nd Edition), Handbooks in Health Care Co., Newtown, PA, 2004.

3.4. Greenberg BH, Barnard D. Contemporary Diagnosis and Management of Congestive

Heart Failure. (3rd Edition), Handbooks in Health Care Co., Newtown, PA, 2005.

5. Greenberg BH, Barnard D., Amsterdam EA, Liebson P, Grundy SM. Contemporary Cardiovascular Continuum. Handbooks in Health Care Co, Newtown, PA (In Press)

6. Greenberg BH, Barnard DD, Narayan SM, Teerlink JR. Management of Heart Failure, Wiley-Blackwell, A John Wiley & Sons, Ltd., Chichester, West Sussex, UK, 395 pages, 2010.

D. BOOKS (Edited)

1. Greenberg BH, Murphy E (eds.). Valvular Heart Disease. 296 pages, Littleton, Massachusetts, PSG Publishing Company, 1987

2. Hosenpud JD, Greenberg BH (eds). Congestive Heart Failure: Pathophysiology, Diagnosis, and Comprehensive Approach to Management (1st Edition), Springer-Verlag, New York, 769 pages, 1994.

3. Hosenpud JD, Greenberg BH (eds). Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Management (2nd Edition), Lippincott, Williams & Wilkins, Philadelphia, PA. 858 pages, 2000.

4. Greenberg, BH (ed). Cardiac Remodeling: Mechanisms and Treatment. Marcel Dekker, Philadelphia, PA 569 pages, 2006.

5. Hosenpud JD, Greenberg BH (eds). Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Management (3rd Edition), Lippincott, Williams & Wilkins, Philadelphia, PA. 869 pages, 2007.

E. BOOK CHAPTERS

1. Greenberg BH. Management of post-infarction congestive heart failure. In JD Bristow and W Connor (eds.): Coronary Artery Disease, J. B. Lippincott, Philadelphia, pp 419-436,1985.

2. Greenberg BH. Acquired aortic valve disease. In BH Greenberg and E Murphy (eds.): Valvular Heart Disease. John Wright (PSG) Boston, pp 147-173, 1987.

37

3. Greenberg B. Vasodilator therapy of chronic aortic insufficiency. In Gaasch W and Levine H (eds): Aortic Insufficiency. Kluwer Academic Publishers, Boston, pp 143-160, 1988.

4. Greenberg B. Pro Digitalis glycosides are useful in the treatment of congestive heart failure. In Fortuin, N. (ed): Debates in Cardiology. Year Book Medical Publishers, Boston, Chicago, pp 118-137, 1988.

5. Larsen G, Greenberg B. Treatment of endocarditis In R. Rakel (ed): Conn's Current Therapy. W.B. Saunders Co., Philadelphia, pp 218-225, 1988.

6. Lewis HS, Greenberg BH. Does the patient with infective endocarditis and a large vegetation on the mitral or aortic valve need surgery? In M. Cheitlin (ed): Dilemmas in Clinical Cardiology. Cardiovasc Clin (Albert N. Brest, Editor-in-Chief), F.A. Davis Co., Philadelphia, pp 215-228, 1990.

7. Greenberg B. Effects of dietary fish oil in experimental models of atherosclerosis. In P.M. Vanhoutte and Ph. Douste-Blazy (ed): Fish oil and blood vessel wall interactions. Editions John Libbey Eurotext, Paris:81-88, 1990.

8. Greenberg B. Medical therapy for patients with aortic insufficiency. In B. Carabello (ed): Cardiology Clinics. W.B. Saunders Co, Philadelphia, pp 255-270, 1991.

9. Gorlin R, Hosenpud J, Greenberg B. Evolution of concepts of myocardial function in the treatment of congestive heart failure in man. In Hosenpud J and Greenberg B (eds): Congestive Heart Failure. Springer-Verlag, New York, pp 3-10, 1993.

10. Greenberg B. The medical management of chronic congestive heart failure. In Hosenpud J and Greenberg B (eds): Congestive Heart Failure. Springer-Verlag, New York, pp 628-644, 1993.

11. Greenberg B. Congestive heart failure secondary to valvular heart disease. In Hosenpud J and Greenberg B (eds): Congestive Heart Failure. Springer-Verlag, New York, pp 234-245, 1993.

12. Hosenpud J and Greenberg B. The diagnosis and management of congestive heart failure: What does the future hold? Hosenpud J and Greenberg B (eds): Congestive Heart Failure. Springer-Verlag, New York, pp 741-746, 1993.

13. Greenberg B. Role of vasodilator therapy in CHF: Effects on mortality. Cardiology Clinics. WB Saunders Co. Philadelphia, pp 87-99, 1994.

14. Ambrose J, Greenberg B. Treatment of Infectious Endocarditis. In R. Rakel(ed): Conn's Current Therapy. W.B. Saunders Co., Philadelphia, pp 284-292, 1996.

15. Hermann DH, Greenberg BH. Prognostic factors in heart failure. In P Poole-Wilson, W Colacci, K Chatterjee, B Massie and A Coats (eds): Heart Failure: Scientific Principles and Clinical Practice, Churchill Livingstone, New York, pp 439-454. 1997.

16. Ambrose J, Greenberg B. Treatment of infectious endocarditis In R Rakel (ed): Conn’s Therapy, W.B. Saunders Co., Philadelphia, pp 294-306, 1997.

17. Ambrose, J, Greenberg BH. Acute Presentations of Valvular Heart Disease. In Brown (ed.): Cardiac Intensive Care, W.B. Saunders, Philadelphia, pp 427-446, 1998.

38

18. Greenberg B. The Medical Management of Chronic Congestive Heart Failure. In Hosenpud JD and Greenberg BH (eds): Congestive Heart Failure (2nd Edition). Lippencott, Williams & Wilkins, Philadelphia, pp 673-693, 2000.

19. Montiel-Trujillo A, Mahon NG, Greenberg BH, McKenna WJ. Congestive Heart Failure as a Consequence of Valvular Heart Disease. In Hosenpud J and Greenberg B (eds): Congestive Heart Failure (2nd Edition). Lippencott, Williams & Wilkins, Philadelphia, pp 325-342, 2000.

20. Greenberg BH and Hosenpud JD. Future Directions. In Hosenpud J and Greenberg B (eds): Congestive Heart Failure (2nd Edition). Lippencott, Williams & Wilkins, Philadelphia, pp 811-815, 2000.

21. Hermann DD, Greenberg BH. Refractory Heart Failure. In Sharpe N (ed): Heart Failure Management 2000. Martin Dunitz Ltd., London, pp 199-216, 2000.

22. Hassankhani A, Sawney N and Greenberg BH. Heart Failure in Patients with Chronic Renal Failure. In Willenheimer R and Swedberg K (eds): Tailored Heart Failure Therapy: Special Therapeutic Consideration in Heart Failure. Martin Dunitz, Ltd., London pp 107-120, 2003.

23. Greenberg BH. Cardiac Remodeling. In Walsh A (ed): Molecular Mechanisms for Cardiac Hypertrophy and Failure. Taylor and Francis, Milton Park, Abington, Oxon, U.K. pp 247-264, 2005.

24. Greenberg BH. The Renin-Angiotensin System in Cardiac Remodeling. In Greenberg BH (ed) Myocardial Remodeling: Mechanisms and Treatment. Taylor and Francis Group, New York, NY. pp 247-264, 2005.

25. Greenberg BH Future Directions in Cardiac Remodeling. In Greenberg BH (ed) Myocardial Remodeling: Mechanisms and Treatment. Taylor and Francis Group, New York, NY. pp 553-558, 2006.

26. Greenberg BH. Role of the Renin-Angiotensin Aldosterone System. In Hosenpud J and Greenberg B. (ed) Congestive Heart Failure (3 rd Edition). Lippincott, Williams and Wilkins, Philadelphia, PA. pp 167-177, 2007

27. Hosenpud, JD and Greenberg, BH. What Does the Future Hold? In Hosenpud, JD and Greenberg BH. Congestive Heart Failure (3 rd Edition). Lippincott, Williams and Wilkins, Philadelphia, PA. pp 829-833, 2007.

28. McKenna WJ, Pollerin D, Mahon NG, and Greenberg BH. Heart Failure as a consequence of Valvular Disease. In Hosenpud JD and Greenberg BH. Congestive Heart Failure (3 rd Edition). Lippincott, Williams, and Wilkins, Philadelphia, PA. pp 336-353, 2007.

29. Greenberg BH. The Medical Management of Chronic Heart Failure in Patients with Systolic Dysfunction. In Hosenpud JD and Greenberg BH. Congestive Heart Failure (3 rd Edition). Lippincott, Williams and Wilkins, Philadelphia, PA. pp 621-646, 2007.

30. Fraley A, Greenberg BH. How to Use Neurohormonal Antagonists in Heart Failure. In Abraham WT, Henry Krum. Heart Failure: A Practical Approach to Treatment. The McGraw –Hill Companies Inc. New York, NY. pp 105 -125, 2007.

39

31. Redwine LS, Greenberg BH, Mills PJ. A Behavioral Medicine Approach to the Study of Heart Failure. In Waldstein S, Katzel L, Kop W (eds): Handbook of Cardiovascular Behavioral Medicine. Spring Publishing, New York, NY (In Press) 2010.

32. Austen WJ, Ambrose, J, Greenberg BH. Acute Presentations of Valvular Heart Disease. In Brown (ed.): Cardiac Intensive Care (2 nd Edition) , W.B. Saunders, Philadelphia pp 339-354, 2010.

33. Greenberg B, Kahn AM. Clinical Assessment of Heart Failure. In (ed). Braunwald’s Heart Disease, 9th Edition, Elsevier, Philadelphia pp 505-516, 2012.

34. Greenberg BH, Barnard DD. Preventing heart failure. In Greenberg BH, Barnard DD, Narayan SM, Teerlink JR (eds): Management of Heart Failure, Wiley-Blackwell, A John Wiley & Sons, Ltd., pp 3-26, 2010.

35. Dutta R, Greenberg BH. Neurohormonal blocking agents in the treatment of patient with left ventricular dysfunction and heart failure. In Greenberg BH, Barnard DD, Narayan SM, Teerlink JR (eds): Management of Heart Failure, Wiley-Blackwell, A John Wiley & Sons, Ltd., pp 85-116, 2010.

36. Greenberg BH, Cleland JGF. Emerging therapies for heart failure. In Greenberg BH, Barnard DD, Narayan SM, Teerlink JR (eds): Management of Heart Failure, Wiley-Blackwell, A John Wiley & Sons, Ltd., pp 157-175, 2010.

37. Iwata M, Greenberg BH. Ectodomain shedding as a regulator of cellular functions: from bench to bedside. In R.M. Mohan, Ed; Research Advances in Cell Physiology, Global Research Net Work:, 2011 (In press).

38. Cowling RT, Greenberg BH. Angiotensin receptors and response to angiotensin peptides in cardiac fibroblasts. In Turner NA (ed): The Cardiac Fibroblast, Research Signpost, pp 173- 195, 2011.

F. OTHER EDUCATIONAL MATERIAL

1. Pitt B, Greenberg B, Konstam M and Pina, I. Clinical Trials in Heart Failure. A Continuing Medical Education Slide Lecture Program. Jointly sponsored by the Dannemiller Memorial Education Foundation and Health Education Alliance, Inc. Released September, 2000.

2. Greenberg BH. Audio-Digest in Internal Medicine. Vol 48, Number 21. November 7, 2001. Congestive Heart Failure.-Pathophysiology and prevention of heart failure.-Beta blockers and ACE inhibitors in CHF.

3. Greenberg BH. Audio-Digest in Internal Medicine. Heart Failure 2003: Update for the Primary Care Physician-Identifying and Treating the Patient at Risk. Special Topics Volume 7, Number 2. April 2003.

4. Greenberg, BH. Audio-Digest Family Practice. Volume 51 Issue 38, October 14, 2003.-Case Studies. Heart disease and biventricular failure (moderator).

40

5. Greenberg, BH. Audio-Digest in Internal Medicine. Vol 51, Issue 10. May 21, 2004. Heart Failure: How experts handle challenging cases: case presentation 1.

6. Greenberg, BH. Millennium CME Institute, Inc. Certified Monograph. “Evidence-based Approach for the Management of Post-myocardial Infarction With or Without Left Ventricular Dysfunction.” Release Date: December 2004.

7. Greenberg BH. Audio-Digest in Family Practice. Heart Failure: Dealing With Difficult Cases. Volume 53, Issue 32. August 28, 2005.

8. Greenberg BH. Audio-Digest in Family Practice. Heart Failure: Congestive Heart Failure Update. Volume 54, Issue 18. May 14, 2006.

G. SELECTED ABSTRACTS

1. Greenberg BH, Chatterjee K, Werner J, Hart R, Tyberg JV, Parmley WW. Lack of deleterious effect of asynchronous ventricular contraction on ventricular performance. Clin Res 24:89A, 1977.

2. Massie B, Greenberg BH, Botvinick E, Shames D, Brundage B, Parmley WW. Agreement of Tl 201 scintigraphy and intervention ventriculography in detecting reversible segmental ischemia. Circulation 55, 56 (Suppl. III):230, 1977.

3. Schutz R, Greenberg BH, Rodgers L, Rahimtoola S. Improved cardiac performance with after-load reduction using hydralazine in patients with aortic valve prosthesis. Am J Cardiol 43:414, 1979.

4. Greenberg BH, Walsh W, Griswold H, Rodgers L, Rahimtoola S. Pre-load reduction following moderate doses of oral alcohol in patients with chronic congestive heart failure. Clin Res 27:171A, 1979.

5. Walsh W, Greenberg BH. Late results of oral hydralazine in patients with refractory heart failure. Circulation 59, 60 (Suppl. II):130, 1979.

6. Kovaric T, Greenberg BH. Oral after-load reduction: Predictors of initial response and subsequent survival. Clin Res 28:9A, 1980.

7. Karaian CH, Greenberg BH. Importance of exercise induced abnormalities in patients with aortic insufficiency. Clin Res 28(2):8A, 1980.

8. Greenberg BH, Murphy E, DeMots H, Rahimtoola S. Mechanisms of improved cardiac performance with after-load reduction in aortic insufficiency. Am J Cardiol 45:410, 1980.

9. Greenberg BH, DeMots H, Murphy E, Rahimtoola SH. After-load reduction therapy for chronic severe aortic insufficiency: Beneficial effects during rest and exercise. Am J Cardiol 45:441, 1980.

10. Greenberg BH, Massie B. Arteriolar dilators improve cardiac performance in patients with congestive heart failure despite moderate aortic stenosis. Clin Res 28(2):176A, 1980.

41

11. Greenberg BH, DeMots H, Murphy E, Rahimtoola S. Effects of arteriolar dilation on cardiac performance during rest and exercise in mitral regurgitation. Clin Res 28(2):176A, 1980.

12. Karaian CH, Greenberg BH, Rahimtoola SH. Non-invasive assessment of the left ventricle in chronic aortic insufficiency. Circulation 62 (Suppl. III):187, 1980.

13. Karaian CH, Greenberg BH, Rahimtoola SH. The tenuous relationship between functional class and hemodynamics in chronic isolated aortic insufficiency. Circulation 62 (Suppl. III):304, 1980.

14. Kerr H, Greenberg BH. Does the magnitude of post-extra systolic potentiation predict improvement in systolic pump function following aortic valve replacement? Clin Res 29(2):214A, 1981.

15. Greenberg BH, Schutz R, Griswold HE. Acute effects of alcohol on cardiac performance in patients with congestive heart failure. Clin Res 29(2):200A, 1981.

16. Hosenpud JD, Greenberg BH. Does cardiac catheterization add to the preoperative evaluation of endocarditis? Clin Res 30(1):12A, 1982.

17. Kramer B, Massie B, Loge D, Cheitlin M, Greenberg B, Bristow J D, Byrd R, Topic N. Hemodynamic correlates of the exercise ejection fraction in asymptomatic aortic regurgitation. Circulation 68 (Part II):298, 1983.

18. Siemienczuk D, Greenberg B, Broudy D, Morris C. Factors influencing the response to arterial dilation in severe chronic left heart valvular regurgitation. Circulation 68 (Part II):299, 1983.

19. Broudy D, Greenberg B, Morris C, Siemienczuk D. Effects of hydralazine on the response to static (isometric) exercise in patients with heart disease. Clin Res 32(1):3A, 1984.

20. Greenberg B, Massie B, Bristow D, Cheitlin M, Broudy D, Kramer B, Krishnamurthy G, Cox D, Loge D, Thomas D. Association between echocardiographic variables and the exercise ejection fraction response in aortic insufficiency. Clin Res 32(1):70A, 1984.

21. Massie B, Greenberg B, Cheitlin M, Thomas D, Bristow JD. Inter-test variability of echo and x-ray measurements: Implications for decision making in patients with valvular regurgitation. Clin Res 32(1):71A, 1984.

22. Massie B, Kramer B, Topic N, Greenberg B, Loge D, Cheitlin M, Bristow JD, Byrd R. Exercise hemodynamic responses in asymptomatic aortic regurgitation. Clin Res 32(1):71A, 1984.

23. Broudy D, Greenberg B, Siemienczuk D. Beneficial effects of the calcium antagonist PN 200-110 in patients with congestive heart failure. JACC 3:479, 1984.

24. Massie B, Greenberg B, Cheitlin M, Thomas D, Bristow JD. Inter-test variability of echo and x-ray measurements: Implications for decision making in patients with valvular regurgitation. J Am Coll Cardiol 3:493, 1984.

25. Broudy D, Greenberg B, Siemienczuk D, Reinhart S, DeMots H, Morris C. Static Exercise and the Response to Vasodilators. J Am Coll Cardiol 3:S33, 1984.

42

26. Massie B, Kramer B, Topic N, Greenberg B, Loge D, Cheitlin M, Bristow JD, Byrd R. Exercise hemodynamic responses in asymptomatic aortic regurgitation. J Am Coll Cardiol 3:534, 1984.

27. Greenberg B, Massie B, Bristow D, Krishnamurthy G, Cox D, Loge D, Thomas D. Association between echocardiographic variables and the exercise ejection fraction response in aortic insufficiency. J Am Coll Cardiol 3:S34, 1984.

28. Greenberg B, Massie B, Bristow D, Cheitlin M, Cox D, Loge D, Broudy D, Kramer B, Krishnamurthy G, Thomas D. Response to sub-maximal and maximal exercise in aortic insufficiency. Clin Res 1984.

29. Loge D, Cox D, Greenberg B, Krishnamurthy G, Massie B. Inter-institution variability in ejection and volume determination. J Nucl Med 12:91, 1984.

30. Siemienczuk D, Greenberg B, Broudy D. Improved cardiac performance in patients with heart failure following meal ingestion. Circulation 70:II-306, 1984.

31. Broudy D, Greenberg B, Siemienczuk D. Effects of static versus dynamic exercise on cardiac performance in patients with congestive heart failure. Clin Res 33:4A, 1985.

32. Greenberg B, Rhoden K, Barnes P. Evidence of endothelial cell dependent relaxation of pulmonary artery in man. Thorax, 1985.

33. Greenberg B, Rhoden K, Barnes P. Characteristics of VIP and PHI relaxation of bovine and human pulmonary artery. Thorax, 1985.

34. Greenberg B, Rhoden K, Barnes P. VIP causes endothelium independent relaxation in bovine and human pulmonary artery. Circulation 72:111-183, 1985.

35. Bouchard A, Yock PG, Schiller NB, Newlands JB, Massie BM, Botrimik EH, Greenberg B, Cheitlin MD. Quantitation of chronic aortic insufficiency using color doppler flow mapping. Circulation 72:111-100, 1985.

36. Cornyn J, Massie BM, Greenberg B, Loge D, Thomas D, Bristow J D, Cheitlin M, Krishnamurthy G. Reproducibility at rest and exercise radionuclide ventriculography in chronic aortic regurgitation. Circulation 72:111-152, 1985.

37. Wilson RA, Greenberg B, Siemienczuk D, Bristow D, Cheitlin M, Broudy D, Krishnamurthy G, Thomas D. Relationship between ejection fraction and the end-systolic pressure-volume ratio in chronic aortic regurgitation. Circulation 72:111-152, 1985.

38. Greenberg B, Rhoden K, Barnes P. Endothelial relaxant factor is present in human pulmonary artery. Circulation 72:111-265, 1985.

39. Cheitlin MD, Bristow JD, Massie B, Greenberg B, Thomas D, Krishnamurthy G, Loge D, Topic N, Siemienczuk D, Newlands J. Correlation of physical findings in aortic insufficiency with hemodynamic severity. J Am Coll Cardiol 7:115, 1986.

40. Wilson RA, Greenberg BH, Massie B, Bristow JD, Cheitlin M, Loge D, Broudy D, Krishnamurthy G, Thomas D. Response to maximal and submaximal exercise in aortic insufficiency. J Am Coll Cardiol 7:172, 1986.

43

41. Greenberg B, Rhoden K, Barnes P. Coronary artery relaxant effects of calcitonin gene-related peptide and vasoactive intestinal peptide. Fed Proc 45:559, 1986.

42. Massie B, Greenberg B, Cheitlin M, Bristow JD, Siemienczuk D, Loge D, Wilson R, Krishnamurthy G, Thomas D. Chronic Hydralazine therapy for aortic insufficiency. Circulation 74:II-55, 1986.

43. Greenberg B, Massie B, Bristow JD, Cheitlin M, Siemienczuk D, Topic N, Wilson R, Thomas D. Factors influencing the response to long-term arterial dilator therapy for aortic insufficiency. Circulation 76(Suppl. IV):516, 1987.

44. Edgar S, Perlmutter N, Tanz R, Greenberg B, Wilson R. Lidocaine induced coronary artery vasodilation: A dose dependent phenomenon. Clin Res 106A, 1988.

45. Jacobson N, Perlmutter N, Wilson R, Siemienczuk D, Szlachcic J, Topic N, Bristow JD, Cheitlin M, Massie B, Greenberg B. Chronic hydralazine therapy leads to improvement in electrocardiographic abnormalities in patients with chronic aortic insufficiency. Clin Res 108A, 1988.

46. Perlmutter N, Wilson R, McDonald R, Greenberg B, Nguyen L, Jacobson N, Siemienczuk D, Massie B, Cheitlin M, Bristow JD. Relationship of aortic compliance and left ventricular performance in patients with chronic aortic insufficiency. Clin Res 113A, 1988.

47. Siemienczuk D, Greenberg B, Morris C, Topic N, Wilson R, Bristow JD, Cheitlin M, Massie B. Factors associated with progression to aortic valve replacement in chronic aortic insufficiency. Clin Res 114A, 1988.

48. Haeusslein EA, Massie B, Greenberg B, Dutton D, Topic N. Is mitral regurgitation necessary for hydralazine to be an effective agent in congestive heart failure. J Am Coll Cardiol 11:143A, 1988.

49. Siemienczuk D, Greenberg B, Morris C, Topic N, Wilson R, Bristow JD, Cheitlin M, Massie B. Factors associated with progression to aortic valve replacement in chronic aortic insufficiency. J Am Coll Cardiol 11:159A, 1988.

50. Perlmutter N, Wilson R, McDonald R, Greenberg B, Nguyen L, Jacobson N, Siemienczuk D, Massie B, Cheitlin M, Bristow JD. Effect of aortic compliance on left ventricular volume and function in patients with aortic insufficiency. J Am Coll Cardiol 11:160A, 1988.

51. Greenberg B, Siemienczuk D, Massie B, Wilson R, Bristow JD, Cheitlin M. Effects of long-term vasodilator therapy on left ventricular size and function during exercise in chronic aortic insufficiency. Circulation 78(Suppl. II):208, 1988.

52. Siemienczuk D, Greenberg B, Morris C, Wilson R, Massie B, Topic N, Bristow JD, Cheitlin M. Abrupt cessation of hydralazine in chronic aortic insufficiency does not result in clinical deterioration. Circulation 80(Suppl. II):529, 1989.

53. Ontkean M, Greenberg B, Lewis H, Gay R. Endothelium-derived relaxation factor (EDRF) is diminished in congestive heart failure. Circulation 80(Suppl. II):436, 1989.

54. Wilson RA, McDonald RW, Siemienczuk D, Joyce M, Bristow JD, Cheitlin M, Massie B, Greenberg B. Relationship of aortic distensibility to systolic wall stress and left ventricular mass in patients with asymptomatic aortic insufficiency. J Am Coll Cardiol 15:6A, 1990.

44

55. Lewis H, Ontkean M, Greenberg B. The effects of fish oil on vascular reactivity in rabbits. FASEB Journal 4:A 1148, 1990.

56. Greenberg B, Kishiyama S. Rat pulmonary artery demonstrates a biphasic response to anoxia. Circulation 82 (Suppl.III):22,1990.

57. Benedict C, Johnstone DE, Bourassa M, Bittner V, Blackburn G, Greenberg B, Kay R, Kirlin P, Kohn R, McIntyre K, Weiss MB, Weiner D, Yusuf S for the SOLVD Investigators. Relationship between neurohumoral activation, severity of left ventricular dysfunction (LVD) and clinical status. JACC 17:21A, 1991.

58. Kishiyama S and Greenberg B. Hypoxic vasoconstriction in primate arteries is due to inhibition of EDRF. FASEB Journal 5:A401,1991.

59. Ontkean M, Perkins K, Gay R, Greenberg B. Effects of chronic captopril therapy on endothelium-derived relaxing factor in heart failure. Clin Res 1991 (In Press).

60. Greenberg B and the SOLVD Investigators. Long-term effects of enalapril on NYHA functional class in patients with left ventricular dysfunction. J Am Coll Cardiol 19:(215A), 1992.

61. Ontkean M, Gay R, Greenberg B. ACE inhibition with captopril improves EDRF activity in an experimental model of chronic heart failure. J Am Coll Cardiol 19:(207A),1992.

62. Greenberg B, Quinones M, Koilpillai C, Limacher M, Schindler D, Shelton D for the SOLVD investigators. Effects of long-term enalapril therapy on echocardiographic variables in SOLVD patients. Circulation 86:1-251, 1992.

63. Benedict CR, Johnstone DE, Bourassa M, Weiner D, Kirlin P, Greenberg B, Quinones M, Nicklas J for the SOLVD Investigators. Circ 86 (Suppl I)1-120, 1992.

64. Greenberg B, Perkins K, Ontkean M, Gay R. Captopril reverses progressive abnormalities in EDRF activity in chronic heart failure. J Am Coll Cardiol 21: 268A, 1993.

65. McIntyre KE, Yusuf S, Greenberg B, Mathew J, Ekelund L, Woods P, Pinkett T. Impact of atrial fibrillation on mortality, strokes and ischemic events in Studies of Left Ventricular Dysfunction (SOLVD) patients. J Am Coll Cardiol 21:102A, 1993.

66. Benedict CR, Francis G, Johnstone D, Shelton B, Kubo S, Kirlin P, Nicklas J, Chang-Seng L, Konstam M, Greenberg B, Yusuf S for the SOLVD Investigators. Effect of enalapril on plasma norepinephrine in patients with congestive heart failure. J Am Coll Cardiol 21:314A, 1993.

67. Llorens-Cortes C, Greenberg B, Huang H, Monnot C, Michel JB, Corvol P. Modulations of mRNA expression for angiotensin II (Ang II) receptor subtypes (AT1A and AT1B) analyzed by quantitative RT-PCR quantification. FASEB 7:A341, 1993.

68. Ghali JK, Weiner DH, Quinones MA, Greenberg BH, Pratt CM for the SOLVD Registry Investigators. Characteristics and prognosis of patients with preserved versus impaired left ventricular systolic function. Circ 88:I-56, 1993.

45

69. Quiñones MA, Weiner DH, Shelton BJ, Greenberg BH, Limacher MC, Koilpillai C, Shindler DM, Yusuf S for the SOLVD Investigators. Echocardiographic predictors of one-year clinical outcome in the Study of Left Ventricular Dysfunction (SOLVD) Trial and Registry: An analysis of 1172 patients. Circ 88:I-304, 1993.

70. Greenberg B, Ambrose J, Pribnow D, Perkins K, Gasc J-M. Expression of the AT1 Receptor in the heart following myocardial infarction (MI). J Am Coll Cardiol 27:16A, 1996. (Presented at key contributions poster session).

71. Ambrose J, Giraud G, Pribnow D, Greenberg G. Angiotensin II Type 1 Receptor (AT1) Blockade Improves Ventricular Relaxation After Myocardial Infarction (MI). J Invest Med, 44:147A, 1996.

72. Ghali JK, Weiner D, Greenberg B, Adams K, Benedict C, Quinones MA. Survival of patients with heart failure and preserved versus impaired left ventricular systolic function: findings from the SOLVD Registry. Circ 94:I-692, 1996.

73. Ghali JK, Weiner DH, Greenberg B, Adams K, Benedict C, Quinones for the SOLVD Registry Investigators. Does gender have an impact on survival of patients with heart failure? Findings from the SOLVD registry. J Am Coll Cardiol 29: 246A, 1997.

74. Ghali JK, Nicklas JM, Quinones MA, Benedict C, Adams KF, Greenberg B, Konstam M, Weiner D, Francis G. Prognostic value of atrial natriuretic peptide in patients with heart failure. Circ 96:Suppl I-266, 1997.

75. Slawsky MT, Colucci WS, Leier CV, Gottlieb SS, Greenberg BH, Lejemtel TH. Hemodynamic effects of levosimendan, a novel calcium sensitizer with vasodilating properties, in patients with severe heart failure: A double-blind, placebo-controlled trial. Circulation 96: Suppl I-712, 1997.

76. Gurantz D, Villarial F, Greenberg BH. Tumor necrosis factor (TNF) upregulates angiotensin II (Ang II) receptor AT1 in cardiac fibroblasts. J Molecular Cell Cardiol 30 (7):A258, 1998.

77. Greenberg BH, Gurantz D, Ruston V. Growth factor regulation of Type 1 Angiotensin II Receptor (AT1R) Expression in cardiac fibroblasts. J. Card Failure 4(3): 8, 1998.

78. Hermann DD, Kuiper JJ, Shabetai R, Carethers D, Shaw DJ, Greenberg, BH. Herbal and nutritional supplement use in heart failure populations. J. Cardiac Failure 4(1):52, 1998.

79. Nicklas JM, Gottleib SS, Greenberg BH, Hare JM, Hutchins SW, Leier CV, Singh BN, Slawski M, Smith WB, Lehtonen L. Levosimendan decreases plasma endothelin-1 levels in patients with severe heart failure. Circ 98:1-211, 1998.

80. Hermann DH, Kuiper JJ, Shabetai R, Carethers D, Shaw DJ, Greenberg BH. Herbal, Megavitamin and Nutritional Supplement (Naturoceutical) Use is Common in Heart Failure Patient Populations. J Am Coll Cardiol 33:201A, 1999.

81. Greenberg BH. Ventricular Remodeling – Implications for Pharmacologic Interventions. J Heart Disease 1:191, 1999.

46

82. Nicklas JM, Gottlieb SS, Greenberg BH, Hare JM, Hutchins SW, Leier CV, Singh BN, Slawski M, Smith WB, Lehtonen L. Levosimendan rapidly lowers plasma endothelin –1 and TNF-alpha levels in patients with severe heart failure. J Cardiac Failure, 5:Suppl 1-18, 1999.

83. Greenberg BH, Lazio LV, Cloutier D, Hermann D. Thoracic Electrical Bioimpedance measurement of cardiac performance is highly reproducible in heart failure patients. J Cardiac Failure, 5:Suppl 1-66, 1999.

84. Peng JF, Gurantz D, Cowling RT, Greenberg B. TNFa alters Angiotensin II mediated cardiac fibroblast functions in favor of fibrosis. J Cardiac Failure, 6:Suppl 2-21,2000.

85. Cowling RT, Peng JF, Gurantz D, Greenberg B. Nuclear Factor-kB activation is necessary for Type 1 Angiotensin II receptor upregulation in rat cardiac fibroblasts treated with tumor necrosis factor-alpha or Interleukin-1b. J Cardiac Failure, 6:Suppl 2-28, 2000.

86. Franciosa, JA, Abraham WT, Fowler M, Gilbert EM, Greenberg B, Massie BM, Lukas MA, Chen T, Nelson JJ, and COHERE Participant Physicians. Rationale, design and methods for COHERE (the Coreg Heart Failure Registry). J Cardiac Failure, 6 Suppl 2-50, 2000.

87. Peng J, Gurantz D, Cowling RT, Greenberg BH. TNF Induction of the AT1 Receptor Enhances Cardiac Fibroblast Functions That Favor Fibrosis. Circulation 102:11-132, 2000.

88. Exner DV, Dries DL, Domanski MJ, Konstam MA, Quinones MA, Greenberg BH. Prognostic Value of a Central, Core Laboratory, Left Ventricular Ejection Fraction Measurement Over Routinely-Determined Values: Implications for Future Cardiovascular Trials. Circulation 102:11-412, 2000.

89. Eichhorn EJ, Grayburn PA, Mayer S, St. John Sutton M, Appleton , Phehn J, Oh J, Greenberg B, DeMaria A, Krause-Steinrauf H, for the BEST Investigators. Myocardial Viability by Dobutamine Stress Echocardiography Predicts Improvement in Ejection Fraction with Beta Blockade in Patients with Heart Failure. The BEST Trial. J Am Coll Cardiol 37:179A, 2001.

90. Cintron GB, Aranda JM, Greenberg BH, Heng M, Renlund DG, Thaneemit-Chen S, Krause-Steinrauf H, for the BEST Investigators. Beta Blockade is Tolerated and Improves Cardiac Function in Elderly Heart Failure Patients. J Am Coll Cardiol 37:196A, 2001.

91. Mayer S, Grayburn PA, Eichhorn EJ, St. John Sutton M, Appleton C, Phehn J, Oh J, Greenberg B, DeMaria A, Krause-Steinrauf H, for the BEST Investigators. “Wall Motion Scone Index During Dobutamine Stress Echocardiography Best Predicts Improvement with -blocker Therapy in Heart Failure Patients”. J Am Coll Cardiol 37:389A, 2001.

92. Cowling RT, Peng JF, Gurantz D, Dillmann WH, Greenberg BH. Mechanism of Cardiac Fibroblast Type 1 Angiotensin II (AT1) Receptor Up-Regulation by Cytokines. J Cardiac Failure 7 (Suppl 2): 36, 2001.

93. Massie BM, Greenberg B, Gilbert EM, Fowler M, Abraham WT, Franciosa JA, Lukas MA, Nelson JJ, the COHERE Physicians. Carvedilol Initiation by Community Physicians in COHERE: Comparison with US Carvedilol Trials and Compassionate Use Protocols. J Cardiac Failure 7 (Suppl 2): 60, 2001.

47

94. Franciosa JA, Abraham WT, Fowler M, Gilbert EM, Greenberg B, Massie BM, Lukas MA, Nelson JJ, the COHERE Participant Physicians. Coreg® Heart Failure Registry (COHERE): Characteristics of Participating Physicians, Their Patients, and Dose-Titration Experience. J Cardiac Failure 7 (Suppl 2): 94, 2001.

95. Franciosa JA, Abraham WT, Fowler M, Gilbert EM, Greenberg B, Massie BM, Lukas MA, Nelson JJ, the COHERE Participant Physicians. Coreg® Heart Failure Registry (COHERE): Characteristics of Participating Physicians, Their Patients, and Dose-Titration Experience. Circulation 104 (Suppl II): 801, 2001.

96. Massie BM, Greenberg B, Gilbert EM, Fowler M, Abraham WT, Franciosa JA, Lukas MA, Nelson JJ, the COHERE Participant Physicians. Carvedilol Initiation by Community Physicians in COHERE: Comparison with U.S. Carvedilol Trials and Compassionate Use Protocols. ” J Am Coll Cardiol 39:461A (Suppl. A), 2002.

97. Massie BM, Franciosa JA, Abraham WT, Nelson JJ, Lukas MA, Lottes SR, Gilbert EM, Fowler M, Greenberg B, the COHERE Participant Physicians. Beta-Blockers in Patients with Left Ventricular Ejection Fraction >40%: Results from a Community- Base Registry.J of Card Failure 9, issue 5 (Suppl 1): S57, 2003

98. Abraham WT, Massie BM, Franciosa JA, Lukas MA, Lottes SR, Fowler M, Greenberg, B, Nelson JJ, Gilbert EM, the COHERE Participant Physicians. Tolerability, Safety, and Efficacy of Beta-Blockade in Black Patients with Heart Failure in the Community Setting: Insights from a Large Prospective Beta-Blocker Registry. J of Card Failure 9, issue 5 (Suppl 1):S94, 2003

99. Franciosa JA, Massie BM, Greenberg B, Gilbert EM, Fowler M, Abraham WT, Lukas MA, Nelson JJ, Lottes SR, the COHERE Participant Physicians. Titration, Titration, Tolerability, and Results of Beta-Blocker Therapy for Heart Failure in the Community: Findings of a Community- Based Registry. J of Card Failure 9, issue 5 (Suppl 1): S96, 2003.

100. Fonarow G, Abraham W, Albert N, Gheorghiade M, Greenberg B, O’Connor C, Stough W, Yancy C, Young J, She L. Should Beta Blocker Use at the Time of Hospital Discharge Be Included as a Heart Failure Performance Measure? A Report from OPTIMIZE-HF. J of Card Failure 11, 6:S182, 2005.

101. Yancy C, Stough W, Abraham W, Greenberg B, She L, Fonarow G. Defining the Natural History and Improving Quality of Care for African Americans Hospitalized with Heart Failure. A Report from OPTIMIZE-HF. J of Card Failure 11, 6:S190, 2005.

102. Greenberg B, Stough W, Albert N, Young J, She L, Fonarow G. Influence of Diabetes on Characteristics and Outcomes in Patients with Heart Failure: A Report from OPTIMIZE-HF. J of Card Failure 11, 6:S193, 2005.

103. Gheorghiade, M, Stough , O’Connor C,W, Abraham W, Greenberg B, Young J, She L, Albert N, Yancy C, Fonarow G. Serum Sodium Concentration and Mortality in Patients Admitted with Heart Failure: An Analysis of OPTIMIZE-HF. J of Card Failure V11, 6:S183, 2005.

104. Gheorghiade, M, Klein, L, Abraham, W, Albert, N, Greenberg, B, O’Connor, C, She, L,

48

Stough, W, Yancy, C, Young, J, Fonarow, G. The Relation between Admission Systolic Blood Pressure and Outcomes in Hospitalized Patients with Heart Failure: An OPTIMIZE-HF Analysis. J of Card Failure 11, 6:S196, 2005.

105. Colucci, W S, Kolias, T J, Adams, K F, Armstrong ,W F, Ghali, J K, Gottlieb, S S, Greenberg, B, Kilbaner, M, Kukin, M L, Sugg, J. Remodeling is Reversed by Metoprolol Succinate in Patients with Asymptomatic Left Ventricular Systolic Dysfunctions: The REVERT Trial. Circulation 112 (suppl II) 452, 2005.

106. Yancy, CW, Abraham, WT, Albert, NM, Gattis Stough, WA, Gheorghiade, M, Greenberg, BH, O’Connor, CM, She, L, Young, JB, Fonarow, GC. Defining the Natural History and Improving Quality of Care for African Americans Hospitalized with Heart Failure: A Report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure. Circulation 112 (Suppl II) 506, 2005.

107. Abraham WT, Albert NM, Gattis Stough WA, Gheorghiade M, Greenberg BH., O’Connor CM, Sun J, Yancy CW, Young JB, Fonarow GC. Predictors of In-Hospital Mortality in Patients Hospitalized with Heart Failure: An Analysis if 48,612 Hospitalizations from the Organized Program to Initiate Life Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Circulation 112 (Suppl II) 507, 2005.

108. Gheorghiade, M, Klein, L, Abraham, WT, Albert, NM, Greenberg, BH, O’Connor, CM,

She, L, Stough, W, Yancy, CW, Young, JB, Fonarow, GC. The Relation between Admission Systolic Blood Pressure and Outcomes in Hospitalized Patients with Heart Failure with Reduced or Preserved Sytolic Function: An OPTIMIZE-HF Analysis. Circulation 112 (Suppl II) 599, 2005.

109. Greenberg, BH, Abraham, WT, Albert, NM, Gattis Stough, WA, Gheorghiade, M,

O’Connor, CM, She, L, Yancy, CW, Young, JB, Fonarow, GC. Influence if Diabetes Mellitus on Characteristics and Outcomes in Patients Hospitalized with Heart Failure: A Report from the Organized Program to Initiate Life Saving Treatment in Hospitalized Patients with Heart failure (OPTIMIZE-HF). Circulation 112 (Suppl II) 829, 2005.

110. Gattis Stough, W, Fonarrow, GC., Abraham, WT., Albert, NM, Gheorghiade, M, Greenberg, BH., O’Connor, CM., Sun, J, Yancy, CW. Jr., Young, JB., OPTIMIZE-HF Investigators and Hospitals, Duke University Medical Center, Durham, NC. “Characteristics, Treatments and Outcomes of Patients Hospitalized for Heart Failure With Preserved Systolic Function”. JACC, 47:47A 2006.

111. Fonarrow, GC., Abraham, WT., Albert, NM., Chiswell, K, Gattis Stough, W, Gheorghiade, M, Greenberg, BH., O’Connor, Christopher M., Sun, J, Yancy, C, Young, JB., OPTIMIZE-HF Investigators and Hospitals, UCLA, Los Angeles, CA. “Performance Measures for Patients Hospitalized with Heart Failure: Are They Predictive of Clinical Outcomes?” JACC 47:255A 2006.

112. Fonarrow, Gregg C., Abraham, William T., Albert, NM., Gattis Stough, W, Gheorghiade, M, Greenberg, BH., O’Connor, CM., Sun, J, Yancy, CW. Jr., Young, JB., OPTIMIZE-HF Investigators and Hospitals, UCLA, Los Angeles, CA. “Carvedilol Use at Discharge in Patients Hospitalized for Heart Failure Is Associated with Markedly Improved Survival”. JACC 47:53A 2006.

113. Abraham, WT., Greenberg, BH., Fonarrow, GC., Albert, NM., Chiswell, K, Gattis Stough, W, Gheorghiade, M, O’Connor, CM., Sun, J, Yancy, CW. Jr., Young, JB., OPTIMIZE-HF

49

Investigators and Hospitals, The Ohio State University Heart Center, Columbus, OH. “Resynchronization Device Placement During Hospitalization for Heart Failure Is Associated with a Significant Improvement in Early Clinical Outcomes”. JACC, 47:19A 2006.

114. Gattis Stough, W, Fonarrow, GC., Albert, NM., Abraham, WT., Lokhnygina, Y, Gheorghiade, M, Greenberg, BH., O’Connor, CM., Yancy, CW. Jr., Young, JB., OPTIMIZE-HF Investigators and Hospitals, Duke University Medical Center, Durham, NC . “Comparison of Factors Identified as Precipitating Heart Failure Hospital Admissions and Clinical Outcomes”. JACC 47:263A 2006.

115. Albert, NM., Fonarrow, GC., Abraham, WT., Chiswell, K, Gattis Stough, W, Gheorghiade, M, Greenberg, BH., O’Connor, CM., Yancy, C, Young, JB., OPTIMIZE-HF Investigators and Hospitals, Cleveland Clinic Foundation, Cleveland, OH. “Do Hospitals That Provide Heart Failure Patient Education Prior to Discharge Also Promote Continuity of Care?” JACC 47:267A 2006.

116. O’Connor, CM., Abraham, WT., Albert, NM., Clare, R, Gattis Stough, W, Gheorghiade, M, Greenberg, B, Yancy, C, Young, JB., Fonarrow, GC, OPTIMIZE-HF Investigators and Hospitals, Duke University Medical Center, Durham, NC. “Predictors of Mortality After Discharge in Patients Hospitalized with Heart Failure: An Analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)”. JACC 47:83A 2006.

117. Ghali JK, Anand I, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Armstrong P. “Randomized, Double-Blind Placebo-Controlled Trial to Assess the Impact of Darbepoetin Alfa Treatment on Exercise Tolerance in Anemic Patients with Symptomatic Heart Failure: Results from STAMINA HeFT.” European Journal of Heart Failure 5(Suppl 1):122 2006.

118. Iwata M, Silva Enciso JE, Cowling RT, Greenberg BH, Department of Medicine. “Regulatory Mechanisms of Ectodomain Cleavage of Angiotensin-Converting Enzyme 2.” J. Card Fail 12:005 2006.

119. Packer M, Lukas MA, Tenero D, Baidoo C, Greenberg BH, 369 study group. “Controlled-Release Carvedilol in Heart Failure and Post-MI LVD: Pharmocokinetics , Pharmocodynamics and Safety.” J. Card Failure 12:228 2006.

120. Reynolds DM, Smith DM, Kar B, Greenberg BH, Czerska B, Abraham WT, Radovancevic B, Bergheim M, Parker I, Konstam MA. “Lessons on the Patient Population for Device Trials in Heart Failure: Early Baseline Characteristics in the MOMENTUM Trial.”J, Cardiac Failure 12:258 2006.

121. Albert, NM., Fonarrow, GC., Abraham, WT., Chiswell, K, Gattis Stough, W, Gheorghiade, M, Greenberg, BH., O’Connor, CM., Yancy, C, Young, JB.“Do Hospitals That Provide Heart Failure Patient Education Prior to Discharge Also Promote Continuity of Care?” J. of Cardiac Failure 12:368 2006.

122. Hong S, Geske D, Pung MA, Redwine L, Linke S, Greenberg BH, Mills PJ. Central vs. Effector Memory T Cell Trafficking in Response to a Physical Stressor in Congestive Heart Failure (CHF). (Psychosomatic Medicine)

50

123. Redwine LS, Linke S, Reis V, Rutledge TR, Pung MA, Hong S, Ziegler M, Greenberg B, Mills PJ. Depressive symptoms in heart failure (HF) patients are associated with reduced chemotaxis of lymphocytes. (Psychosomatic Medicine)

124. Mills PJ, Pung MA, Hong S, Redwine L, Reis V, Linke S, Rutledge TR, DimsdaleJE, Nelesen RA, Ziegler MG, Greenberg BH. Sleep Onset Insomnia in Patients with Heart Failure (HF) and Depressive Symptoms. (Psychosomatic Medicine)

125. Fonarow GC, Albert NM, O’Connor CM, Stough WG, Nunez E, Abraham WT, Gheroghiade M, Greenberg BH, Yancy CW, and Young JB. Predictors of Length of Stay in Patients Hospitalized with Heart Failure: A Report from OPTIMIZE-HF. J of Card Failure 13:285 2007.

126. Albert NM, Fonarow GC, O’Connor CM, Stough WG, Nunez E, Abraham WT, Gheorghiade M, Greenberg BH, Yancy CW, and Young JB. Is History of Depression a Predictor of In-Hospital Treatment and Early Post-discharge Outcomes in Patients with Heart Failure? A Report from OPTIMIZE-HF. J of Cardiac Failure 13:305 2007.

127. Fonarow GC, Albert NM, O’Connor CM, Stough WG, Nunez E, Abraham WT, Gheorghiade M, Greenberg BH, Yancy CW, and Young JB. Does the Day of the Week Heart Failure Patients Are Admitted Influence Length of Stay or Mortality Risk? Findings from OPTIMIZE-HF. J of Card Failure 13:347 2007.

128. Hong S, Pruitt C, Woods BG, Zapanta C, Linke S, Redwine L, Dejardin D, Rutledge TR, Dimsdale JE, Greenberg BH, Maisel A, Mills PJ. Depressive Symptoms & Inflammation in Congestive Heart Failure Patients vs. Healthy Individuals. Psychosomatic Medicine 70(3):A49-50, 2008

129. Mills PJ, Woods B, Pruitt C, Zapanta C, DeJardin D, Linke SE, Hong S, Redwine LS, Dimsdale JE, Rutledge T, Maisel A, Ziegler MG, Greenberg BH. The Effects of Psychological and Exercise Stressors on Inflammatory and Blood Pressure Responses in Heart Failure (HF). Psychosomatic Medicine 70(3):A108, 2008.

130. Redwine LS, Carter S, Linke S, Hong S, Dejardin D, Rutledge T, Greenberg B, Mills PJ.

Cynicism and Hostility are Associated with Reduced Cell Mediated Immune Function and Circulating Cellular Adhesion Molecules but not Inflammatory Cytokines in Heart Failure and Healthy Individuals. Psychosomatic Medicine 70(3):A117, 2008.

131. Redwine LS, Hong S, Linke S, DeJardin D, Greenberg B, Mills PJ. Depressive Symptoms are Associated with Cellular Immune Dysregulation in Heart Failure (HF) and Healthy Individuals. Annals of Behavioral Medicine 35:s37, 2008.

132. Mills PJ, Dimsdale JE, Ziegler MG, Maisel A, Greenberg BH. Sleep, Sleep-Disordered

Breathing, and Markers of Severity in Heart Failure (HF). Journal of the American College of Cardiology, 51(10):A72, 2008.

133. Hong S, Redwine L, Linke S, DeJardin D, Greenberg B, Mills PJ. A Potential Effect of

Beta-Blockers on Inflammatory Responses to a Psychological Stressor in Congestive Heart Failure Patients, Brain, Behavior & Immunity 2008 (in press).

134. Mills PJ, Linke S, Hong S, Redwine L, Dimsdale J, Rutledge T, Greenberg BH. Predictors

of depressed mood in heart failure (HF). Brain, Behavior & Immunity 2008 (in press)

51

135. Mills PJ, Dimsdale JE, Rutledge T, Hong S, Redwine L, Greenberg BH. Depression, Sleep, and Sleep-Disordered Breathing in Congestive Heart Failure (CHF). Sleep 2008 (in press).

136. Daniels LB, Clopton P, Jiang K, Greenberg B, and Maisel AS. Stage 0, A or B, Heart Failure with Elevated BNP Carries as Poor a Prognosis as Stage C or D with Low BNP. J Card Failure 2008(in press).

137. Zile MR, Colombo P, Mehra M, Greenberg B, Brown C, Konstam M. Progressive Improvement in Cardiac Performance produced by Continuous Aortic Flow Augmentation in Patients Hospitalized with Acute Decompensated Heart Failure: Results from the MOMENTUM Trial. Circulation, 118 (18): 2416, 2008.

138. Mills PJ, Hong S, Redwine LS, Rutledge T, Dimsdale JE, Greenberg BH. Sleep-Disordered Breathing and Health-Related Physical and Emotional Quality of Life in Heart Failure. Psychosomatic Medicine 2009 (in press).

139. Greenberg B, Chou W, Escandon R, Lee J, Saikali K, Wolff A, Shaburishvili T. Phase II safety study evaluating the novel cardiac myosin activator, CK-1827452, in patients with ischemic cardiomyopathy and angina. European Journal of Heart Failure 2009

140. Felker GM, Teerlink JF, Ponikowski P, Voors AA, Filippatos G, Greenberg BH, Teichman SL, Metra M. The impact of time to treatment on vasodilator efficacy in acute heart failure: Results from the Pre-RELAX-AHF study. European Journal of Heart Failure 2009.

141. Davison Weatherley B, Cotter G, Felker GM, Teerlink JR, Filippatos G, Voors A, Greenberg B, Metra M. Early in-hospital worsening HF predicts adverse outcome in patients admitted for AHF: results from the Pre-RELAX-AHF study. European Journal of Heart Failure 2009.

142. Teerlink JR, Metra M, Voors AA, Felker GM, Ponikowski P, Filippatos GS, Greenberg BH, Teichman SL. Vasodilators in acute heart failure (AHF): is there a blood pressure threshold? Results from the Pre-Relax-AHF study. European Journal of Heart Failure 2009

143. Voors AA, Felker GM, Metra M, Teerlink JR, Ponikowski P, Greenberg BH, Unemori E, Teichman S. Relaxin in acute heart failure: should renal dysfunction guide administrations? Results from the pre-relax AHF study. European Journal of Heart Failure 2009.

144. Udelson J, Feldman A, Greenberg B, Bertram P, Mukherjee R, Solomon H, Konstam M.Randomized, Double Blind, Multicenter, Placebo-Controlled Study Evaluation the Effect of Aldosterone Antagonism with Eplerenone on Ventrcular Systolic Dysfunction. Circulation Heart Failure 2010.

145. Wirtz P, Redwine L, Hong S, Rutledge T, Dimsdale J, Greenberg B, Mills P. Increases in B-Type Natruretic Peptide after Acute Mental stress in Heart Failure patients

are associated with Alcohol Consumption. Psychosmatic Medicine 72:A40, 2010.

146. Jimenez J, Greenberg B, Mills P. Disease Severity, Inflamation, and Sleep among Heart Failure Patients. Psychomatic Medicine72:A79, 2010.

52

147. Seon Ju Yeo, Greenberg B, Cowling R. Genetic Deletion of the Collagen Receptor, DDR2, in Mice Leads to Slower Deposition of Fibrillar Collagen by Cardiac Fibroblast. J Card Failure, 2010.

148. Jimenez JA, Greenberg BH, Dimsdale JE, Rutledge TR, Pung MA, Redwine LS, Ziegler MG, Hong S, Mills PJ. Characteristics of Antidepressant Use in Heart Failure Patients. Psychosomatic Medicine 73: A49-50, 2011.

149. Redwine LS, Hong S, Rutledge T, Dimsdale J, Greenberg B, Mills, PJ. Somatic Versus Cognitive Symptoms of Depression Associated with Specific Pro-Inflammatory Markers in Heart Failure Patients. Psychosomatic Medicine 73: A111-112, 2011.

150. Maisel A, Barnard D, Jaski B, Frivold G, Marais J, Greenberg B: HF Assessment with BNP in the Home: Primary Results of the Mulitcenter HABIT Trial. J Cardiac Failure. 2011

151. Greenberg B, Yaroshinsky A, Dittrich H, Rudy J, Zsebo K: Evaluation of the Long-Term Effects of AAV1/SERCA2a Gene Therapy on Clinical Events in Heart Failure Patients Using a Novel Statistical Model: Results and Implications for Future Trials. J Cardiac Failure 18:S59, 2011.

152. Greenberg BH, Verbalis JG, Fonarow GC, Clark MA, Lenhart J, Eckert S: Measuring CME Outcomes: Assessment of an HFSA Annual Meeting Symposium. J Cardiac Failure 18:S84, 2012.

H. NATIONAL/INTERNATIONAL PRESENTATIONS

Greenberg BH, Blackwelder W, Levy RI: "Primary type V hyperlipoproteinemia", presented at 32nd annual meeting of Am Fed Clin Res, Atlantic City NJ, May 1975.

Greenberg BH, Chatterjee K, Werner J, Hart R, Drew D, Parmley WW. "Relative importance of atrial contribution to cardiac output at various left ventricular filling pressures", presented at 49th scientific session of Am Heart Assoc, Miami Beach FL, Nov. 1976.

Greenberg BH, Hart R, Werner J, Brundage B, Botvinick E, Chatterjee K, Parmley WW: "Thallium-201 stress imaging in the follow-up evaluation of coronary bypass patients", presented at 50th scientific session of Am Heart Assoc, Miami Beach FL, Nov. 1977.

Continuing Medical Education Course: "Current concepts in clinical cardiology, "Ashland, Oregon, Sept., 1979.

CIBA/GEIGY Medical Horizons Lecturer: "The use of vasodilators in congestive heart failure", Vancouver, Washington, Sept. 20, 1979.

Providence Hospital Medical Grand Rounds: "Clinical spectrum of coronary artery spasm", Portland, Oregon, Oct. 10, 1979.

Providence Hospital M & M Conference: "Cardiovascular manifestations of Marfan's disease", Portland, Oregon, Dec. 5, 1979.

CIBA/GEIGY Medical Horizons Lecturer: "Congestive heart failure and the use of vasodilators", Allenmore Community Hospital, Tacoma, Washington, Dec. 16, 1979.

53

Oregon Critical Care Society: "Hemodynamic Workshop", Portland, Oregon, Jan. 25, 1980.

11th Annual Family Practice Review: "Vasodilator drugs in the treatment of congestive heart failure", Portland, Oregon, Jan. 13, 1980.

Greenberg BH, DeMots H, Murphy E, Rahimtoola S: "Hydralazine therapy in mitral regurgitation: Beneficial effects on cardiac performance during rest and exercise", presented at Western Section of Am Fed Clin Res, Carmel CA, Feb. 1980.

Greenberg BH, Murphy E, DeMots H, Rahimtoola S: "Mechanisms of improved cardiac performance with after load reduction in aortic insufficiency", presented at 29th annual scientific session of Am Coll Cardiol, Houston TX, March 1980.

CIBA/GEIGY Medical Horizons Lecturer: "Arterial dilator therapy in patients with valvular heart disease", Cardiovascular Research Conference, University of Washington School of Medicine, Seattle, Washington, April 15, 1980.

Continuing Medical Education Circuit Course, Coos Bay/North Bend, Oregon, May 8, 1980.Greenberg BH, DeMots H, Murphy E, Rahimtoola S: "After load reduction therapy for chronic severe aortic insufficiency: Beneficial effects during rest and exercise", presented at 8th European Congress of Cardiology, Paris, France, June 1980.

Continuing Medical Education MKSAP Course, Portland, Oregon, June 16, 1980.

Kaiser Sunnyside Hospital, Department of Medicine Lecture: "Clinical spectrum of coronary artery spasm", July 18, 1980.

Oregon Heart Association 9th Annual Session for Nurses: "Invasive versus noninvasive monitoring techniques: Which to use and when", Portland, Oregon, Sept. 18, 1980.

St. Vincent Hospital & Medical Center Medical Grand Rounds: "Cardiology update: After load reduction", Portland, Oregon, Oct. 15, 1980.

CIBA/GEIGY Medical Horizons Lecturer: "Treatment of valvular regurgitation with vasodilators", Department of Medicine, San Francisco Veterans Administration Medical Center, Nov. 1980.

CIBA/GEIGY Medical Horizons Lecturer: "Presentation of a protocol to evaluate the effects of long term arterial dilation in aortic insufficiency", Cardiovascular Research Conference, University of California, San Francisco, California, Nov. 1980.

Greenberg BH, Conway D, DeMots H, Murphy E, Rahimtoola S: "Hydralazine improves rest and exercise cardiac performance in mitral regurgitation", presented at 53rd scientific session of Am Heart Assoc, Miami Beach FL, Nov. 1980.

Oregon Psychiatric Association Annual Meeting: "Cardiovascular manifestations of cardiovascular drugs", Portland, Oregon, Jan. 23, 1981.

Greenberg BH, Kerr H: "Does the magnitude of post-extrasystolic potentiation predict improvement in systolic pump function following aortic valve replacement", presented at Western Section of Am Fed Clin Res, Carmel CA, Feb. 1981.

54

Greenberg BH, Kerr H: "Does the magnitude of post-extrasystolic potentiation predict improvement in systolic pump function following aortic valve replacement", presented at the 30th Annual Scientific Session of Am Coll Cardiology, San Francisco CA, March 1981.

CIBA/GEIGY Medical Horizons Lecturer: "Medical management of left heart valvular regurgitation", St. Patrick's Hospital, Missoula, Montana, April 3, 1981.

CIBA/GEIGY Medical Horizons Lecturer: "Current concepts in the treatment of heart failure", Kalispell, Montana, April 6, 1981.

Greenberg B, Schutz R, Griswold HE: "Acute effects of alcohol on cardiac performance in patients with congestive heart failure", presented at the 38th Annual Meeting of the American Federation of Clinical Research, San Francisco CA, April 25-27, 1981.

Continuing Medical Education Circuit Course: "Modern treatment of congestive heart failure", Ontario, Oregon, May 6, 1981.

Continuing Medical Education Circuit Course: "Rational use of antiarrhythmic agents", Medford, Oregon, May 13, 1981.

10th Annual Symposium for Acute Care Nurses, Myocardial Infarction: "Newer concepts of medical management of valvular insufficiencies", Salem Hospital, Salem, Oregon, June 5, 1981.

Salem Hospital Medical Grand Rounds: "Vasodilator therapy of valvular heart disease", Salem, Oregon, June 5, 1981.

Recent Advances in Nuclear Medicine and the Medical Practice: "Aortic Valve Regurgitation: Evaluation by radionuclide technique", Veterans Administration Medical Center, Sept. 17, 1981.

Medical Grand Rounds: "Vasodilator therapy of aortic insufficiency", St. Vincent's Hospital, Portland, Oregon, Feb. 17, 1982.

Medical Grand Rounds: "Management of post-MI patient in the year following infarction", Kaiser Hospital, San Francisco, California, April 16, 1982.

Continuing Medical Education Telephone Course: "Treatment of congestive heart failure", May 21, 1982.

Oregon Heart Association 11th Annual Session for Nurses: "Cardiovascular effects of alcohol", Portland, Oregon, Sept. 23, 1982.

Oregon Heart Association Annual Medical Sessions: Panel Discussion "Current treatment of congestive heart failure", Portland, Oregon, Sept. 24, 1982.

Medical Grand Rounds: "Vasodilator therapy or aortic insufficiency", Kaiser Hospital, Portland, Oregon, Oct. 14, 1982.

Continuing Medical Education Course: "Technetium-99 pyrophosphate scanning in acute myocardial infarction", Salishan, Oregon, Oct. 29, 1982.

Continuing Medical Education Course: "Thromboembolic complications of valvular heart disease", Salishan, Oregon, Oct. 30, 1982.

55

Medical Grand Rounds: "Vasodilator therapy of aortic insufficiency", Good Samaritan Hospital, Portland, Oregon, Nov. 10, 1982.

Continuing Medical Education Course on Swan Ganz Catheterization: "Indications, problems, and complications", Red Lion Motor Inn, Portland, Oregon, Jan. 29, 1983.

Medical Grand Rounds: "Vasodilator therapy of left heart valvular regurgitation", Providence Hospital, Portland, Oregon, Feb. 9, 1983.

14th Annual Family Practice Review: "Advances in the treatment of heart failure", Portland, Oregon, Feb. 14, 1983.

Medical Grand Rounds: "Management of the myocardial infarction survivor", Emanuel Hospital, Portland, Oregon, April 1, 1983.

Medical Staff Conference: "Treatment of the catastrophic myocardial infarction", Emanuel Hospital, Portland, Oregon, Aug. 31, 1983.

American Association Critical Care Nurses Annual Meeting: "Calcium channel blocking agents", Portland, Oregon, Oct. 5, 1983.

American College of Physicians, Idaho Regional Meeting: "Modern management of congestive heart failure and the proper place for vasodilator therapy", Boise, Idaho, Oct. 14, 1983.

Medical Staff Conference: "Current concepts in the management of heart failure", Pacific Shores Community Hospital, Newport, Oregon, Nov. 9, 1983.

Greenberg B, Massie B, Bristow D, Cheitlin M, Broudy D, Kramer B, Krishnamurthy G, Cox D, Loge D, Thomas D. "Association between echocardiographic variables and the exercise ejection fraction response in aortic insufficiency." Presented at the Western Society for Clinical Investigation, Carmel, CA, Feb. 1984.

Medical Staff Conference: "Management of congestive heart failure in 1984", St. Charles Hospital, Bend, Oregon, Jan. 5, 1984.

Greenberg B, Massie B, Bristow D, Krishnamurthy G, Cox D, Loge D, Thomas D. "Association between echocardiographic variables and the exercise ejection fraction response in aortic insufficiency." Presented at the 33rd Annual Scientific Sessions of the American College of Cardiology, Dallas TX, March 1984.

Continuing Medical Education Course on Exercise and Cardiovascular Fitness: "High altitude syndromes", Portland, Oregon, June 23, 1984.

Medical Staff Conference: "Newer cardiovascular drugs", Good Samaritan Hospital, Corvallis, Oregon, Aug. 5, 1984.

Greenberg B, Rhoden K, Barnes P. "Evidence of endothelial cell pendent relaxation of pulmonary artery in man." Presented at the British Thoracic Society, York, England, July 3, 1985.

Greenberg B, Rhoden K, Barnes P. "Characteristics of VIP and PHI relaxation of bovine and human pulmonary artery." Presented at the British Thoracic Society, York, England, July 3, 1985.

56

Greenberg B, Rhoden K, Barnes P. "Endothelial relaxant factor is present in human pulmonary artery." Presented at the 58th Scientific Session of the American Heart Association, Washington, DC, Nov. 1985.

Greenberg B, Rhoden K, Barnes P. "VIP causes endothelium independent relaxation in human pulmonary artery." Presented at the 58th Scientific Session of the American Heart Association, Washington, DC, Nov. 1985.

Greenberg B, Rhoden K, Barnes P. "Coronary Artery relaxant effects of calcitonin gene related peptide and vasoactive intestinal peptide." Presented at the Federation of American Societies for Experimental Biology, April 1986.

Medical Grand Rounds: "New aspects of vascular smooth muscle control", Oregon Health Sciences University, Portland, Oregon, May 12, 1986.

Annual Scientific Session of the American Heart Association of Idaho: "Newer modalities in the treatment of congestive heart failure", Boise, Idaho, May 16, 1986.

Cardiology Grand Rounds: "Vasodilator therapy of aortic insufficiency", George Washington University Hospital, Washington, DC, May 23, 1986.

Harvard Medical School Symposium on Calcium Antagonists: "Hemodynamic effects of PN 200-110 in congestive heart failure", Boston, Massachusetts, Sept. 11-12, 1986.Practical aspects of ACE inhibition in clinical practice: “Overview of ACE inhibition in heart failure: Rationale, efficacy, and comparative evaluation", Detroit, Michigan Sept. 13, l986.

Medical Grand Rounds: "Vasodilator Therapy of Congestive Heart Failure", Good Samaritan Hospital, Portland, Oregon, Sept. 30, 1986.

15th Annual Cardiology Symposium: "Management of Aortic Insufficiency", Fresno Community Hospital and Medical Center, Fresno, California, Nov. 8, 1986.

Greenberg B, Massie B, Cheitlin M, Bristow JD, Siemienczuk D, Loge D, Wilson R, Krishnamurthy G, Thomas D. “Chronic hydralazine therapy for aortic insufficiency.” Presented at the 59th Scientific Session of the American Heart Association, Dallas, Texas, Nov. 1986.

Greenberg B, Massie B, Bristow D, Cheitlin M, Siemienczuk D, Topic N, Wilson R, Thomas D. "Factors influencing the response to long-term arterial dilator therapy for aortic insufficiency."

Medical Grand Rounds: "Treatment of Congestive Heart Failure", St Charles Hospital, Bend, Oregon, Feb. 6, 1987.

Practical Aspects of Office and Hospital Cardiology: "Management of Congestive Heart Failure", Rogue Valley Medical Center, Medford, Oregon, Oct. 2, 1987.

Satellite Symposium at the Second Cardiovascular Pharmacotherapy International Symposium on Expanding Role of Calcium Antagonists in Cardiovascular Therapy: "New Therapies in Congestive Heart Failure", San Francisco, California, Oct. 18, 1987.

Presented at the 60th Scientific Session of the American Heart Association, Anaheim, CA, Nov. 19, 1987.

57

Greenberg B, Siemienczuk D, Morris C, Topic N, Wilson R, Cheitlin M, Bristow JD, Massie B. "Factors associated with progression to aortic valve replacement in chronic aortic insufficiency", presented at Western Section of Am Fed Clin Res, Carmel, CA, Feb. 1988.

Satellite Symposium at American College of Cardiology Scientific Sessions on the Heart in Hypertension: "Can calcium channel blockers be effective in congestive heart failure?", Atlanta, Georgia, March 31, 1988.

Oregon Heart Association Annual Meeting: "Congestive heart failure-natural history and vasodilators", Portland, Oregon, April 15, 1988.

Medical Grand Rounds: "Newer strategies in the management of congestive heart failure", Sacred Heart Hospital, Eugene, Oregon, Nov. 29, 1988.

Greenberg B, Siemienczuk D, Massie B, Wilson R, Bristow JD, Cheitlin M. "Effects of long-term vasodilator therapy on left ventricular size and function during exercise in chronic aortic insufficiency." Presented at 61st Scientific Session of the American Heart Association, Washington, D.C., Nov. 16, 1988.

Medical Grand Rounds: "Recent observations regarding evaluation and treatment of aortic insufficiency", Oregon Health Sciences University, Portland, Oregon, Jan. 31, 1989.

Medical Grand Rounds: "Management of congestive heart failure", Tuality Hospital, Hillsdale, Oregon, March 9, 1989.

Cardiology Grand Rounds: "Treatment of hypertension in the 1990's", Cook County Hospital, Chicago, Illinois, May 10, 1989.

Sommer Memorial Lectures Symposium: "The failing myocardium - lessons learned from past experience", Portland, Oregon, Oct. 21, 1989.

Sommer Memorial Lectures Symposium: "Advances in medical therapy for the failing heart - current perspective and future directions", Portland, Oregon, Oct. 21, 1989.

Medical Conference: "Management of congestive heart failure", Willamette Hospital, Oregon City, Oregon, Oct. 31, 1989.

Satellite Symposium of the American Heart Association: "Management of the hypertensive patient with congestive heart failure", New Orleans, Louisiana, Nov. 12, 1989.

Medical Grand Rounds: "Current therapy of hypertension", St. Johns Hospital, Longview, Washington, Dec. 5, 1989.

Satellite Symposium of the American Society of Nephrology: "Cardiac contractility and conduction: A comparison of the anti-hypertensives", Washington, DC, Dec. 21, 1989.

Greenberg B. "Dietary fish oil in experimental models of atherosclerosis. "International Symposium on Fish Oil and Blood-Vessel Wall Interactions.” Granada, Spain, February 23, 1990.

Annual Meeting of the American Heart Association, Oregon Affiliate: "Serendipity and Scientific Inquiry", Portland, OR, June 21, 1990.

58

Medical Grand Rounds: "New directions in the treatment of congestive heart failure", Kaiser Foundation Hospital, San Jose, CA, June 27, 1990.

Medical Conference: "Current management of heart failure", Kennewick General Hospital, Kennewick, WA, July 17, 1990.

Medical Grand Rounds: "Problems and solutions in the management of congestive heart failure", Sacred Heart Hospital, Spokane, WA, July 31, 1990.

Medical Grand Rounds: "Pathophysiology and treatment of left ventricular dilatation", Madigan Army Hospital, Tacoma, WA, August 10, 1990.

Greenberg B, Kishiyama S. "Hypoxia induces endothelium-dependent constriction in primate cerebral arteries." VIth International Symposium on Biology of Vascular Cells, Paris, France, August 29, 1990.

Cardiology Update for the Primary Care Physician (Cardiology Division yearly CME course): "Current concepts and pathogenesis of acute coronary syndromes", Salishan Lodge, Oregon, October 13, 1990.

Greenberg B, Kishiyama S. "Rat pulmonary artery demonstrates a biphasic response to anoxia." Presented at the 62nd Scientific Session of the American Heart Association, Dallas, Texas, November 12, 1990.

UCLA sponsored CME course: "Current trends in the treatment of congestive heart failure", Marina Del Rey, CA, May 29, 1991.

Medical Grand Rounds: "Rationale and use of ACE inhibitors in the treatment of congestive heart failure", Providence Hospital, Medford, OR, June 25, 1991.

Medical Grand Rounds: "Remodeling of the left ventricle", Emanuel Hospital, Portland, OR, July 23, 1991.

UCSF Tri-Hospital Cardiology Conference: "Effects of vasodilator therapy on remodeling the left ventricle in chronic volume overload, UCSF Medical Center, San Francisco, CA, July 24, 1991.

Greenberg B. "Hypoxic vasoconstriction is impaired in chronic heart failure." Presented at FASEB Summer Research Conference on "Endothelium and Cardiovascular Function", July 28-August 2, 1991 Copper Mountain, Colorado.

Medical Grand Rounds: "Remodeling in the compromised left ventricle", VA Medical Center, Tacoma, WA, Sept. 17, 1991.

Cardiovascular Update Pacific NW Medical Education Institute: "Therapeutic strategies in congestive heart failure", Everett, WA, Sept. 24, 1991.

American College of Cardiology - 8th Santa Fe Colloquium on Cardiovascular Therapy: "Endothelial function in health and disease (including CHF)", sponsored by the University of New Mexico School of Medicine, Oct. 10, 1991.

59

American College of Cardiology - 8th Santa Fe Colloquium on Cardiovascular Therapy: "The vasodilator concept: Prevention and/or improvement of left ventricular dysfunction", sponsored by the University of New Mexico School of Medicine, Oct. 10, 1991.

American College of Cardiology - Cardiology Update 1991: "Management of the asymptomatic patient with aortic or mitral regurgitation", sponsored by the University of Calif., San Francisco, CA, Oct. 11, 1991.

Continuing Medical Education Course on Heart Failure: Current and Future Strategies for Management: "Review of current and future studies relating to long-term management of chronic heart failure and left ventricular dysfunction", sponsored by the Oregon Health Sciences University, Portland, OR, Oct. 17, 1991.

Symposium on Recent Advances in the Management of Heart Failure: Focus on the Effects of Angiotensin-Converting Enzyme Inhibitors: "Long-term effects of enalapril on left ventricular structure and function in SOLVD patients".Sponsored by the Working Group on Drug Therapy in Cardiology of the European Society of Cardiology, Cologne, Germany, November 23, 1991.

IFECCII International Forum for the Evaluation of Cardiovascular Care: "Treatment and Prevention of Left Ventricular Dysfunction: SOLVD Results and Echocardiographic Data", Monte Carlo, January 24, 1992

Workshop on Heart Failure: "Long-term Effects of ACE Inhibition in Congestive Heart Failure: Results of the SOLVD Study", sponsored by the 3rd International Congress of Cardiology: Prospects and Strategies, Brussells, Belgium, February 17, 1992.

Greenberg B. for the SOLVD Investigators. "Long-term effects of enalapril on NYHA functional class in patients with left ventricular dysfunction.” Presented at the 41st annual scientific sessions of the American College of Cardiology. Dallas, April 14-18, 1992.

Greenberg B. "Captopril improves EDRF activity in congestive heart failure.” Presented at the 2nd International Symposium on Endothelium-Derived Vasoactive Factors, Basel, Switzerland, April 22-25, 1992.

Greenberg B. "Effects of long-term enalapril therapy on echocardiographic variables in SOLVD patients." Presented at the 63rd Annual Scientific Sessions of the American Heart Association, New Orleans, November 15-19, 1992.

Cell Biology and Anatomy Department Seminar: "Quantification of AT1 Receptor Gene Expression Using RT-PCR", Oregon Health Sciences University, February 3, 1993.

Visiting Professor USC-LA County Hospital: "Use of Prophylactic Vasodilator Therapy in the Management of Patients with Valvular Insufficiency or Left Ventricular Dysfunction", Los Angeles, CA, February 8, 1993.

Los Angeles Area Heart Failure Club: "Nitric Oxide and its Role in the Pathogenesis of CHF", Los Angeles, CA, February 8, 1993.

Medical Grand Rounds Long Beach Veterans Administration Medical Center: "The Effects of ACE-Inhibition on Mortality in Heart Failure", Long Beach, CA, February 9, 1993.

60

Cardiology Grand Rounds, University of California, San Francisco: "Clinical Review of Mortality Studies in Congestive Heart Failure", San Francisco, CA, February 24, 1993.

Medical Grand Rounds, University of So Calif/LA County Hospital: "Update on the Role of ACE Inhibitors in CHF", Los Angeles, CA, June 9, 1993.

Medical Grand Rounds, Wadsworth Veterans Administration Medical Center: "ACE Inhibitors in CHF-Effects on Mortality and Potential Mechanisms", Los Angeles, CA, June 10, 1993.

Medical Grand Rounds, Hood River Memorial Hospital: "Recent Advances in the Treatment of Heart Failure", September 14, 1993.

Continuing Medical Education Course on Cardiology for the Primary Care Physician: Update 1993: "Myocardial Infarction Survivors (What have SOLVD, SAVE, V-HeFT, etc. done for them lately?)", Sponsored by the Oregon Health Sciences University, Salishan, OR, October 15, 1993.

Symposium on Management of Patients after MI: Role of ACE Inhibitors: "Effects of Enalapril in Post-MI Patients: Results of the SOLVD Echocardiographic Sub-Study", Satellite Symposium of the AHA Scientific Sessions, Atlanta, GA, November 7, 1993.

Medical Grand Rounds, Oregon Health Sciences University: "Cardiac Hypertrophy Post-MI: Description, Causes and Sequelae", Portland, OR, January 25, 1994.

Cardiology Grand Rounds, Scripps Clinic: "Post-MI Cardiac Remodeling", La Jolla, CA, February 10, 1994.

Cardiology Rounds, Valley Medical Center: "Effect of ACE Inhibitors on Survival in Patients with LV Dysfunction", Fresno, CA, March 2, 1994.

Cardiology Grand Rounds, Good Samaritan Hospital: “Left Ventricular Remodeling after Myocardial Infarction", Portland, OR, March 3, 1994.

Latin American Symposium on Advances in Cardiovascular Care: Strategies for Prevention and Treatment: “Remodeling Post-Myocardial Infarction", Orlando, Florida, May 13-14, 1994.

OHSU Internal Medicine Review Course: “Mechanisms and Management of Congestive Heart Failure", Portland, OR, May 19, 1994.

International conference on Progression of Atherosclerosis in Anginal Syndromes and Heart Transplantation: “Influence of ACE-Inhibitors on Major Ischemic Events", Sponsored by the Working Group on Microcirculation (European Society of Cardiology), Lugano, Switzerland, June 23, 1994.

Satellite Symposium of the XII World Congress and XVI Congress of the European Society of Cardiology: Post-Infarct Remodeling and Expansion: Rationale and Time of Treatment: “Effect of ACE Inhibition on Cardiac Remodeling After MI", Berlin, Germany, September 12, 1994.

10th Asian Congress of Cardiology: “The Role of ACE Inhibitors in Heart Failure and Left Ventricular Dysfunction", Bangkok, Thailand, November 30, 1994.

Medical Grand Rounds, Medical College of Wisconsin: “Role of the Renin-Angiotensin System in Cardiac Remodeling", Milwaukee, Wisconsin, January 13, 1995.

61

Cardiology Primary Care Conference: "Congestive Heart Failure", Oregon State University, Corvallis, OR, January 27, 1995.

Medical Grand Rounds: “Cardiac Remodeling Post-MI”, Alvarado Hospital, San Diego, CA, April 25, 1995.

Cardiology Grand Rounds: “Effects of ACE Inhibitors on Acute Coronary Events”, University of California, San Diego, April 26, 1995.

Cardiology Grand Rounds: “Medical Management of the Symptomatic Patient with Aortic Insufficiency”, Lenox Hill Hospital, New York City, May 1, 1995.

AHA Symposium Cardiology for the Primary Care Provider: “Therapeutic Advances in Congestive Heart Failure”, Boise, ID, May 19, 1995.

Medical Grand Rounds: “Cardiac Transplantation”, Scripps Memorial Hospital, Encinitas, CA, May 22, 1995.

Medical Grand Rounds: “The role of AT1 receptor blockers in the treatment of cardiovascular disease”, Alvarado Hospital, San Diego, CA, May 23, 1995.

UCSD Symposium Heart Failure in 1995: “Beta blocker therapy of heart failure - Is it time to break the taboo?”, San Diego, CA, June 3, 1995.

American College of Cardiology sponsored course in Critical Care Cardiology: “Refractory Heart Failure”, Organized by the University of California, San Francisco, August 11, 1995.

Medical Grand Rounds: “Current trends in the treatment of heart failure”, Paradise Valley Hospital, San Diego, CA, September 20, 1995.

Medical Grand Rounds: “New approaches to the treatment of heart failure”, Palomar Hospital, Escondido, CA, September 21, 1995.

15th Annual Madera Cardiology Symposium: “Ventricular remodeling after myocardial infarction: New interventions and strategies for preventing left ventricular dysfunction”, Saint Agnes Medical Center, Madera, CA, September 27, 1995.

3rd Annual Cardiology Update for Primary Care Physicians: “Congestive heart failure”, Heart Institute of Western Medical Centers, Costa Mesa, CA, October 14, 1995.

EDEN Investigators Meeting: SOLVD: Results of the main trials and Echo sub-study, Madrid, Spain, November 7, 1995.

Heart Failure Summit: Mending the Broken Heart: “Beta-blockers: Have they been vindicated in heart failure”, Satellite symposium to the AHA Scientific Sessions, Anaheim, CA, November 12, 1995.

Merck International Cardiovascular Council: “SOLVD: Major Results: The Importance of Ventricular Remodeling”, London, England, December 2, 1995.

Cardiology Grand Rounds: “Management of the patient with refractory heart failure”, University of California, Irvine, January 5, 1996.

62

Family Practice Grand Rounds: “Heart Failure”, University of California, San Diego, January 24, 1996.

UCSD 21st Annual Postgraduate Course in Internal Medicine: “Meet the Professors: Ins and Outs of Heart Failure”, San Diego, CA, February 26, 1996.

Greenberg B, Ambrose J, Pribnow D, Perkins K, Gasc J-M. “Expression of the AT1 receptor in the heart following myocardial infarction (MI).” Presented at the 45 th Annual Scientific Session of American College of Cardiology, Orlando, March 24, 1996.

American Heart Association Oregon Affiliate Annual Scientific Symposium: “New Directions in CHF - Beyond ACE Inhibitors”, Portland, OR, April 12, 1996.

Critical Care Nursing Symposium Presented by Mercy Healthcare and Scripps Health: “New Developments in the Treatment of Heart Failure”, San Diego, CA, April 16, 1996.

NIH Sponsored CME Program: Can We Reverse Remodel the Failing Ventricle?: “Effect of ACE Inhibitors on Pathological Remodeling in Heart Failure”, Baltimore, MD, April 18, 1996.

UCSD 2nd Annual Heart Failure Symposium: “Role of the Renin-Angiotensin System in the Development of Heart Failure”, San Diego, CA, June 1, 1996.

UCSD 2nd Annual Heart Failure Symposium: “Beta-blocker Therapy of Heart Failure”, San Diego, CA, June 1, 1996.

Nevada Academy of Family Physicians Membership Meeting: “The Role of the Renin-Angiotensin System in Cardiovascular Disease”, Las Vegas, Nevada, June 20, 1996.

San Diego Academy of Family Physicians 40th Annual Postgraduate Symposium: “Treatment of Heart Failure”, San Diego, California, June 30, 1996.

Pan-Asian Symposium: “Benefits of ACE Inhibition in Hypertensive Patients with Left Ventricular Dysfunction”, Hong Kong, July 28, 1996.

University of Arizona Cardiology Grand Rounds: “Role of Hypertension in Heart Failure”, Tucson, Arizona, September 6, 1996.

Smith-Kline Beecham US Heart Failure Advisory Council Meeting: “Lessons Learned from Recent Mortality Trials with Positive Inotropic Drugs”, Dallas, Texas, September 10, 1996.

Medical Grand Rounds: “Treatment of Refractory Heart Failure”, Alvarado Hospital, San Diego, California, September 23, 1996.

UCSD Medical Grand Rounds: “Beta-Blocker Therapy of Heart Failure - Where Do We Stand?”, University of California, San Diego, October 2, 1996.

Medical Grand Rounds: “Congestive Heart Failure”, Mercy Hospital, San Diego, California, December 5, 1996.

Medical Grand Rounds: “Reducing the Clinical and Economical Costs of Heart Failure”, St Jude’s Medical and Rehabilitation Center, Fullerton, California, December 17, 1996.

63

UCSD 22nd Annual Topics and Advances in Internal Medicine: “Update on Beta-Blocker Therapy of Heart Failure”, San Diego, California, February 17, 1997.

UCSD Cardiology Grand Rounds: “Aortic Regurgitation”, San Diego, California, February 19, 1997.

Medical Grand Rounds: “Congestive Heart Failure”, Annenberg Center for Health Sciences at the Eisenhower Hospital, Palm Springs, California, March 20, 1997.

Cardiovascular Physiology Seminar: “The Role of Renin-Angiotensin System in Cardiac Remodeling”, Tufts-New England Medical Center, Boston, Massachusetts, March 27, 1997.

Medical Grand Rounds: “Improving Prognosis in Heart Failure: Advances in Intervention”, Rancho Los Amigos Medical Center, Downey, California, April 24, 1997.

UCSD 3rd Annual Heart Failure Symposium: “Treatment of Refractory Heart Failure”, San Diego, California, June 7, 1997.

UCSD 3rd Annual Heart Failure Symposium: “New Approaches to the Management of Heart Failure”, San Diego, California, June 7, 1997.

San Diego Academy of Family Physicians 41st Annual Postgraduate Symposium: "Heart Failure 1997: An Approach to Optimal Therapy for the Primary Care Physician", San Diego, California, June 28, 1997.

Medical Grand Rounds: "Improve Prognosis in Heart Failure: Advances in Intervention", Daniel Freeman Hospital, Marina Del Rey, California, July 18, 1997.

Cardiology Conference: "Improving Prognosis in Heart Failure", Grossmont Hospital, La Mesa, California, September 17, 1997.

First Annual Scientific Meeting of the Heart Failure Society of America: Improving Clinical Outcomes and Cost Effectiveness in the Advanced Heart Failure Patient: "Implementing Aggressive Therapeutic Strategies for Improving Patient Outcomes", Baltimore, Maryland, September 23, 1997

Invited Speaker: "Update on Beta-blocker Therapy for Heart Failure", Medical College of Wisconsin, Milwaukee, Wisconsin, October 16, 1997.

Medical Director Summit Faculty, National Managed Health Care Congress: Sixth Annual Corporate and Managed Cared Medical Director Summit, "Treatment Advances in Congestive Heart Failure", Los Angeles, California, November 2-3, 1997.

Invited Speaker: "New and Investigational Therapies of Heart Failure", Balboa Naval Hospital, San Diego, California, November 6, 1997.

American Heart Association 70th Scientific Sessions Satellite Symposium on Controversies and Consensus: Addressing Challenges on Heart Failure Management: "Mild heart failure is increasingly managed by the primary care physician: How should carvedilol be managed in these situations?" Orlando, Florida, November 8, 1997.

American Heart Association 70th Scientific Sessions Satellite Symposium: New Standard of Care in Heart Failure: "Symptomatic Systolic Heart Failure", Orlando, Florida, November 9, 1997.

64

Alvarado Hospital Medical Center Medical Grand Rounds: "New Advances in the Treatment of Heart Failure", San Diego, California, November 25, 1997.

Medical Grand Rounds: "New Therapies for Congestive Heart Failure", Saddleback Memorial Medical Center, Laguna Hills, California, January 14, 1998.

Residents' Conference: "Carvedilol" Mercy Hospital & Medical Center, San Diego, California, February 5, 1998.

Invited Speaker, 23rd Annual Postgraduate Course, Topics & Advances in Internal Medicine: "Recent Advances in Heart Failure", La Jolla, California, February 9, 1998.

Invited Speaker, Fourth Annual Cardiovascular Symposium: The Failing Heart--Current Concepts in Management:

1) “Evolving Concepts of the Pathogenesis of Heart Failure”2) “The Medical Management of Heart Failure in 1998 (and peek into the future)”3) “Current Approaches to the Surgical Management of Heart Failure”4) “Update on Cardiac Transplantation--Evaluation, Referral and Results”

White Memorial Medical Center, Los Angeles, California, February 11, 1998.

Invited Speaker: Council on National Cardiac Education for Registered Nurses: "Redefining Standard Therapy: Current Strategies to Improve Prognosis", Dallas, Texas, March 14, 1998.

Medical Grand Rounds: "Advances in the Treatment of Congestive Heart Failure", Mercy Hospital, San Diego, California, April 7, 1998.

Kaiser Permanente 2nd Cardiology Retreat-Symposium on Heart Failure: "Beta-blockers: Why, When and How?", Napa, California, May 1, 1998.

Cardiology Grand Rounds: "Recent Advances in Treating Heart Failure", Henry Ford Hospital, Detroit, Michigan, May 6, 1998.

Cardiology Conference: "Recent Advances in Treating Heart Failure", William Beaumont Hospital, Royal Oak, Michigan, May 6, 1998.

Cardiology Grand Rounds: "Post-MI Cardiac Remodeling", University of California, Los Angeles, May 8, 1998.

Medical Grand Rounds: "New Directions in the Treatment of Heart Failure", Providence St. Peter's Hospital, Olympia, Washington, May 15, 1998.

University Hospital Grand Rounds: "Pathophysiology and Treatment of Cardiac Remodeling", University of Hawaii, Honolulu, Hawaii, May 19, 1998.

Queen's Heart Institute Distinguished Lecturer: "New Concepts in the Treatment of Hypertension and Heart Failure", Honolulu, Hawaii, May 19, 1998.

Medical Grand Rounds: "New Approaches and Current Management of Heart Failure", Maui Memorial Hospital, Maui, Hawaii, May 21, 1998.

Hawaii Chapter Society of Critical Care Medicine: "Management of End-Stage Heart Failure", Honolulu, Hawaii, May 21, 1998.

65

QMC Grand Rounds: "New Approaches and Current Management of Heart Failure", Queen's Medical College, Honolulu, Hawaii, May 22, 1998.

University of Cincinnati CME Course: "The New Standard Therapy: How Your Patients Will Benefit", Cincinnati, Ohio, June 19, 1998.

UCSD 4th Annual Heart Failure Symposium: "Cardiac Remodeling - Pathogenesis, Clinical Implications and Treatment", La Jolla, California, June 20, 1998.

UCSD 4th Annual Heart Failure Symposium: "Beta Blocker Therapy of Heart Failure", La Jolla, California, June 20, 1998.

Satellite Symposium of the XX Congress of the European Society of Cardiology: New Concepts in Cardiac Remodeling and their Clinical Relevance, "Cardiac Remodeling: Implications for the Clinician", Vienna, Austria, August 25, 1998.

Satellite Symposium of the 2nd Annual Scientific Meeting of the HFSA: "Frontiers of Angiotensin Research in the Management of Heart Failure", Boca Raton, Florida, September 13, 1998.

Greenberg BH, Gurantz D, Ruston V. “Growth factor regulation of Type 1 Angiotensin II Receptor (AT1R) Expression in cardiac fibroblasts.” 2nd Scientific Meeting of the HFSA, Boca Raton, Florida, September 14, 1998.

Cardiology Grand Rounds: "Cardiac Remodeling: Pathogenesis and Clinical Implications", Tulane University, New Orleans, LA, September 17, 1998.

USC Heart Failure Symposium: "Beta Blockers for Treatment of Congestive Heart Failure-From Theory to Practice", Los Angeles, January 30, 1999.

USC Heart Failure Symposium: New Drugs for the Treatment of Congestive Heart Failure-Natriueretic Peptides and Endothelin Inhibitors: Mechanisms of Action and Results of Clinical Trials, Los Angeles, January 30, 1999.

24th Annual UCSD Postgraduate Course: Topics and Advances in Internal Medicine: "Meet the Professor: Beta-Blocker Therapy of Heart Failure-Where do we start in 1999", San Diego, February 24, 1999.Moderator for Satellite Symposium of the American College of Cardiology 48th Annual Scientific Sessions "Heart Failure Treatment 1999: Challenges and Consensus, New Orleans, LA, March 6, 1999.

American College of Cardiology 48th Annual Scientific Session:1) Luncheon Panel Program Participant "Drug Therapy of Heart Failure", New Orleans, LA, March 8, 1999.2) Speaker at Symposium on Cardiac Remodeling "Molecular Mechanisms Responsible

for Remodeling", New Orleans, LA, March 9, 1999.3) Meet the Experts Co-Chair "Beta Blockers on Heart Failure", New Orleans, LA, March

10, 1999.

Medical Grand Rounds “Beta-Blockers”, Mercy Hospital, San Diego, CA, April 1, 1999.

66

Symposium at the ACCP/ESCP International Congress on Clinical Pharmacology "Emerging Treatment Approaches: Natrueretic Peptides, Inodilators and other IV agents, Orlando, FL, April 14, 1999.

UCSD 5th Annual Heart Failure Symposium. “Blockade of the Renin-Angiotensin-Aldosterone and Sympathetic Nervous Systems – Why, When, How”, La Jolla, CA, June 12, 1999.

UCSD 5th Annual Heart Failure Symposium. “New Approaches to Treating Heart Failure”, La Jolla, CA, June 12, 1999.

AstraZeneca 1999 West Coast Managed Care Advisory Board Meeting. “Pharmacologic Approach to Treating Hypertension in Cardiovascular Disease”, Coronado, CA, June 26, 1999.

ACC California Chapter Meeting. “Role of the Renin Angiotensin System in Cardiac Remodeling”, Costa Mesa, CA, Sept. 2, 1999.

Queens Medical Center Symposium Cardiovascular Disease 1999. “Heart Failure: Recent Developments in Management”, Honolulu, HI, Sept. 18, 1999.

Greenberg BH. “Ventricular Remodeling – Implications for Pharmacologic Interventions.” 1st International Congress on Heart Disease. Washington, DC, September 19, 1999.

Satellite Symposium of the 3rd Annual Scientific Sessions of the Heart Failure Society of America on Management of Acute Heart Failure: Update on Calcium Sensitizers. “Calcium sensitization: The Mechanism of Action”, San Francisco, CA, Sept. 22, 1999.

Satellite Symposium of the 3rd Annual Scientific Sessions of the Heart Failure Society of America on Cardiac Resynchronization Through Biventricular Pacing. “An Overview of Clinical Trials”, San Francisco, CA, September 23, 1999.

Satellite Symposium of the 3rd Annual Scientific Sessions of the Heart Failure Society of America on Optimal Care Strategies for Chronic Heart Failure. “Clinical Case Review”, San Francisco, CA, September 25, 1999.

UC Davis Cardiology Grand Rounds. “New Insights into Post-MI Cardiac Remodeling”, Davis, CA, October 8, 1999.

1999 Annual Cardiology Symposium for Southern California Kaiser Permanente. “Neurohormonal Blockade: Why, When and How to Block the Renin-Antiotensin-Aldosterone and Sympathetic Nervous Systems in Heart Failure”, San Diego, CA, October 23, 1999.

Oschner Foundation Medical Grand Rounds. “Post-MI Cardiac Remodeling”, New Orleans, LA, October 27, 1999.

Oschner Foundation Medical Grand Rounds. “Beta-Blocker Therapy of Heart Failure”, New Orleans, LA, October 27, 1999.

Medical Grand Rounds. “New Directions in Heart Failure Treatment”, Eisenhower Medical Center, Palm Springs, CA, November 4, 1999.

Satellite Symposium on Heart Failure Management of the 72nd Scientific Sessions of the AHA. “Cardiodynamic Effects and Mechanisms of Action of Beta Blockers”, Atlanta, GA, November 6, 1999.

67

Cardiology Grand Rounds. “Beta Blocker Therapy of Heart Failure”, Grossmont Hospital, San Diego, CA, November 18, 1999.

Cardiology Grand Rounds. “Molecular Mechanisms of Cardiac Remodeling”, Mayo Clinic, Rochester, Minnesota, December 1, 1999

Molecular Biology Seminar Series. “Post-MI Cardiac Remodeling”, San Diego State University, San Diego, CA, February 3, 2000.

UCSD Symposium on Heart Failure for the Primary Care Physician: 1) “Management of the Patient with Refractory Heart Failure” 2) “Rationale and Practical Aspects of Beta Blocker Therapy”

San Diego, CA, February 12, 2000.

Medical Grand Rounds. “Update on CHF”, Cottage Hospital, Santa Barbara, CA, March 2, 2000.

Symposium at the 49th Annual Scientific Sessions of the ACC “Is It Possible to Prevent Heart Failure? Reviewing the Evidence” – Management of Valvular Heart Disease. Anaheim, CA. March 13, 2000.

American Heart Association Regional Symposium “Heart Failure 2000”:1) “What are the Mechanisms and Clinical Significance of Left Ventricular Remodeling?”2) “Neurohormonal Blockade: ACE Inhibitors, Angiotensin Receptor Blockers, Aldactone”3) “New Approaches to Medical Therapy in Heart Failure: Nitrates (revisited), Natriuretic

Peptides, Endothelin Blockers, Cytokine Inhibitors”4) “Medical Approach to the Patient with Refractory Heart Failure”

Monterey, CA. April 7-8, 2000.

UCSD Cardiovascular Center Faculty Ambassador Series. “Heart Failure: The Silent Epidemic in the U.S. – What is it? How to Recognize it and New Treatments.” San Diego, CA. April 11, 2000

Medical Grand Rounds. “Preventing Heart Failure.” West LA Veterans Administration Hospital, Los Angeles, CA. April 19, 2000.

Greenberg BH. “Treatment of CHF: state of the art and perspectives.” New insights and their therapeutic strategies in cardiovascular diseases: Focus on endothelial targets. Venice, Italy, April 28-29, 2000.Hospital Staff Conference. “Treatment of Heart Failure in 2000.” Paradise Valley Hospital, San Diego, CA. May 4, 2000.

Cardiology Grand Rounds. “Post-MI Cardiac Remodeling.” Case Western Reserve University, Cleveland, Ohio. May 11, 2000.

UCSD Conference for visiting cardiologists from the Netherlands “Molecular Basis of Cardiovascular Disease” – Cardiac Fibrosis and ECM Remodeling. La Jolla, CA. May 15, 2000.

Medical Grand Rounds “Cardiac Remodeling: Clinical Implications”. St. Charles Memorial Hospital, Bend, OR. June 2, 2000.

36th Annual Meeting of the Drug Information Association “The DSMB from the Physician’s Perspective”. San Diego, CA. June 14, 2000.

68

UCSD 6th Annual Heart Failure Symposium: Heart Failure in the New Millennium 1) “Prevention of Heart Failure” 2) “Treatment of Heart Failure in the Year 2000”

La Jolla, CA, June 17, 2000.

Cardiology Symposium 2000 “Beta Blockade in Heart Failure: Examining the Issues”. Encino-Tarzana Regional Medical Center, Tarzana, CA. June 27, 2000.

Symposium for Glendale Hospital “Treatment of Heart Failure in Y2K”. Glendale, CA. July 8, 2000.

Satellite Symposium of the XXII Congress of the European Society of Cardiology “Management of acute heart failure: are there new options?” Amsterdam, Netherlands, August 29, 2000.

Heart Failure Society of America 4th Scientific Meeting:1) “Attenuation of Remodeling by Medical Therapy Prevents Heart Failure”2) “Does Extracellular Matrix Remodeling Contribute to Cardiac Dysfunction in the Failing

Heart?”Boca Raton, Florida. September 10-13, 2000.

Medical Staff Meeting “Update on Cardiac Transplantation”. Alvarado Medical Center, San Diego, CA. September 26, 2000.

CME Meeting “The Current Treatment of Heart Failure”. Kaiser Permanente Medical Center, Woodland Hills, CA. October 24, 2000.

Medical Staff Meeting “Congestive Heart Failure – Disease Update”. Presbyterian Intercommunity Hospital, Whittier, CA. October 25, 2000.

AHA Western States Affiliate 68th Annual Fall Symposium “Pathophysiology of Heart Failure”. Los Angeles, CA. October 28, 2000.

3rd Annual Symposium on Biotechnology in Cardiovascular Medicine: Current and Future Innovations” at the 73rd Scientific Sessions of the AHA: “New Targets in Heart Failure: Focus on Endothelin Antagonists”. New Orleans, LA. November 11, 2000.

Hospital Grand Rounds “Congestive Heart Failure”. Regional Medical Center of San Jose, San Jose, CA. December 5, 2000.

Hospital Grand Rounds “Congestive Heart Failure”. Good Samaritan Hospital, San Jose, CA. December 6, 2000.

Symposium on Congestive Heart Failure: From Genomics to the Clinic. Lilly Pharmaceuticals, Indianapolis, Indiana. December 12, 2000.

Medtronic Executive Forum on Chronic Heart Disease. “Technology Based Breakthroughs in Heart Failure – A Clinical Update” La Jolla, CA. January 19, 2001.

Colorado Conference 2001 on Trends in Prognosis and Treatment of Heart Failure “Cardiac Remodeling”, Denver, Colorado. January 27, 2001.

2nd Annual UCSD CME Symposium “Heart Failure for the Primary Care Physician”:1) “Preventing Heart Failure”

69

2) “How, When and Why to Use Beta Blockers in Heart Failure Patients”3) Interactive Case Presentations

San Diego, CA. February 10, 2001.

13th Annual Cardiology Symposium of the Loma Linda International Heart Institute “Advances in the Treatment of Heart Failure”:

1) “Beta Blockers: The New Standard in Congestive Heart Failure Therapy”2) “New Concepts in the Pathophysiology of Heart Failure”

Loma Linda, CA. February 21, 2001.

UCSD Cardiovascular Science Research Conference: “Consequences and Mechanisms of TNF Regulation of the AT1 Receptor During Cardiac Remodeling”, La Jolla, CA. March 2, 2001.

UCSD Annual Topics and Advances in Internal Medicine “Meet the Professor Lectures – Rationale and Practical Aspects of Beta Blockade in Heart Failure”, San Diego, CA. March 15, 2001.

American College of Cardiology 50th Annual Scientific Session:1) Basic Mechanisms in Heart Failure: Why Does the Heart Fail Symposium “Role of the

Renin-Angiotensin System”2) Cardiac Remodeling from Animal Models to Patients Symposium “Role of

Neurohormones”Orlando, FL. March 18-21, 2001.

UCSD 7th Annual Heart Failure Symposium: 1) “Use of Drugs that Affect the Renin-Angiotensin Aldosterone System to Prevent and

Treat Heart Failure”2) “Beta Blocker Therapy – Extending the Options for Treatment”3) “New Drugs (and Devices) for the Treatment of Heart Failure”4) Presentation and Discussion of Interesting Cases (Moderator)

La Jolla, CA. May 26, 2001.

Cardiology Grand Rounds: “Cardiac Remodeling”. University of Southern California, Los Angeles, CA. June 5, 2001.

CME-Certified Lecture “New Frontiers and Challenges in Heart Failure: Focus on the Renin-Angiotensin System”, Thousand Oaks, CA . June 5, 2001.

Congestive Heart Failure, Today and Tomorrow Symposium: “Current Approaches to Pharmacologic Therapy: Beta Blockers, Mode of Action and Use”, University of Wisconsin Medical School, Milwaukee, WI. June 9, 2001.Alaska Chapter ACP-ABIM Annual Meeting

1) “Pathophysiology and Prevention of Congestive Heart Failure”2) “The Use of Beta Blockers and ACE Inhibitors in Heart Failure”

Anchorage, AK. June 28-30, 2001.

Summit Medical Center Cardiology Conference: “The Basis for Beta-Blockade in the Management of Congestive Heart Failure”, Oakland, CA. July 12, 2001.

Post-conference Satellite Meeting of XVII World Congress of the ISHR on Remodeling and Progression of Heart Failure: “Effect of ACE-I on Remodeling in Clinical Trials”.Minneapolis, MN. July 14, 2001.

70

Medical Grand Rounds. “Beta-Blockade in Heart Failure Management”, Providence Portland Medical Center, Portland, OR. July 18, 2001.

UCSD Critical Care Symposium “Treatment of Heart Failure in the CCU” San Diego, CA. July 28, 2001.Mayo Clinic 6th Annual Mountain Course “Success with Failure: New Strategies for the Evaluation and Treatment of Congestive Heart Failure”:

1) “Early Heart Failure: A Clinical Dilemma” 2) TNF Inhibitors and Congestive Heart Failure

Whistler, B.C., Canada. August 19-21, 2001.

Mercy Hospital Resident’s Medical Conference “Advances in the Treatment of Heart Failure”, San Diego, CA. September 6, 2001.

Satellite Symposia of the 5th Annual Scientific Meeting of the Heart Failure Society of America: 1) Managing the Patient Hospitalized with Decompensated Heart Failure: Can We Improve Outcomes “New Treatments for Decompensated Heart Failure: Will they make a difference?” September 9, 2001. 2) Moderator for “Extending the benefits of beta-blockade to patients across the heart failure

spectrum.” September 10-12, 2001.

Heart Failure Society of America 5th Annual Scientific Meeting:1) “Angiotensin Receptor Blockers: Have They Found a Role?” 2) Case Discussion Panel.

Washington, D.C. September 9-12, 2001.

Clinical Pathological Correlation Conference at Scripp’s Memorial Hospital, Chula Vista “Restrictive Cardiomyopathy”. San Diego, CA. September 26, 2001.

The 18th Annual Santa Fe Colloquium on Cardiovascular Therapy: The Contemporary Therapy of Congestive Heart Failure and Asymptomatic Left Ventricular Dysfunction.

1) “Pathhophysiology of Heart Failure-Humoral Factors: Norepinephrine, Endothelin, Cytokines, etc.”

2) “Unconventional Approaches-Tomorrow’s Headlines?-Endothelin Receptor Blockers”Santa Fe, NM. October 4-6, 2001.

University of Kentucky CME Program entitled From Bench to Practice: Implementing Advances in Cardiovascular Care. “From Basic Science to Clinical Practice: Heart Failure Pathophysiology and Current Therapeutic Options” Lexington, KY. October 12, 2001.

Medical Grand Rounds “Beta Blocker Therapy of Heart Failure-Rationale and Emerging Indications”, Overlook Hospital, Bellevue, WA. October 26, 2001.Cardiology Grand Rounds “Caridac Remodeling-Role of Neurohormonal Activation”, University of Washington, Seattle, WA. October 26, 2001.

UCSD CME Course Diagnostic Cardiac Catheterization 2001. “Endomyocardial Biopsy”. La Jolla, CA. October 27, 2001.

Plenary Session I “Congestive Heart Failure: Concept to Care-Myocardial Remodeling: Mechanisms and Modifiers” at the 2001 Scientific Sessions of the American Heart Association. Anaheim, CA. November 11, 2001.

71

Perspectives in Clinical Cardiology Conference: “Emerging Trends in the Treatment of Heart Failure”. University of California, Davis, Sacramento, CA. November 30, 2001

Medical Grand Rounds “Beta Blockers in Heart Failure-Theory, Practice and Emerging Indications” San Juan Mercy Hospital, Carmichael, CA. November 30, 2001 Primary Care Grand Rounds: “New Advances in Treatment of Acute Congestive Heart Failure”. Tri-City Medical Center, Oceanside, CA. December 19, 2001.

Greenberg BH. “New Therapies in Acute Heart Failure.” Presented at the American College of Cardiology’s 33rd Annual Cardiovascular Conference, Snowmass, CO, January 15, 2002.

Sutter Heart Institute Cardiovascular Symposium – Current Therapy in Cardiovascular Disease –2002 “CHF Therapy Today and Tomorrow.” Sheraton Grand, Sacramento, CA. January 26, 2002.

Continuing Medical Education lecture: “ In-Hospital Treatment for Congestive Heart Failure.” Lutheran Heart Hospital, Mesa AZ. February 1, 2002

Grand Rounds for the Annenberg Center for Health Sciences: “New Advances in the Treatment of Acute CHF. Eisenhower Hospital, Rancho Mirage, CA. February 7, 2002.

HFSA Symposium, Heart Failure 2002: Update for the Primary Care Physician1) Recognizing Patients at Risk and Strategies for Preventing Heart Failure2) Case Presentation

La Jolla, CA. February 9, 2002

Grossmont Hospital Cardiology Conference: “ New Advances in the Treatment of Acute Congestive Heart Failure.” La Mesa, CA. February 20, 2002

Grand Rounds: “Emerging Role of Beta-Blockers in Heart Failure.” California Pacific Medical Center. San Francisco, CA. February 27, 2002

Grand Rounds: “Cardiac Remodeling- Clinical Insights and Mechanisms.” University of California, Irvine. Irvine, CA. March 1, 2002

UCSD School of Medicine Topics and Advances in Internal Medicine Postgraduate Course. “New Treatments for Congestive Heart Failure. Hilton, San Diego, CA. March 2, 2002

Inland Empire Heart Institute 4th Annual Cardiac Symposium. “2002 Update in the Management of CHF.” St. Bernadine Medical Center, San Bernardino, CA. April 27, 2002.

Medicine Grand Rounds: “Cardiac Remodeling: Implications Regarding Heart Failure Progression and Treatment.” Saint Luke’s Hospital, Kansas City, MO. May 10, 2002

Ed Bixby Institute of Postgraduate Medical Education 19th Annual Practical Cardiology Symposium“Cardiac Remodeling: Implications Regarding Heart Failure Progression and Treatment.” The Fairmont Kansas City at the Plaza, Kansas City, MO. May 10, 2002

Good Samaritan Hospital Critical Focus on Cardiovascular Diseases. “Management of Heart Failure in the Office Setting.” Ritz Carlton, Marina del Rey, CA. May 11, 2002

72

Medicine Grand Rounds: “New Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Examining the Issues.” Memorial Hermann Southwest Hospital, Houston, TX. May 14, 2002.

Grand Rounds: “ New Developments in the Use of Neurohormonal Antagonists for the Treatment of Heart Failure.” Methodist Healthcare System, San Antonio, TX. May 15, 2002

UCSD 8th Annual Heart Failure Symposium: 1) “Strategies for Preventing Heart Failure”2) “Emerging Indications for Beta Blocker Therapy”3) Case Presentation and Discussions (Moderator)

La Jolla, CA. May 25, 2002.

Grand Rounds: “Emerging Concepts in Beta Blocker Therapy in Heart Failure.” Providence St. Vincent Medical Center, Portland, OR. June 12, 2002

Cardiology Grand Rounds: “Cardiac Remodeling-Mechanisms and Therapeutic Implications.” UCSF Medical Center-Moffitt Long Hospital, San Francisco, CA. June 26, 2002

San Diego Academy of Family Physicians Postgraduate Symposium: “2002 Update in the Management of Heart Failure.” Loews Coronado Bay Resort, San Diego, CA. June 29, 2002

Grand Rounds: “Novel Neurohormonal Strategies in the Treatment of Heart Failure.” Fresno Community Hospital, Fresno, CA. July 16, 2002

Cardiology Conference: “New Paradigms in the Treatment of Heart Failure.” Sharp Chula Vista Medical Center. August 13, 2002

Heart Failure Society of America 6th Annual Scientific Meeting:1) “Therapeutic Strategies in the Management of Structural Heart Disease in Asymptomatic

Heart Failure Patients”2) “Progression for Valve Disease to Heart Failure: Natural History and Prevention”3) Case Discussion Panel.

Boca Raton, FL September 22-25, 2002.

Cardiology Noon Conference: “Treatment of Heart Failure” Scripps Mercy, San Diego, CA. October 24, 2002.

Therapeutic Horizons in Heart Failure; La Jolla-Rome-Yamaguchi Research Conference on Cardiac Function: “Review of Latest Heart Failure Trials: Implications for Therapy.” Hilton La Jolla Torrey Pines, La Jolla, CA. December 7th, 2002

CME Conference: “Beta Blockers: New Standard of Care in Heart Failure”. Palomar Medical Center, Escondido, CA. December 19, 2002.

Biomedical and Clinical Research Center Seminar: “Cytokine Induced Expression of Angiotensin Receptors on Cardiac Fibroblasts: Mechanisms and Consequences.”, UCSD Medical Center, San Diego, CA. January 22, 2003.

Grand Rounds: “Heart Failure: The New Vascular Biology Imperative to Blunt Progression”, UCLA Medical Center, Santa Monica, CA. January 23, 2003.

22nd Annual Educational Meeting, Association of Physician Assistants in Cardiovascular Surgery

73

“Cardiac Remodeling: 2003 and Beyond”, Westin Horton Plaza, San Diego, CA. January 29, 2003.

HFSA Symposium, Heart Failure 2003: Update for the Primary Care Physician1) Identifying and Treating the Patient at Risk2) Clinical Case Presentations

New Orleans, LA. February 1, 2003.

3rd Annual UCSD CME Symposium “Heart Failure for the Primary Care Physician”:1) “The New ACC/AHA Guidelines-Focus on Early Recognition and Treatment of Patients

at Risk”2) Extending the Use of Beta Blockers in Heart Failure”3) Interactive Case Presentations


St. Charles Medical Center “ACC & AHA Guidelines and Treatment from High-risk Hypertension”, Bend, OR. February 28, 2003.

Winters Center For Heart Failure Research Seminar Series, Baylor College of Medicine “Cardiac Remodeling-Mechanisms & Clinical Implications”. Houston, TX. March 4, 2003.

UCSD Topics and Advances in Internal Medicine Conference “Criteria for Selection for Heart Transplantation”, San Diego, CA. March 12, 2003.

UCSD M&M Conference “A Case of Heart Failure Masquerading as Liver Failure”, San Diego, CA April 4, 2003.

Sinai Samaritan Cardiology: “Cardiac Remodeling: Insights into the Progression of Cardiac Dysfunction and Options”, Milwaukee, WI. April 23, 2003.

Froedtert Medical College Grand Rounds: “Cardiac Remodeling: Insights into the Progression of Cardiac Dysfunction and Options”, Wauwatosa, WI. April 23, 2003.

All Saints Medical Center “Can Heart Failure be Prevented?”, Racine, WI, April 24, 2003.

St. Lukes Medical Center: “Heart Failure 2003: New Trends in Management”, Milwaukee, WI. April 24, 2003.

9th Annual UCSD Heart Failure Symposium. 1) “Identifying and Treating the Patient at Risk”2) “When and How to Block the Sympathetic Nervous and Renin- Angiotensin

Systems”3) Case Presentations and Discussions (Moderator)

La Jolla, CA. May 3, 2003

Medical World Conferences.1) “Managing Heart Failure: The Electronic Revolution”2) “New and Emerging Therapies in Post-Myocardial Infarction Patients”

San Diego, CA. May 10, 2003

Bay Area Heart Failure Club: “Cardiac Remodeling- Mechanisms and Clinical Implications”, San Mateo, CA. May 22, 2003.

74

St. Joseph’s Hospital Grand Rounds: “Neurohomonal Strategies in the Treatment of Heart Failure” Phoenix, AZ. June 11, 2003.

Medical World Conferences:a. “Managing Heart Failure: The Electronic Revolution”b. “New and Emerging Therapies in Post-Myocardial Infarction Patients”

Pasadena, CA. June 21, 2003.

St. Bernardine 5th Annual Cardiology Symposium: “Advances in the Management of Congestive Heart Failure and Biventricular Pacing and Other Recent Advances”, San Bernadino, CA. June 28, 2003.

UCSD Critical Care Summer Session 2003: “Heart Failure”, San Diego, CA. July 25, 2003

Satellite Symposia of the Heart Failure Society of America 7 th Annual Scientific Meeting:2) Charm Results Meeting “Should the HFSA and ACC/AHA HF Guidelines be Updated”

(September 19, 2003)3) From Risk Factors to Heart Failure: Prevention and Treatment with a Focus on Diastolic

Heart Failure- Co- Chair and Case Presentation (September 21, 2003) 4) Following Comet’s Trail Program Chair, Moderator and Panel Discussion (September 21,

2003).5) Rational Approaches to Management of the Post-MI Patient with LV Dysfunction.

Program Chair (September 24, 2003)

Heart Failure Society of America 7th Annual Scientific Meeting:1) Neurohormonal Modulation in Heart Failure: New Insights “ACE Inhibitor and Beta

Blockade in Heart Failure: Synergistic Effects”.2) Case Discussion Panel

Las Vegas, Nevada, September 21-24, 2003

Medical Grand Rounds: “A Focus on the Management of Patients with Post-MI LVD and Heart Failure”, Torrance Memorial Medical Center, Torrance, CA. October 1, 2003.

Medical Grand Rounds: University of Alabama-Birmingham: “Post-MI Cardiac Remodeling”, Birmingham, AL. October 8, 2003.

Escondido Cardiology Program: “A Focus on the Management of Patients with Post-MI LVD and Heart Failure”, Escondido, CA October 13, 2003.

Arizona Chapter, ACC: “Heart Failure Update: Issues in Beta-Blocker Treatment in Heart Failure”, Sedona, AZ. October 18, 2003.

University of California-Davis Medical Center: “Updates on Congestive Heart Failure”, Sacramento, CA. October 23, 2003.

Pri-Med Updates, “Cardioprotection with beta blockers: Breaking the chain of cardiovascular events” Los Angeles, CA November 7, 2003.

San Diego Heart Failure Club: “Can We Apply Results From CHARM, COMET and VALIANT to Clinical Practice?” San Diego, CA. November 13, 2003.

Medical World Conferences Continuing Medical Education seminar:1) “Managing Heart Failure: The Electronic Revolution”

75

2) “New and Emerging Therapies in Post-Myocardial Infarction Patients”San Francisco, CA. December 13, 2003.

Eisenhower Medical Center Grand Rounds: “Treatment of Heart Failure in 2004: Implications of Recent Clinical Trials.” Annenberg Center for Health Sciences at Eisenhower, Rancho Mirage, CA. January 8, 2004

Heart Failure Society of America’s “Conference for Fellows: Establishing a Career in Heart Failure”

1) Heart Failure in Clinical Trials: How to Interpret Clinical Trials2) Moderator of Panel Discussion: Research Initiatives

Boca Raton, FL. January 18, 2004

4th Annual UCSD CME Symposium “Heart Failure for the Primary Care Physicians”:1) “Will the Results of Recent Clinical Trials (CAPRICORN, CHARM, COMET,

EPHESUS) alter management strategies?”2) “Medical and Surgical Options for Advanced Heart Failure Patients”3) Moderator of Case Presentations

San Diego, CA. January 31, 2004

HFSA Symposium, Heart Failure 2004: Update for the Primary Care Physician1) Recognition of Patients with “Early” Heart Failure and Those at High Risk for Developing Heart Failure2) Moderator of Case Presentations

Dallas, TX. February 7, 2004

UCSD Topics and Advances in Internal Medicine Conference “New Treatment for Congestive Heart Failure”, San Diego, CA. February 19, 2004

CME Conference: “New Insights into Neurohormonal Blockade in the Treatment of Heart Failure: Implications for Therapy”. St. Jude’s Medical Center, Fullerton, CA. March 26, 2004.

Medical Grand Rounds: “A Focus on the Management of Patients with Post-MI LVD and Heart Failure”, Marshall Hospital, Placerville, CA, April 21, 2004

Medical Grand Rounds: “A Focus on the Management of Patients with Post-MI LVD and Heart Failure”, Sierra Nevada Memorial Hospital, Grass Valley, CA, April 21, 2004

SCAI Symposium: “Unmet Needs in the Long-term Management of PMI LVD”. San Diego, CA, April 29, 2004

10th Annual San Diego Heart Failure Symposium. 1) “New Insights Into the Role of the Renin-Angiotensin-Aldosterone System in Heart

Failure – How Does This Impact Management Strategies?”2) “When, Why, and How to Use Beta Blockers in Heart Failure”3) Case Presentations and Discussions (Moderator)

La Jolla, CA, May 8, 2004

Cardiology Grand Rounds: “When, Why, and How to Use Beta Blockers to Treat Heart Failure”, Grossmont Hospital, San Diego, CA, June 16, 2004Medical Grand Rounds: Management of Post-MI Left Ventricular Dysfunction”, Providence St. Peters Hospital, Olympia, WA, June 17, 2004

76

Cardiology Grand Rounds: “Insights and Implications of Recent Clinical Trials in Heart Failure”, University of Washington, Seattle, WA, June 17, 2004

CME Cardiology Symposium: “Perspective on Cardiac Resynchronization Therapy in the Treatment of Heart Failure”, St. Bernardine Medical Center, San Bernardino, CA, June 18, 2004

Mountaintop II Heart Failure Symposium: Medical Therapy for Heart Failure. Colorado Springs, CO, August 5-8, 2004

Heart Failure Society of America 8th Annual Scientific Meeting:1) Neurohormonal Activation: A Critical Player in the Progression of Heart Failure.2) Hemodynamic Factors in Heart Failure: Diagnostic, Prognostic and Therapeutic Role of

Impedance Cardiography.3) Hemodynamic Factors in Heart Failure: Diagnostic, Prognostic and Therapeutic Role of

Impedance Cardiography.i. Hemodynamics in Heart Failureii. ICG Method and Validity

4) Case Discussion Panelist for the 8th Annual Heart Failure Society of America Annual Meeting

Toronto, Ontario, Canada. September 14, 2004.

Cardiology Grand Rounds: “Differences Among B-Blockers in Heart Failure”, University of New Mexico, Albuquerque, NM, September 30, 2004

John M. Wilson Lectureship in Cardiovascular Diseases: “Management of Post-MI LV Dysfunction”, Presbyterian Healthcare Services, Albuquerque, NM, October 1, 2004

American Heart Association 72nd Annual Fall Symposium: “Management of Heart Failure with Device Therapy: Use and Abuse of CRT and Other Devices”, Los Angeles, CA, October 2, 2004

Satellite Symposium on Heart Failure Management of the 77th Scientific Sessions of the AHA. “How to Treat Advanced Heart Failure”, New Orleans, LA, November 10, 2004.

Heart Failure 2005: An Update on Therapy. “Myocardial Infarction and Heart Failure: New Trials and Their Clinical Implications.” University of Southern California, Los Angeles, CA, January 29, 2005

Guest Lecturer. “Heart Failure: What Is It and How Do We Treat It.” San Diego Rotary Club, San Diego, CA, February 1, 2005

5th Annual UCSD CME Symposium “Heart Failure for the Primary Care Physician”1. Program Presenter - “The Neurohormonal Basis of Heart Failure: Insights

Regarding Mechanisms and Implications for Treatment”2. Program Presenter - “Emerging Therapies for Heart Failure”3. Moderator - Case Presentations


Heart Failure Society of America 5th Annual Primary Care Symposium “Update for the Primary Care Physician”

1. Program Presenter “Why is Heart Failure the Only Cardiovascular Disease that is Increasing in Prevalence: Implications Regarding Prevention”

2. Moderator-Case Presentations February 5th, 2005

77

43rd Annual Symposium on Critical Care, Trauma and Emergency Medicine1. “Management of Acute Heart Failure”2. “Evidence-based Pharmacological Management of Acute Myocardial Infarction”3. “Management of Chronic Heart Failure”

Las Vegas, NV. February 9, 2005.

Heart Failure 2005: HFSA Annual Update for the Primary Care Physician1. “Long-term Management of the Post-MI Patient”2. “Case Presentation III (Management of Decompensated Heart Failure)”

Sacramento, CA. February 12, 2005

The San Fernando Valley Heart Institute’s 11th Annual Cardiac Symposium: “Management of Post Management of Post Myocardial Infarction Left Ventricular Dysfunction”, Woodland Hills, CA, February 16, 2005

CME Cardiology Presentation “Fluid Matrix: Managing Neurohormones and Electrolytes”, Alvarado Hospital Medical Center, San Diego, CA, February 24, 2005

Cardiac Issues 2005: “Congestive Heart Failure”, Yakima Regional Medical and Cardiac Center, Yakima, WA, March 23, 2005

1st Annual UCSD Cardiovascular Center Symposium: in Heart Disease. Moderator: “Congestive Heart Failure”

1. Panelist: “Simultaneous Panel Discussions (Biomarkers: Issues in Congestive Heart Failure)

San Diego, CA, March 26, 2005

2005 Cardiovascular Health Summit “Recent Clinical Trials in Heart Failure: Insights into the disease and implications for treatment”, Big Sky, MT, April 8, 2005

Guest Lecturer: Ochsner Cardiology Clinic “Medical Management of Post-MI Left Ventricular Dysfunction”, New Orleans, LA, April 28, 2005

Cardiology Grand Rounds: “Medical Management of Post-MI Left Ventricular Dysfunction”, Louisiana State University Medical Center, New Orleans, LA, April 29, 2005

28th Annual Scientific Sessions of the SCAI: “The ‘High-Risk’ AMI Patient: Early and Long-Term Benefits of Selective Aldosterone Blockade”, Ponte Vedra Beach, FL, May 6, 2005

Guest Lecturer: Management of Left Ventricular Dysfunction in the Post-MI Patient: Medical and Device Aspects. “Long-term Management of Post-MI Left Ventricular Dysfunction”. Ponte Vedra Beach, FL, May 6, 2005

Heart Rhythm Society Satellite Dinner Symposium: Factors Determining ICD Implantation in Post-MI and Heart Failure Patients.

1. Moderator2. Lecturer: “Optimal Medical Management of the Post-MI Patient”

New Orleans, LA, May 6, 2005

Invited Lecturer: VA West Los Angeles: “A/CD or Resynchronization”, Los Angeles, CA, May 11, 2005

78

Inland Empire Heart Institute’s 7th Annual Cardiac Symposium: Advances in the Management of Cardiovascular Disease. “Optimizing Management of Heart Failure 2005: Role of Pharmacological & Device Based Therapies”. St. Bernardine Medical Center. San Bernardino, CA, May 21, 2005

UCSD 11th Annual Heart Failure Symposium “Advances & Recognition in the Treatment of Heart Failure”

1. Heart Failure in 2005: New Trends in Management2. Case Presentation (Moderator)

La Jolla, CA, June 11, 2005

San Diego Academy of Family Physicians 49th Annual Postgraduate Symposium: “Congestive Heart Failure Update”. San Diego, CA, June 24, 2005

Heart Failure Society of America 9th Annual Scientific Meetinga. “Optimal Medical and Device Management of Heart Failure: What Do the Guidelines

Recommend?”b. Case Discussion Panelist for the 9th Annual Heart Failure Society of America Annual

Scientific Meetingc. Moderator for Plenary Sessions. “Recent and Late Breaking Clinical Trials”d. Hyde Park Hypotheses Lecture. “Clinical Trials are to Clinical Medicine as Muzak is to

Mozart”Boca Raton, FL. September 18 – 21, 2005.

UCSD 1st Annual Symposium Device Therapy for Heart Failure: To Select Patient, Devices and Settings: “Therapy of Heart Failure (Current Status): Role of Drugs and Devices – Have Exhausted the Potential for Pharmacologic Treatment?” La Jolla, CA, October 1, 2005

UCSD Cardiovascular Center Ambassador Lecture Series:” The Failing Heart-Current Success and Future Challenges”, La Jolla, CA, October 5, 2005

Cardiology Conference: “Ventricular Dysfunction”, Sinai Samaritan Hospital, Milwaukee, WI, October 19, 2005

Cardiology Grand Rounds: “Therapeutic Strategies in Management of Structural Heart Disease in the Asymptomatic Heart Failure”, Froedtert Medical College, Milwaukee, WI, October 19, 2005

Cardiology Grand Rounds: “Management of Patients with Post-MI LV Dysfunction”, All Saints Hospital, Racine, WI, October 20, 2005.

Medical Grand Rounds: “Novel Approaches to the Prevention and Reversal of Remodeling”,St. Lukes Medical Center, Milwaukee, WI, October 20, 2005.

American Heart Association 78th Annual Scientific Sessions. 1) Oral Presentation “Influence of Diabetes Mellitus on Characteristics and Outcomes

in Patients Hospitalized with Heart Failure” 2) Panelist “How to Establish Best Practices For Medical Therapy of Heart Failure”

Dallas, TX. November 12-16, 2005.

San Diego Yacht Club: “Your Failing Heart – Current Success and Future Challenges”. San Diego, CA, November 30, 2005.

Heart Failure University 2005: Pharmacologic Treatment of Chronic Heart Failure: Guideline Update. Los Angeles, CA. December 3, 2005.

79

HFSA Conference for Fellows: Establishing a Career in Heart Failure, “The Academic Clinician” Aventura, FL January 21, 2006.

UCSD Medical House Staff Conference: “Treatment of Heart Failure”, San Diego, CA, February 2, 2006.

6th Annual UCSD CME Symposium “Heart Failure for Primary Care Physicians”1. Program Presenter - “What Do the New ACC/AHA and HFSA Guidelines Tell Us about the

Treatment of Heart Failure” 2. Moderator - Case Presentations

La Jolla, CA February 4, 2006

44th Annual Symposium on Critical Care, Trauma and Emergency Medicine1. “Evidence based Priorities in the Pharmacological Management of Heart Failure”2. “Cardiac Remodeling and Heart Failure: What does It Imply for Management?” 3. “Management of the Patient Following Hospitalization for Acute Myocardial Infarction”

Las Vegas, NV. February 8, 2006

Heart Failure Society of America 5th Annual Update for the Primary Care Physician. 1. “Why is Heart Failure the only Cardiovascular Disease that is Increasing in Prevalence:

Implications Regarding Prevention” 2. Management of a Patient at High Risk for Developing Heart Failure

Houston, TX. February 11, 2006

Medical Grand Rounds: “Guidelines for Optimizing Therapeutic Treatment for Heart Failure”, Alvarado Hospital, San Diego, CA. February 14, 2006.

Southwest Washington Medical Center CME Presentation: “Emerging Concepts in the Treatment of Heart Failure”, Vancouver, WA, February 27, 2006.

Loma Linda University School of Medicine’s 18th Annual Cardiology Symposium “Cardiac Emergencies”: “Cardiac Remodeling: Mechanisms and Clinical Implications of Acute Decompensated Heart Failure”. Loma Linda, CA, March 1, 2006.

UCSD Topics and Advances in Internal Medicine: “New Approaches to the Treatment of Heart Failure”, San Diego, CA, March 2, 2006.

Greenberg, Barry H. “Progression From Myocardial Infarction to Heart Failure: Epidemiology and Prevention.” Presented at the American College of Cardiology’s 55 th Annual i2 Summit and Scientific Sessions, Atlanta, GA, March 14, 2006.

UCSD Primer Lecture: “Clinical Trials are to Clinical Medicine as Muzak is to Mozart”, San Diego, CA, March 27, 2006.

University of California Irvine Orange County Cardiac Conference: Echocardiography and Cardiac Imaging for the Practitioner

1. Heart Failure with Normal EF: Clinical Profile?2. Optimizing Medical Therapy For Acute Systolic HF Post-MI3. My Most Challenging Cases in Systolic HF after MI

Irvine, CA, March 31, 2006

80

UCSD Second Annual Course of Biomarkers in Heart Disease: “What Every Health Care Practitioner Needs to Know”

1. Moderator San Diego, CA, April 1, 2006

El Centro Regional Medical Center Symposium “CHF Guidelines” La Jolla, CA, April 29, 2006

Palomar Hospital CME Conference “Advances in Heart Failure Therapy: Translating the CHARM Trials to Clinical Practice” Escondido, CA, June 1, 2006

12th Annual San Diego Heart Failure Symposium1. The Optimal Treatment of Heart Failure in 2006. What Do the Guidelines Tell Us?2. Emerging Trends in the Treatment of Heart Failure and Pulmonary Hypertension: What

Therapies Will Be Included in the Next Set of Guidelines.3. Case Presentation (Moderator).

La Jolla, CA, June 6, 2006

Heart Failure Society of America 10th Annual Scientific Meeting Satellite Symposium “The Heart of the Controversies in Heart Failure Management: Case Perspectives from the Experts”

1. Data for ACEIs and ARBs: Mixing the Old with the New2. Managing Special Populations in HF with and without Preserved LVEF

Seattle, WA September 10th, 2006

Heart Failure Society of America 10th Annual Scientific Meeting1. “Randomized Clinical Trials on Trial” Prosecuting Team Leader2. Modulating the Matrix “Molecular Basis for Cardiac Fibrosis

Seattle WA, September 10th – 13th, 2006

The 5th Annual Symposium: The Cutting Edge – Cardiology for the Future. “Optimal Therapy for Heart Failure in 2006”Long Beach, CA, September 29, 2006

2nd Annual UCSD Course on Arrhythmias and Heart Failure: Selecting the Best Treatment for Each Patient. “Management of the Complex Heart Failure Patients-What Clinical Trials have Shown” La Jolla, CA, September 30, 2006

American College of Cardiology: Controversies and Advances in the Treatment of Cardiovascular Disease: The Sixth in the Series “Medical Therapy Will Improve and Obviate the Need for Expensive Devices”Beverly Hills, CA, October 5th and 6th, 2006

50th Annual Scientific Meeting of the Korean Society of Circulation 1. “Cardiac Remodeling: Mechanisms Involved and Implications for Patient Management”2. “Pharmacologic Management of Heart Failure in 2006”

Seoul, Korea October 10th – 15th, 2006

Cleveland Clinic Symposium: 21st Century Treatment of Heart Failure: Synchronization Surgical and Medical Therapies for Better Outcomes “The Future of Clinical Drugs Trials in Heart Failure: Lessons learned from the study of Neseritide and Levosimendan”

81

Cleveland, OH, October 20th, 2006

American Heart Association Scientific SessionsClinical Practice 2006: Practical Management of HF “Advances in Pharmacological Management” Chicago, IL November 12th-15th, 2006 Heart Failure University 2006. “Pharmacologic Treatment of Chronic Heart Failure: Guideline Update.” Los Angeles, CA, December 1st-3rd, 2006

University of Southern California Annual Symposium Heart Failure 2007 “Update on the Treatment of Heart Failure”. Los Angeles, CA Jan 19, 2007

Heart Failure 2007: An Update on Therapy“Management of the Patient with Left ventricular Dysfunction Following Acute Myocardial Infarction”Los Angeles, CA, January 20th, 2007

4th Annual Cardiology Fellows Symposium 1.“New Treatment Guidelines in Heart Failure: Case Presentation” Moderator

Aventura, FL, January 27, 2007

Heart Failure 2007: Update for the Primary Care Physician1. Use of Neurohormonal Blocking Agents to Treat Heart Failure2. Case Presentations (Moderator)

San Francisco CA February 10, 2007

San Bernardino Medical Center 10th Annual Cardiac Symposium “Emerging Approaches For Treating Heart Failure”. San Bernardino, CA, April 28, 2007

13th Annual San Diego Heart Failure Symposium1. Treating Acutely Decompensated Heart Failure: Current Success and Future Challenges.2. Case Presentations (Moderator)

La Jolla, CA, May 5, 2007

UCSD Medical Housestaff Noon Lectures “Treatment of Heart Failure”. August 8, 2007.

Heart Failure Society of America 11th Annual Scientific Meeting Satellite Symposium “Beta Blockade in 2007: Misconceptions and Best Practices Across Diverse Patient Populations”

1. A look at the Most Recent Evidence Spanning Hospital and Community-Based Heart Failure Patient Populations.

2. Panel Discusion Washington, DC September 16, 2007

Heart Failure Society of America 11th Annual Scientific Meeting1. Opening Remarks2. President’s Forum3. Debate Moderator4. “The Need: Expression of the Clinical Problem and of Available Management

Strategies” in Symposium on “ Advances in Heart Failure and Transplantation Cardiology: An Emerging Secondary Subspecialty “. Washington, DC September 14th – September 19th, 2007.

82

Heart Failure Society of America Sponsored Symposium on Treating Heart Failure: Answering the Important Questions at the American Association of Family Practice Annual Meeting.

1. What Can You Do To Prevent Heart Failure.2. Panel Discussion.

Chicago, IL, October 2 and 3 (Presented 3 times), 2007.

UCSD Cardiology Fellow Core Lecture Series “Management of Heart Failure”. San Diego, CA, October 9, 2007.

UCSD Department of Medicine Grand Rounds “Heart Failure in 2007: Challenges and Opportunities”. San Diego, CA, October 10, 2007

Update in Management of Cardiovascular Disease Symposium “Managing Heart Failure in 2007”. Riverside, CA, October 13, 2007

University of Wisconsin Cardiology Division Grand Rounds “The Renin-Angiotensin System in Cardiac Remodeling: Mechanisms and Clinical Implications”. Madison, WI, October 18, 2007

Satellite Symposium at the Scientific Sessions of the American Heart Association “The Next Generation of Treatment Strategies for Acute Decompensated Heart Failure”.

1. Patient Characteristics and Practice Patterns.2. Panel Discussion.

Orlando, FL, November 5, 2007. Cardiological Society of India 59th Annual Conference.

1. Use of Biomarkers in Heart Failure.2. New Approaches for Treating Heart Failure.

Hyderabad, India, December 5-8, 2007.

University of California, San Francisco, 24th Annual Advances In Heart Disease.1. Acute Decompensated Heart Failure: Can We Do Better?2. New Strategies For Treating Patients With Chronic Heart Failure.

San Francisco, CA, December 14-16, 2007

8th Annual UCSD Heart Failure Symposium for Internists and Primary Care Physicians.1. How To Interpret The Chest X-ray When Heart Failure Is Suspected.2. Case Presentation.3. How And When To Use Beta Blockers In Heart Failure Patients Across The Continuum

From ACC/AHA Stage A-D.San Diego, CA, January 19, 2008

HFSA Conference For Fellows: Establishing a Career in Heart Failure.1. Welcome and Opening Remarks.2. New Treatment Guidelines in Heart Failure: Case Presentations (Moderator)3. Heart Failure and Investigation: Clinical Trials, Basic Science, Translational Research

(Workshop panelist).4. Closing Remarks.

Aventura, FL, January 25-27, 2008

International Society for Cardiovascular Translational Research: Innovation Translation Education. “Gene Transfer Therapy.” San Diego, CA. February 10, 2008

83

7th Annual HFSA Primary Care Conference “What To Do and When: Managing Heart Failure in 2008.”

1. Heart Failure with Reduced Ejection Fraction Status Post Myocardial Infarction2. Panel Discussion

New Orleans, LA. February 9, 2008

UCSD CV Research Conference “An ACE in the Hole: Alternate Pathways of the RAS and Their Importance in Cardiac Remodeling”. March 14, 20083rd Annual UCSD Course on Arrhythmias and Heart Failure: Selecting the Best Treatment for Each Patient. “Treatment of Cardiac Remodeling Using Drugs and Devices.” San Diego, CA. March 22, 2008

Cedars Sinai Medical Center Cardiology Grand Rounds “New Developments in the Management of Acute Decompensated Heart Failure” Los Angeles, CA. March 25, 2008

American College of Cardiology 2008 Scientific Sessions 1. Late Breaking Clinical Trial Presentation “Efficacy and Safety of Continuous Aortic Flow

Augmentation in Patients Hospitalized With Acute Decompensated Heart Failure: results of the MOMENTUM Trial”

2. Program Chair “New Insights Into Dilated Cardiomyopathy: Implications for Clinical Evaluation and Management”

Chicago, IL, March 29 – April 1, 2008

Experimental Biology 2008: Focus on the Fibroblast: Therapeutic Target for the Failing Heart? “Angiotensin Receptor Signaling in the Cardiac Fibroblast”. San Diego, CA, April 5-9, 2008.

Anaheim Memorial Medical Center Grand Rounds ”Vascular Disfunction: Sequelae of Acute Hypertension” Anaheim, CA. April 15, 2008

Sharpe Chula Vista Hospital Grand Rounds “Management of Heart Failure. State of the Art in 2008”. Chula Vista, CA, April 22, 2008

San Bernardino Medical Center 10th Annual Cardiac Symposium “Congestive Heart Failure Management, State-of-the-Art 2008. Evidence-Based Approach. What do the ACC/AHA guidelines tell us?” San Bernardino, CA, April 26, 2008

14th Annual Heart Failure Symposium: Advances in Recognition and Treatment of Heart Failure1. Program Director2. “Preventing Heart Failure: Managing the High Risk Stage A and B Patients” 3. “Strategies for Preventing and Detecting Decompensation

LaJolla, CA, May 3, 2008

American College of Cardiology Vital Summit “Upgrading Knowledge in Cardiovascular Medicine.”1. Preventing Heart Failure2. Treating Heart Failure: State of the Art in 2008

Presented in Delhi, Kolkata, Chennai and Mumbai, India. May 23-28, 2008

Heart Failure 2008: Congress Organized by the Heart Failure Association of the ESC 1. ”The Changing Epidemiology of Heart Failure”2. “Treatment of Heart Failure in 2018: US Perspective”

Milan, Italy, June 14-15, 2008.

84

Satellite Symposium of the American Association of Heart Failure Nurses on ADHF: Pathophysiology of Volume Overload “Current evidence-based practice guidelines for ADHF treatment in hospital and prognostic indicators of outcome”.Boston, MA June 27, 2008.

Queen of the Valley Medical Center Grand Rounds “Vascular Dysfunction: Sequelae of Acute Hypertension.” Napa, CA, July 11, 2008.

UCSD Family Medicine Grand Rounds: “Optimal Treatment of Heart Failure in 2008.”San Diego, CA. August 6, 2008

Tutorials in the Tetons: 34th Annual Update in Cardiovascular Diseases 1. “What is the Optimal Treatment of Heart Failure in 2008?” 2. “New and Emerging Strategies for Treating Acute Decompensated Heart Failure”

Grand Teton National Park, WY August 29-September 1, 2008.

Heart Failure Society of America 12th Annual Scientific Meeting1. President’s Address2. “Management of chronic heart failure: What are the opportunities for improvement” in

Satellite Symposium on Perspective on Endpoints in Heart Failure Trials: Where are we now and where are we going?

3. “Hypotension and hypertension in decompensated heart failure” in Satellite Symposium on Making the Best Case for Patients with Acute Decompensated Heart Failure.

4. LBCT presentation “Results of a multicenter, randomized, double-dummy, parallel group study to compare effects of coreg CR and coreg IR on left ventricular end systolic volume index in subjects with stable chronic heart failure (The COMPARE Trial).

5. Judge in Heart Failure Court of Appeals Session. 6. Effects of Ang-(1-7) on cardiac structure and function. 7. Moderator of Joint HFSA and HF Association of the ESC Session on Perspective on Recent Clinical Trials: The Great Divide?

Toronto, CA September 21–24, 2008.

19th Annual Trends in Cardiovascular Medicine: Cardiology for the Primary Physician “Achieving Best Quality Care for the Heart Failure Patient”. Olympic Valley, CA, October 17-19, 2008.

University of California, Davis .Cardiology Grand Rounds. “Vascular Sequelae of Acute Hypertension.” Davis, CA, January 16, 2009.

9th Annual UCSD Heart Failure and Hypertension Symposium for Primary Care and Internal Medicine Physicians.

1. Program Director2. The Use of Direct Renin Inhibitors in Hypertension and Heart Failure3. Treatment of Congestion: Diuretics and Alternative Approaches (Ultra- infiltration, AVP

Antagonists and Adenosine Receptor Antagonists)4. Optical Medical Treatment of the Patient with Heart Failure and Diastolic Dysfunction5. Case Presentation

San Diego, CA, January 17, 2009.

University of California, Irvine. Cardiology Grand Rounds. “Vascular Sequelae of Acute Hypertension.” Irvine, CA, January 22, 2009.

HFSA Conference For Fellows: Establishing a Career in Heart Failure.

85

1. New Treatment Guidelines in Heart Failure: Case Presentation2. Heart Failure and Investigation: Clinical Trials, Basic Science, Translational Research

Aventura, FL, January 23-25, 2009.

UCSD Cardiovascular Center Ambassador Lecture Series “Heart Failure or Heart Success? New and Emerging Approaches for Treating the Failing Heart.” January 28, 2009

28th Annual UCSD Course on Advanced Nephrology: Nephrology for the Consultant “.La Jolla, CA, January 29, 2009.

University of Southern California Annual Symposium Heart Failure 2009: An Update of Therapy1. Innovations in the Management of Acute Decompensated Heart Failure: Drugs and

Devices2. Hyponatremia and Heart Failure: Incidence, Prognosis and Therapy

Los Angeles, CA, February, 28, 2009.

Rady Children’s Hospital Cardiology Grand Rounds “Management of Heart in 2009”.San Diego, CA, March 20, 2009.

East Escondido Rotary Club “Heart Failure or Heart Success? New and Emerging Approaches for Treating the Failing Heart.” March 20, 2009.

Satellite Symposium of the American College of Cardiology Annual Scientific Sessions “Beta Blockers Across the Risk Spectrum for Heart Disease”

1. Beta Blockers in the Setting Heart Failure and Other Compelling Indications.2. Panel Discussion.

Orlando, FL March 28, 2009.

Satellite Symposium of the American College of Cardiology Annual Scientific Sessions“Working in Concert to Slow the Progression of Heart Failure: Medical and Device Management Strategies”

1. Hospitalization and the Economic Impact of Heart Failure.2. Panel Discussion.

Orlando, FL March 28, 2009.

UCSD Medical Housestaff Noon Lectures: “Cardiomyopathy” San Diego, CA, April 8, 2009.

Cardiology Grand Rounds University of California, San Diego: “Acute Decompensated Heart Failure” San Diego, CA, April 13, 2009.

University of Washington Cardiology Grand Rounds “The Cardiorenal Syndrome”.Seattle, WA, April 17, 2009.

San Bernardino Medical Center 11th Annual Cardiac Symposium “Innovations in the Management of the Decompensated Heart: Drugs and Devices 2009.” San Bernardino, CA, April 25, 2009.

British Cardiovascular Society Annual Conference and Exhibition “Challenges and Prospects for the Management of Heart Failure Over the Next Decade.” London, June 2, 2009.

86

2nd Annual Meeting of the Minds: Advances in Therapy for Cardiovascular Disease “Contemporary Management of Acute Decompensated Heart Failure.” Montauk, NY, June 5, 2009.

15th Annual San Diego Heart Failure and Hypertension Symposium.1. Program Director2. Case Presentation I: Management of a High Risk Hypertensive Patient. (Moderator)3. Emerging Strategies for Inhibiting the Renin Angiotensin System in Hypertension and

Heart Failure.4. Defining and Treating the Cardiorenal Syndrome in Patients with Decompensated Heart

Failure. 5. New Approaches for Treating Heart Failure.

LaJolla, CA, June 13, 2009.

Scripps Mercy Medical Grand Rounds. “Vascular Dysfunction: Sequelae of Acute Hypertension.” San Diego, CA, July 28, 2009.Tutorials in the Tetons: 35th Annual Update in Cardiovascular Diseases:

1. Heart Failure: New and Emerging Therapies.2. Lessons from OPTIMIZE-HF.3. Heart Failure Management: A Successful Model for All.4. Clinical Trial Update in Heart Failure.

Grand Teton National Park, WY, August 29–31, 2009.

California Society of Hospital Systems Pharmacists Annual Meeting. “Treatment of Hypertension”. San Diego, CA, October 3, 2009.

The 8th Annual Symposium sponsored by Long Beach Memorial Medical Center. “The Ellestad Oration: New Guidelines for Heart Failure and New Horizons”. Long Beach, CA, October 9, 2009.

1st Annual UCSD State of the Art Cardiovascular Medicine Conference.1. Program Co-Director2. Heart Failure Section Moderator3. “Acute Decompensated Heart Failure”

San Diego, CA, October 10, 2009.

Cardiology Grand Rounds at Pennsylvania State University. “Emerging Approaches For Treating Atrial Fibrillation in Patients With Heart Failure”. Hersey, PA. October 13, 2009.

Colorado Chapter of the American College of Cardiology. “Management of CHF - Past, Present and Future”. Denver, CO. October 15, 2009.

Cardiology Grand Rounds at University of Colorado. “Treatment of Heart Failure – Current Problems, Future Directions” Denver, CO. October 16, 2009.

Scripps Clinic’s 4th Annual Clinical Update on Heart Failure and Arrhythmias: From Prevention to Cure. “How should we Manage Low EF Heart Failure in the Clinic?” La Jolla, CA. October 17, 2009.

American Heart Association Scientific Sessions 2009. “The Foundation of the Role in Beta-Blockers Across the Cardiovascular Disease Risk Spectrum”. Orlando, FL. November 14-18, 2009.

7th Annual Heart Failure Society of America Cardiology Fellow Symposium: Establishing a Career in Heart Failure.

87

1. Case Presentation: New Treatment Guideline in Heart Failure. (Moderator) 2. Heart Failure and Investigation: Clinical Trials, Basic Science, Translational Research.

Aventura, FL, January 23, 2010.

University of Southern California Annual Heart Failure Symposium; An Update on Therapy: Heart Failure, Arrhythmias and Hypertension. “Effective Management of the Hospitalized Patient with Heart Failure”. Los Angeles, CA. January 30, 2010.

Annual Meeting on UCSD Topics and Advances in Internal Medicine “Optimal Management of Heart Failure”. San Diego, CA. March 8, 2010.

American College of Cardiology Annual Scientific Session Symposium; Emerging Therapies for the Treatment of Acute Decompensated Heart Failure. Myocardial Protection with Adenosine Regulating Agents. Atlanta, GA. March 15, 2010.

American College of Cardiology Annual Scientific Session Symposium; Joint Session of the Israel Heart Society and the American College of Cardiology: Future Treatments. “Over expression of SERCA-2a for the Treatment of Heart Failure. Atlanta, GA. March 15, 2010.

5th Annual Asia Pacific Congress of Heart Failure.1. Molecular Biology in Heart Failure “Basic Research in RAAS”.2. Optimal Treatment of Decompensated Heart Failure.

Busan, Korea April 13-16, 2010.

2010 Cardio Conference Program-Grand Rounds.Sharp Grossmont Hospital “Update on Congestive Heart Failure”.La Mesa, CA April 22, 2010.

12th Annual Cardiac Symposium “Acute and Chronic Decompensated Heart Failure. Success of Current Management Strategies Novel Approaches for Chronic Heart Failure”.San Bernardino, CA April 24, 2010.

UCSD Internal Medicine Grand Rounds “Update on Heart Failure in 2010”.San Diego, CA April 28, 2010.

16th Annual San Diego Heart Failure and Hypertension Symposium 1. Heart Failure with Preserved EF: Diagnosis and Treatment.2. Case Discussion I-Treating Early Stage Heart Failure.3. What’s New and on the Horizon for Treating Heart Failure.

La Jolla, CA May 1, 2010.

Heart Failure Association of the European Society of Cardiology Annual Meeting. Late Breaking Clinical Trials.” Calcium Up-Regulation by Percutaneous Adminstrations of Gene Therapy In cardiac disease:CUPID Trial Phase 2 Results”. Berlin, Germany. May 30, 2010.

Indo-American Heart Failure and Metabolic Summit.1. The Renin-Angiotensin-Aldosterone System: The Evil Ax is Heart Failure.2. Cardiac Resynchronization Therapy in Heart Failure: From Relief of Symptoms To

Reversal of Remodeling. Beijing, China. July 3-6, 2010.

Heart Failure Society of America 15th Annual Scientific Meeting 1. Late Breaking Clinical Trial Presentation: CUPID 1: MYDICAR in Patients with Advanced

88

Heart Failure Continue to Show Significant Improvement in Clinical Outcomes Compared to Optimal Therapy 9 Months Post-Dose. 2. Epidemiology and Pathophysiology of Stage B Heart Failure: Insights from SOLVID

Prevention 30 years later. San Diego, CA. September 12-15, 2010.

Heart Failure Society of America Board Review Course: Advanced Heart Failure and Transplant Cardiology. “Clinical Assessment of Heart Failure”. Minneapolis, MN. October 1, 2010.

American Heart Association Annual Scientific Sessions. Moderator: “Remodeling the Left Ventricle”. Chicago, IL. November 17, 2010

Stanford University Cardiology Grand Rounds: “The RAS in Heart Failure: The Road from SOLVD to the Future”. Palo Alto, CA. December 10, 2010.

Heart Failure Society of America Fellows Conference: Establishing a Career in Heart Failure1. Case Presentation (Moderator)2. What It Means to be a Certified Advanced Heart Failure and Transplant Cardiologist

(Panelist)3. Starting a Career in Heart Failure (Panelist)

Aventura, Florida Jan 23-25, 2011

11th Annual UCSD Heart Failure Symposium:1. Session I “Focus on New Strategies for Detection and Treatment of Heart Failure”

(Moderator)2. “Emerging Trends in Diagnosis and Treatment of HFpEF (Heart Failure Preserved

Ejection Fraction)”3. Case Presentation 1 (Presentor)4. “Following the Heart Failure Patient Post-Discharge”5. Featured Panel Discussion: Focus on the 30 Day Heart Failure Re-Admission Rate:

How Can We Best Identify and Treat Patients at Risk? (Moderator)La Jolla, CA. February 5, 2011

UCSD Endocrinology Grand Rounds: “Consequences and Treatment of Hyponatremia”. La Jolla, CA. Feb 9, 2011.

UCSD 4th Annual Biomarkers in Heart Disease: What Every Healthcare Provider Should Know. 1. Session III: Marriage of the Kidney and Heart (Chair)2. “Defining Cardio-Renal Syndrome”

San Diego, CA. March 5, 2011

UCSD Department of Medicine Grand Rounds. ”The Renin-Angiotensin System in Heart Failure: From SOLVD to the future”. La Jolla, CA. March 9, 2011.

UCSD Topics and Advances in Internal Medicine. “New and Emerging Approaches for Treating the Patient with End-Stage Heart Failure” La Jolla, CA. March 9, 2011.

13th La Jolla-International Cardiovascular Research Conference. “Lost in Translation: Problems in Drug Development”. La Jolla, CA. March 12, 2011.

American College of Cardiology Annual Scientific Session “Clinical Presentations of Decompensated Heart Failure”. New Orleans, LA. April 5, 2011.

89

Visiting Professor at Duke University:1. Cardiology Grand Rounds Presentation “ The Challenge of Improving Outcomes in

Patients with Decompensated Heart Failure”2. Research Conference “Gene Transfer Therapy to Treat Patients with Heart Failure”

Durham, NC. April 25-26, 2011.

Visiting Professor at the Cleveland Clinic: 1. Cardiology Grand Rounds Presentation “Treating Decompensated Heart Failure in 2011: Challenges and New Approaches. 2. Fellows Conference “Building an Academic Career in Cardiology” Cleveland, OH. May 5-6, 2011.

Cardiology Grand Rounds at the University of California, Davis. “Overcoming Stagflation in Heart

Failure Treatment”. Davis, CA. May 20, 2011.

17th Annual San Diego Heart Failure Symposium:1. “Heart Failure in 2011” 2. “Insights and Implications of Recent Clinical Trials in Heart Failure: ASCEND,

ATHENA, EMPHASIS, MADIT-CRT, RE-LY and Others”3. Case Presentations (Presentor/Moderator)

La Jolla, CA. June 25, 2011

UCSD Family Practice Grand Rounds “Advances and Challenges in Recognizing and Treating Patients with Heart Failure and Preserved Ejection Fraction” San Diego, CA. July 6, 2011.

UCSD Medical Housestaff Lecture “Treatment of Decompensated Heart Failure”San Diego, CA. July 11, 2011.

UCSD Cardiology Fellows Conference “Acute Decompensated Heart Failure”. La Jolla, CA. August 2, 2011.

European Society of Cardiology Scientific Sessions. Symposium on New Calcium Based Targets for Treatment of Heart Failure, “SERCA Gene Transfer: CUPID Trial”. Paris, FR. August 29, 2011.

UCSD General Internal Medicine Grand Rounds “Clinical Assessment of Heart Failure”. La Jolla, CA. September 14, 2011.

Heart Failure Society of America 15th Annual Scientific Meeting: 1. Clinical Implication: Approaches to Managing Patients with Heart Failure and

Hyponatremia. 2. Plenary Session Lecture “2012 HFSA Strategic Plan Overview”. 3. Biomarkers for Diagnostic and Rick Stratification

Boston, MA. September 18-21, 2011.

Heart Failure Society of America Annual Heart Failure Review Course. 1. “Clinical Assessment of Heart Failure”.2. Moderator Panel Discussions

Chicago, IL. October 20-23, 2011

90

The 1st Annual International Hawaii Symposium on Diagnostic and Therapeutic Modalities in Heart Failure.

1. Recent Clinical Trials in Heart Failure: What have ATHENA, RE-LY, CHAMPION, MADIT- CRT, and others told us about managing patients? 2. Recognizing and Treating the Patient with Heart Failure and Preserved EF (HFpEF)3. Q/A and Case Studies (Moderator) 4. Mechanical Circulatory Support and Cardiac Transplantation – Defining the Right Time in the Right Patient 5. Case Studies (Moderator)

Kohala Coast, HI. December 1-3, 2011.

12th Annual UCSD Heart Failure Symposium: Focus on New Strategies for Detection and Treatment of Heart Failure

1. Program Director2. Identifying Patients at Risk for Developing Heart Failure: What to Look for and What

Tests to Order3. Panel Discussion and Case Presentation I (Moderator)4. Clinical Implications of Hyponatremia and Treatment Strategies5. Focus on the 30 Day Heart Failure Re-Admission Rate: How Can We Best Identify and

Treat Patients at Risk? (Moderator)6. New Approaches for Anti-Coagulating Patients

La Jolla, CA. February 11, 2012.

San Diego Cardiac Center Friday Morning Conference. “Management of AnginaSan Diego, CA. March 16, 2012.

Atlanta Clinical Cardiology Update (Emory University). “New Insights Into Heart Failure Pathobiology – Implications For Drug Development Atlanta, GA. April 13, 2012.

American College of Cardiology’s 61st Annual Scientific Session & Expo.Joint Symposium of the Heart Failure Society of America and the American College of Cardiology: Contemporary Pharmacological Treatment of Systolic and Diastolic Heart Failure. “Management of the Patient with Stage C Heart Failure. Chicago, IL. March 24-27, 2012.

Dartmouth Advances in Heart Failure Symposium: Special Topics 20121. Special Topics: Heart Failure – New Therapies, New Horizons 2. Acute decompensated Heart Failure 3. “How To Sessions” Bioethics – Thoughts to Ponder in Heart Failure: Difficult Decisions

in Advanced Heart Failure – Devices, VADs, Transplants 4. “How To Sessions” Not the Usual: Constriction vs Restriction

Hanover, NH. May 21, 2012.

Chinese Medical Association Chinese Society of Cardiology: 2012 Heart Failure Academic Conference. “Challenges and Progress in Heart Failure in 2012.” Beijing, China. September 22, 2012.

Heart Failure Society of America 16th Annual Scientific Meeting:1. Late Breaking News (Moderator)2. Strategies for National Heart Failure Care: The View from Washington (Lecture) 3. Supplements or Prescriptors? PUFAs and Others (Lecture)

91

4. Evaluation of the Long-Term Effects of AAV1/SERCA2a Gene Therapy Clinical Events in Heart Failure Patients using a Novel Statistical Model: Results and Implications for Future Trials (Presenter)

5. Measuring CME Outcomes: Assessment of an HFSA Annual Meeting Symposium (Presenter)

Seattle, WA. September 12, 2012.

92

curriculum vitae - university of california, san diego... · web viewtransplant cardiology...

Documents